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ABSTRACT 
Background: Primary hyperparathyroidism (PHPT) is a common endocrine disorder 
with increasing prevalence, but the majority of cases (over 85%) are now perceived 
to be mild and remain untreated.   
 
Objectives: The main focus of this thesis is to provide an accurate update of the 
epidemiology of PHPT based on population data, and to investigate its long-term 
outcomes in the mild untreated subgroup compared with those with severe disease. 
 
Design: A large retrospective cohort study using routinely collected data in Tayside, 
Scotland, 1997-2006. 
 
Results: The prevalence of PHPT is increasing annually during the study period 
with an unexpected cyclic incidence. Although most of the patients do not progress 
in the long-term, patients with mild untreated PHPT have an increased risk of 
mortality and of developing co-morbidities; the risks are similar in those with a 
severe PHPT condition. Parathyroid hormone predicts both disease progression and 
associated adverse outcomes in untreated patients. Parathyroidectomy normalises 
calcium and parathyroid hormone, as well as reducing the risks of adverse outcomes.  
 
Conclusions: Based on the study findings, this thesis concludes that although PHPT 
has become a mild stable condition, the increased risk associated with untreated 
PHPT should not be neglected and requires vigorous management to avoid a future 
ix 
heath burden. Large randomised controlled trials are needed to evaluate the surgical 
outcomes in comparison to the cost-effectiveness of alternative treatments.
1 
CHAPTER 1  
INTRODUCTION 
1.1 Overview 
This first chapter will give an overview of the problem of primary 
hyperparathyroidism (PHPT) and why it is important to undertake the research. 
Calcium homeostasis will be described first, together with some basic concepts of 
PHPT from the literature, including what it is, the current approach to diagnosis and 
treatment, followed by the background to the study. The aims and specific objectives 
of the study, as well as the thesis structure will be provided at the end of this chapter. 
 
1.2 Calcium homeostasis 
PHPT is a condition in which calcium homeostasis is disrupted with the presence of 
elevated serum calcium concentration coexisting with inappropriately normal or 
elevated parathyroid hormone (PTH). The physiology of calcium metabolism is a 
fundamental concept in understanding PHPT and therefore, is briefly described first. 
Calcium is an essential element throughout human‟s myriad biological functions, in 
which calcium ions (Ca
2+
) play critical physiological and biochemical roles, in both 
intracellular and extracellular events.
1,2
 (Table 1.1)  
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Table 1.1 Calcium forms and its biological functions 
Form Location Mass  
(% of total) 
Function 
Intracellular    
 Insoluble Plasma membrane, 
endoplasmic reticulum, 
mitochondria 
9 g (0.9%) Structural integrity, storage 
 Soluble Cytosol, nucleus 0.2 mg Action potentials, contraction 
and motility metabolic 
regulation, cytoskeletal 
function, cell division, 
secretion 
Extracellular    
 Insoluble Bones and teeth 1-2 kg (99%) Protection, locomotion, 
ingestion of minerals and 
other nutrients, mineral 
storage 
 Soluble Extracellular fluid  
(e.g. blood) 
900 mg (0.1%) Blood clotting, kinin 
generation, regulation of 
plasma membrane potential, 
exocytosis
a
, contraction
a 
a
The activation of exocytosis and muscle contraction, in part, depend on cellular uptake of 
extracellular calcium. 
Note, this table is taken from Bilezikian, JP, The parathyroids, Chapter 10
1
 
 
Calcium metabolism involves calcium‟s movements via the gastrointestinal (GI) 
tract, kidney and bone metabolism in the face of calcium fluxes through diet and 
body compartments (Figure 1.1). Although representing only a tiny fraction of the 
total body calcium, both extracellular and intracellular Ca
2+
 is tightly regulated 
within a narrow physiological range in order to provide its proper functions and all 
intracellular Ca
2+
 essentially originates from Ca
2+
 in the extracellular fluid (ECF). 
Thus, maintaining a constant level of Ca
2+
 in the ECF is the challenge of calcium 
homeostasis during the course of calcium metabolism, which is very tightly 
regulated by two key hormones, namely PTH and 1,25-dihydroxyvitamin D 
[1,25(OH)2D] (vitamin D). The secretion of each hormone is sensitive to any small 
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change in serum calcium and is able to regulate calcium exchange across three 
interfaces of the ECF, namely the GI tract, the bone and the kidney. 
 
Figure 1.1 Daily calcium fluxes and overall calcium balance in a normal individual 
 
ECF: Extracellular fluid 
Note: this diagram is created with reference to Bilezikian et al (Chapter 10) and Gardner et al 
(Chapter 9) 
3, 4
 
 
The exact mechanism of this hormonal controlled homeostasis is a complex process 
and is not essential to understand the background to this thesis. In brief, the principle 
of it is illustrated in a simplified diagram (Figure 1.2) as an example and operates as 
follows: a slight decrease in serum Ca
2+
 evokes a prompt increase in the secretion of 
PTH by the parathyroid glands, which then increases the renal retention of Ca
2+
 and 
enhances the biosynthesis of 1,25(OH)2D from 25-hydroxyvitamin D [25(OH)D] in 
the kidney. The increased level of 1,25(OH)2D  circulation directly stimulates the 
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absorption of Ca
2+
 via the GI tract. Increased PTH and 1,25(OH)2D also 
synergistically promotes the net release of skeletal Ca
2+
 through bone resorption. 
This increased movement of Ca
2+
 into the ECF from kidney, GI tract and bones, 
restore the serum Ca
2+
 back to the normal level, thereby reducing the PTH secretion 
and closing this negative-feedback cycle. 
 
Figure 1.2 The hormonal regulation of calcium homeostasis by PTH and vitamin D 
 
 
1.3 PHPT – the basic concepts 
As previously described, PHPT results in hypercalcaemia (elevated serum calcium 
concentration) through excessive secretion of PTH and is by far the most common 
cause of hypercalcaemia.
5
 
6
 
7, 8
 
9
 Once the principle of calcium homeostasis is given, 
the concept of PHPT is more easily understood. This section provides some 
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background information on the condition, including the clinical features of PHPT, 
the diagnosis and the available treatments. 
 
1.3.1 Hyperparathyroidism 
1.3.1.1 Parathyroid glands 
PTH is secreted from four parathyroid glands usually located behind the four poles 
of the thyroid gland in the neck (Figure 1.2).
2
 Normal parathyroid glands weigh 40 
mg each (at the size of a rice grain) on average. They were first found in 1880 by 
Ivar Viktor Sandström, a Swedish medical student, 40 years before the first known 
cases of hyperparathyroidism.
3
 As illustrated in Section 1.2, the predominant 
function of parathyroid glands is to maintain the serum calcium homeostasis within a 
narrow range by secreting PTH within seconds in response to a low or falling serum 
calcium concentration. They act as instant receptors to regulate the calcium level in a 
healthy person. 
9
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1.3.1.2 PHPT and its causes 
When excessive PTH is secreted by one or more overactive parathyroid glands 
causing frank hypercalcaemia, the condition of PHPT occurs.
5
 
6
 
7, 8
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 A sporadic, 
single parathyroid adenoma with no other physiologic or pathophysiologic attributor 
is the most common cause, accounting for nearly 90% of all PHPT cases.
11, 12
 Other 
pathologic lesions include multigland hyperplasia (accounting for less than 10%), 
and very rarely, parathyroid carcinoma (less than 1% with equal risk in both sexes).
9
 
The exact aetiology of the disease is still unknown.
10
 A history of irradiation to the 
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neck and head was found to be associated with PHPT in the 1970s, but the current 
significance is no longer ascertained.
13
 
14
 Thiazide and lithium therapy cause 
overactive parathyroid glands with persistent effects even within the first few months 
after discontinuation of the drugs.
15
 Genetic mutations are also reported as a possible 
cause of PHPT, but are seen more often in children.
16-19
 
20, 21
 
22
 In addition, PHPT 
can also be associated with other endocrine disorders, such as multiple endocrine 
neoplasia (MEN) type 1 or type 2.
2
 
 
1.3.2 Clinical presentation 
Before the 1970s, PHPT was a condition associated with signs and symptoms that 
are classically summarised by the mnemonic, ‘stones, bones, abdominal groans 
and psychic moans’.2 People with PHPT have been traditionally reported to suffer 
from complications such as: renal stones, osteitis fibrosa, constipation, nausea, 
lethargy, fatigue and depression, most of which are associated with hypercalcaemia. 
In addition, cardiovascular disease and higher mortality rates have been observed in 
such patients, and there is well documented evidence of cardiovascular associated 
deaths. 
23-28
 
 
The clinical presentation of PHPT has, however, dramatically changed towards a 
more asymptomatic form over the last four decades, with the introduction of the 
multichannel auto-analyser and an increasing accessibility to biochemical 
screenings. It is now a disease with primarily biochemical and densitometric 
signatures and a condition „in search of symptoms rather than a disease with 
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symptoms‟. 3 More and more patients are picked up by routine blood sample tests 
with mild biochemical abnormality but no obvious clinical symptoms. In fact, over 
80% of PHPT patients presenting today have little or no bony or renal manifestations 
and are, therefore, regarded as „asymptomatic‟ or „at most minimally symptomatic‟. 2 
Some signs, such as fatigue, hypertension, cognitive difficulties, somatic complaints 
and clinical depression, can be presented in these patients but are not clearly 
associated with PHPT. 
5, 10, 15, 29, 30
 
 
1.3.3 Asymptomatic PHPT 
The rising proportion of patients with an absence of traditional symptoms of PHPT 
has made the term „asymptomatic‟ PHPT more commonly recognised. The definition 
of „asymptomatic‟ PHPT has been best defined by Heath.31 as „lacking symptoms 
that are clearly or commonly referable to PHPT or any of its biochemical or 
physiologic effects‟ and the concept of „asymptomatic PHPT‟ has then been 
summarised by Silverberg et al. as „neither complications nor symptoms that are 
clearly and commonly attributable to either hypercalcaemia or PTH excess‟.31, 32  
 
The National Institute of Health (NIH) consensus panel further classified PHPT into 
two types: symptomatic and asymptomatic.
5, 10
 Asymptomatic PHPT accounts for 75 
to 80 percent of all cases.
10, 33
 
34
 A combination of a mildly elevated serum calcium 
concentration (reference range 2.10-2.55 mmol/l in adults and children after 21 days 
from birth), usually within 0.25 mmol/L above the upper normal limit (2.55 
mmol/L), and an inappropriately „normal‟ or elevated PTH level, measured by 
8 
means of immunoradiometric assay and usually within 1.5 to 2.0 times above the 
upper limit (reference range: 1.0-6.9 pmol/L), are the main current diagnostic criteria 
of asymptomatic PHPT (specific diagnostic criteria are described in the next 
section).
10
 
35
 In addition, the 24-hour urinary calcium excretion rate should be near 
the upper limit of the normal index or higher. Symptoms of hypophosphatemia and 
hyperchloremia, which are common among patients with symptomatic disease but 
uncommon with asymptomatic disease, can be used to distinguish between the two.
10
 
Another presentation of asymptomatic PHPT from existing studies also includes an 
abnormal evaluation result of skeletal health, in which the diagnosis was made with 
no apparent cause of secondary elevated PTH level and the serum 25(OH)D level  
not being below the lower limit of physiological normal range (i.e. above 20 
mg/ml).
10
  
 
As asymptomatic patients now represent the majority of PHPT cases, they have 
become an important group for further studies of their long term outcomes. 
Definitions of asymptomatic PHPT, however, vary across studies. Table 1.2 
summarises the selection criteria used in individual studies considering PHPT, with 
particular interest in the mild form.  
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Table 1.2 Definitions of asymptomatic PHPT used in existing studies 
Author Study Design Patients Main definitions of asymptomatic 
Rao36 
2004 USA  
RCT 53 (11 men) Untreated 
S-Ca (2.52-2.87 mmol/l), PTH >4.4 pmol/l 
Normal renal function defined as serum creatinine <133 umol/l 
Forearm bone mineral density (BMI) within 2SD adjusted for age, sex and race 
Absence of relevant symptoms and complications directly attributable to either 
hypercalcemia or excess PTH secretion 
Bollerslev 37 
2007 Europe 
RCT 191 (26 men) Untreated 
2.60≤S-Ca ≤2.85 mmol/l 
50 ≤ age ≤ 80 yr 
No medication  interfering with Ca metabolism 
Ambrogini38  
2007 USA 
Comparative 
study 
50 S-Ca >2.55 mmol/l & S-Ca ≤2.8 mmol/l for at least three occasions 
PTH>6.8 pmol/l 
Age 50-75 yr 
24 hr urine Ca <10 mmol/l, Urine creatinine clearance ≤ 0.3 
Lundgren39  
2001 Sweden 
Cohort study 172 (26 men) Mild hypercalcemia, Ca 2.67±0.07 mmol/l 
Age 50.9±9.44 yr 
10 
1.3.4 Diagnostic criteria 
The current diagnosis of PHPT is normally made biochemically, by measuring the 
serum calcium concentration and serum PTH level (Figure 1.3).
40
 Corrected serum 
calcium concentration (serum calcium concentration corrected for prevailing serum 
albumin), combined with intact PTH (the entire 1 through 84 amino acid sequence) 
measured by immunoradiometric assay, should be used to establish the diagnosis. 
Occasionally ionised calcium measurements are made.  
Figure 1.3 Differential diagnosis according to biochemical test results of serum PTH 
and calcium (reference range for PTH is 1.0-6.9 pmol/l and for serum calcium 2.10-
2.55 mmol/l) 
 
Once the diagnosis is confirmed biochemically, i.e. the coexistence of 
hypercalcaemia and an inappropriate elevated PTH concentration, the possible 
differential diagnosis should be considered, including: thiazide diuretics or lithium 
therapy caused hypercalcaemia, familial hypocalciuric hypercalcaemia (FHH) and 
tertiary hyperparathyroidism.
8
 
10
 FHH can often be distinguished from PHPT by a 
positive family history of hypercalcaemia, such patients usually being in  their young 
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adulthood. A urinary calcium creatinine excretion ratio of less than 0.01 can also be 
used to distinguish between the two.
10, 41
 If a patient is receiving thiazide or lithium 
therapy, the calcium concentration should be re-measured three months after safe 
discontinuation of such drugs. If a continuous elevated calcium concentration is 
measured, the PHPT diagnosis can be established.
10
 
 
In addition, determinations of renal function and/or a plain abdominal radiograph for 
renal stones in such biochemically confirmed patients are often obtained for further 
clinical decision making to distinguish PHPT from the other forms. Secondary 
hyperparathyroidism occurs when a normal parathyroid gland responds to a low 
serum calcium concentration of relative calcium deficiency. This commonly occurs 
in Vitamin D deficiency and is also connected with renal disease and is relatively 
common in this era of hemodialysis and renal transplantation.
9
 
10
 The existence of 
tertiary hyperparathyroidism is believed to represent a prolonged parathyroid gland 
hyperplasia, which usually is in the phase of long-standing secondary 
hyperparathyroidism, such as in chronic renal failure.
9, 10
 An age and sex adjusted 
serum creatinine, with reference to the local normal range, can be used to test for 
renal function, thus enabling identification of renal failure. Renal failure can cause 
tertiary hyperparathyroidism and PHPT can cause renal failure. Thus it is important 
to try identifying the sequence of events when distinguishing primary from tertiary 
hyperparathyroidism.  
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1.3.5 The treatments 
Parathyroidectomy (PTX), surgical removal of the overactive parathyroid gland(s), is 
the only definitive treatment with a 90-95% success rate and few complications 
when performed by experienced surgeons.
8
 The indications for PTX include clear 
clinical presentation symptoms, such as bone disease, renal calculi and pancreatitis 
or peptic ulcer disease, in traditional PHPT patients.
40
 With the dramatic changes of 
its clinical manifestations, the NIH convened a consensus conference in 1990 to 
establish clear referral criteria for surgery, this then being updated in 2002 and 2008, 
respectively, with further acknowledgement of current asymptomatic PHPT.  
 
In the absence of randomised controlled trials (RCTs), the first two guidelines were 
initiated and amended, based on clinical experience and data derived from 
epidemiological studies or non-randomised, prospective cohort studies.
5
 
37
 
42
 In light 
of on newly available evidence from recent RCTs and further knowledge on 
asymptomatic PHPT, a slightly amended guideline was issued  in 2008. A 
comparison of the new and previous guidelines for surgery referral in PHPT patients 
is listed in Table 1.3.
5
 These guidelines are, however, not the absolute criteria to be 
applied to all patients. Surgery is also recommended for patients for whom medical 
surveillance is neither desirable nor possible. 
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Table 1.3 A comparison of new and previous guidelines for parathyroid surgery in 
asymptomatic PHPT 
5 43
 
Measurement Guideline (1990) Guideline (2002) Guideline (2008) 
Serum calcium above upper 
normal limit 0.25-0.4 mmol/l
1 
0.25 mmol/l 
0.25 mmol/l 
24-h urinary calcium >400 mg >400 mg Not indicated 
Bone mineral density 
Z-score<-2.0 
forearm 
T-score<-2.5 at any 
site 
T-score<=2.5 at 
any site and/or 
previous fracture 
fragility
2
 
Creatinine clearance Reduced by 30% Reduced by 30% 
Reduced to <60 
ml/min 
Age < 50 < 50 <50 
Note that surgery remains recommended for symptomatic patients. 
Z-score is the number of SDs above or below the mean BMD of the same age; 
T-score is the number of SD above or below the mean BMD of 30 year olds 
 
Although not curative, other managements of the condition include pharmacologic 
therapies or observations with the aim of either inhibiting the secretion of PTH or the 
effects of PTH. Medical treatments include oestrogen therapy (e.g. Raloxifene) in 
postmenopausal women to decrease serum calcium and increase bone mineral 
density (BMD), and oral bisphosphonates (e.g. Alendronate) to reduce bone 
turnover. Neither Raloxifene nor Alendronate, however, has significant long-term 
effects on serum calcium or PTH concentrations.
38, 44, 45
 There are new calcimimetic 
agents (e.g. Cinacalcet) that have been shown in small clinical trials to lower PTH 
level and, thus, normalise serum calcium concentration.
46, 47
 This provides an 
alternative for patients who cannot or will not undergo surgery, but there has been no 
                                                 
1
 Calcium: mg/dl * 0.25 = mmol/L therefore Guideline (1990) 0.25-0.40 mmol/L; Guideline (2002) 
0.25mmol/L 
2
 Consistent with the position established by the International Society for Clinical Densitmoetry, the 
use of Z-scores instead of T-scores is recommended in evaluating BMD in premenopausal women 
and men younger than 50 years of age. 
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evidence on its effects on BMD or bone turnover markers and it is currently with a 
limited licence (primarily for the management of secondary hyperparathyroid 
patients on dialysis) due to cost. Medical surveillance first raised at the 1990s NIH 
conference for asymptomatic PHPT is recommended to be offered to patients who do 
not meet any of the criteria or who are unfit to undergo surgical procedure. Diverse 
opinions exist, however, regarding the surgical criteria.  
 
1.4 Background of the thesis 
1.4.1 Scope of the problem  
With the advent of multiphasic screening of serum chemistries, PHPT is now the 
third most common endocrine disorder, after diabetes and thyroid disease, and it 
affects 1 to 21 per 1000 population.
6-9, 48
 It is a disease affecting persons of all ages 
but is mostly seen in persons after midlife and has a preponderance in post-
menopausal women. 
 
Despite the fact that currently over 80% of the total cases are asymptomatic, 
outcome evidence on asymptomatic PHPT, in which traditional symptoms are 
absent, is incomplete and remains controversial. Some studies have claimed that the 
overall survival among patients with mild PHPT is not adversely affected.
27, 49, 50
 
Others, on the contrary, have shown an increased risk among mild to moderate 
PHPT patients.
51, 52
 The existing incongruent evidence of the outcomes, in particular 
cardiovascular mortality, in mild PHPT patients has been explained by the variance 
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in disease severity by study regions, the absence of population studies and the 
limited patient numbers involved. As a result, surgery, although the only absolute 
cure, is only recommended to a small sub-group. This is due to the lack of evidence 
of benefit in those asymptomatic PHPTs and uncertainty about any causal 
relationship between adverse endpoints and the mild PHPT but not because of the 
complexity of the surgery or other practical reasons. In the UK, the majority of 
patients defined as „asymptomatic‟ cases (representing about 85% of all patients) are 
currently left untreated.   
 
1.4.2 Need for this research 
It is therefore important to examine further: 
1. The current epidemiology of PHPT; 
2. Whether or not asymptomatic PHPT, which accounts for the current majority 
of cases, will progress to a severe disease if left untreated; 
3. Whether or not untreated asymptomatic PHPT is associated with the same 
endpoints as those observed with the more severe form of the disease.  
 
If so-called mild, untreated, PHPT also contributed to increased morbidity and 
mortality, the management of this condition might be changed so that more patients 
are recommended for surgery. Alternatively, if there were a bigger market for 
pharmacotherapy, the actual costs of drugs, such as Cinacalcet, might decrease, and 
as a consequence they could become more generally available. There is thus a need 
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for high quality population based research examining the outcomes of patients with 
PHPT and in particular, the mild cases, which is currently lacking.  
 
1.4.3 Possibility of undertaking this research in Tayside 
In Tayside, Scotland, all health related records, such as hospital admissions and 
laboratory data, have been routinely collected since the 1980s and are available for 
research, upon rigorous anonymisation (details of Tayside electronic databases and 
record linkage are explained in Chapter 3). This privilege of the availability of highly 
detailed clinical data initiates the possibility of conducting an observational study in 
the region, with the aim of providing an up-to-date accurate portrayal of diagnosed 
PHPT, using complete, large, population data. This study will also, retrospectively, 
investigate the outcomes of PHPT patients living in Tayside.  
 
1.5 Aims and objectives  
1.5.1 Aims of the thesis 
This thesis aims to bridge the gap in existing evidence by systematically identifying 
all diagnosed PHPT patients in Tayside, Scotland, UK. Those with mild PHPT will 
be identified as a subgroup. The overall aim is to provide an up-to-date epidemiology 
of current PHPT and reflect an accurate overview over the past decade, with no 
presumption of the age and gender distribution, and to examine the risks of mortality 
and morbidity to detect whether there is an unmet need for treatment. The study 
results are hoped to provide a better understanding of this condition and offer a basis 
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for further recommendations, in order to improve management in the UK and 
internationally.
48
 
 
1.5.2 Specific objectives 
The specific objectives given below will be embedded in the subsequent chapter. 
1. To identify all patients with PHPT using a biochemical algorithm, classify 
the cohort into subgroups according to the NIH definition and characterise 
the baseline socio-demographic and clinical profile of all patients. 
2. To estimate the prevalence and incidence of diagnosed PHPT and assess the 
changes in clinical presentation. 
3. To examine the disease progression in mild, untreated PHPT patients. 
4. To determine whether all patients with diagnosed PHPT have an increased 
risk of death, in particular cardiovascular death, and other adverse morbidity 
outcomes and to assess the risks in the subgroups.  
5. To determine whether patients with mild PHPT, who do not currently 
warrant treatment (the majority of cases), have an increased risk of mortality 
and an increased risk of developing the same endpoints as those with severe 
conditions. 
6. To examine possible predictors of adverse outcomes in untreated PHPT. 
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1.5.3 Thesis structure 
The structure of the thesis reflects the objectives set for the research, starting with a 
structured review summarising existing evidence and knowledge of PHPT, in terms 
of long-term outcomes of the condition, criteria for surgery and the surgical 
outcomes (Chapter 2).  In addition to the above specific objectives, due to the nature 
of this retrospective observational study record linkage is the key to providing the 
possibility of undertaking subsequent research. Thus, the main analyses will 
commence with a brief discussion on the numerous data sets used (Chapter 3). This 
will allow an understanding of how the data have been collected by the provider, the 
Health Informatics Centre (HIC), University of Dundee, and how research based on 
substantial health care data (from numerous sources) is made available while 
maintaining data protection. Chapter 3 also describes the methods adopted for the 
research. Chapter 4 describes the results of patient identification in Tayside, which 
will provide the basis of the research, and explains how subsequent classification of 
patients is made. Chapter 5 gives an update of the current epidemiology of PHPT in 
Tayside, including the trends and patterns of prevalence and incidence of diagnosed 
PHPT over the ten-year data-collecting period. Chapters 6 and 7 assess the risk 
associated with PHPT from two different approaches. Chapter 6, firstly, provides 
estimates of the risk of mortality and co-morbidity using the Standardised Mortality 
Ratios (SMRs) and the Standard Morbidity Ratios (SMbRs) with comparison to the 
general Tayside population. Based on these preliminary results, further survival 
analyses incorporating matched controls are conducted, to give an accurate estimate 
of risks using person-level data, as presented in Chapter 7. Chapter 8 describes 
disease progression in patients with untreated mild PHPT. Chapter 9 attempts to seek 
possible predictors of adverse outcomes among patients with untreated PHPT. 
19 
Chapter 10 gives an overview of this research and summarises the major findings of 
the thesis. In addition, it identifies the limitations of the study and also provides 
some suggestions as to what may justify further research into the topic, drawing on 
the findings of this work. 
 
1.6 Chapter Summary 
This chapter has briefly introduced the nature and manifestation of PHPT and the 
existing uncertainties in this condition for treatment due to the changes of its 
presentation. It has also introduced the aims and objectives set for the thesis with its 
corresponding structure.  
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CHAPTER 2  
LITERATURE REVIEW  
 
2.1 Overview 
This chapter will discuss the clinical manifestations of PHPT, with a particular focus 
on the mild/asymptomatic form, as well as the surgical outcome, based on evidence 
from the existing literature. The initial section of the chapter will focus on the results 
of risks of mortality and co-morbidities in patients with mild PHPT. The final 
sections will summarise the results of the surgical outcome, including a discussion of 
existing surgical criteria used in practice. This chapter will give a summary of 
existing evidence available on the topic that is relevant to this thesis. 
 
2.2 Introduction 
As mentioned in Chapter 1, PTX is the only definite treatment for PHPT.  The value 
of this surgical option in mild or asymptomatic patients has, however, been a matter 
of discussion due to the equivocal causal relationship between adverse endpoints and 
this mild asymptomatic form.
37
 Currently, most of these patients are untreated, 
because the majority do not have progressive disease in the long term.
53
 Although a 
few drugs have been identified as an alternative management of PHPT, only the new 
calcimimetic agents, e.g. Cinacalcet, provide a medical treatment for the condition. 
Other drugs, such as oral bisphosphonates and estrogens, treat the complications 
21 
rather than the condition.
53
 In this chapter, the existing literature is examined in 
order to unveil to what extent patients with mild or asymptomatic PHPT benefit from 
the risks of undergoing surgical treatment. In this chapter, three primary research 
questions are defined which provide the main framework of the thesis. Findings from 
existing literature on other relevant topics, as summarised in Chapter 1, are presented 
in individual chapters pertinent to the topic. 
 
Q1. Adverse outcomes associated with mild/asymptomatic PHPT, including 
disease progression, mortality and co-morbidities. 
Q2. Existing surgical criteria on mild/asymptomatic PHPT used in practice. 
Q3. Surgical outcomes – are the adverse endpoints, if any, reversible after 
surgery? 
 
Specific co-morbidity endpoints are searched, including the risk of cardiovascular 
disease (CVD), fractures and/or osteoporosis, and impaired renal function which are 
shown to be associated with the traditional form of PHPT. This will allow me to 
study if mild PHPT, which currently accounts for the majority of patients, has the 
same increased risk as those with severe/symptomatic PHPT if left untreated.  
 
2.3 Methods 
All English literature on MEDLINE from 1970 onwards was included in the search 
with the following search terms. Medical subject heading (MeSH, or „MH‟ within 
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searches) terms and free text as search terms, and MedLine limiters as search 
options, were combined to provide a consistent and comprehensive search strategy. 
 
Search terms: 
S1: (MH “Hyperparathyroidism, 
primary/BL/CL/CO/DI/EC/EP/ET/HI/ME/MO/ DT/TH/SU/PX/PC/PP/PA”)* 
S2: TI primary hyperparathyroidism 
S3: S1 or S2 
S4: TI mild or TI asymptomatic 
S5: S3 and S4 (n=82) 
Search options: 
Date of publication from: 19700101-20101231 
Abstract available; 
English Language; 
Human; 
Age Related: All Adult: 19+ years 
*The two-letter terms are subheadings included within the MeSH terms, which stand 
for: blood, classification, complications, diagnosis, economics, epidemiology, 
aetiology, history, metabolism, mortality, drug therapy, therapy, surgery, 
psychology, prevention and control, physiopathology and pathology, respectively. 
 
Studies returned from this initial batch of searching generated a complete data bank 
of available literature on mild/asymptomatic PHPT. Abstracts of each individual 
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paper were read to decide the overall eligibility according to proposed research 
questions and the results were summarised by sub-topics. In addition, keywords 
pertinent to each research question were searched within the initial results using the 
„explode‟ method. This method, which adds a plus sign (+) next to the search query, 
„explodes‟ the subject heading, i.e. the headings are exploded to retrieve all reference 
indexed to the search term, as well as all references indexed to any narrower subject 
terms. The wildcard function, symbol #, was used to include the search term with 
alternative spellings or different endings. These further searches within the initial 
results are summarised in detail in Appendix 1. On all occasions, key references 
from relevant literature were sought manually for further information. Existing 
guidelines, unpublished data, grey literature, including conference abstracts, 
proceedings, and discussion papers introduced by supervisors were included 
wherever appropriate. Full texts of all articles that met the inclusion criteria were 
retrieved and were categorised according to the individual research questions. 
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Figure 2.1 Flow chart showing the search process and results 
 
1
As one paper could address multiple questions, the total number from each question did not add 
up to 68. 
 
2.4 Results 
From the initial MEDLINE search, 82 studies were returned. As a result of reading 
the abstracts of all returned papers, 11 non-eligible studies that were obviously 
irrelevant to the research questions were excluded. After reading the full texts of all 
MEDLINE searches 
(n=82) 
Potential relevant papers for full 
text retrieval 
(n=71) 
Eligible studies 
(n=45) 
Studies included in the review 
(n=68) 
Inclusions 
(n=23) 
Exclusions
 
(n=26) 
) 
Abstracts review 
Full text review 
Manual search 
Q1 
(n=35)
 
Q2 
(n=33) 
Q3 
(n=24) 
Summarise studies by research 
questions1 
Exclusions 
(n=11) 
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the remaining papers, a further exclusion of 26 papers was made and 23 papers were 
added to the databases through cross-referencing or manual searches. Thus, a total of 
68 papers were kept for appraisal. Figure 2.1 illustrates the search process and results 
and Table 2.1 summarises the main findings from key studies which are not 
described in details in the results section. 
 
It is worth noting that the proposed questions are seemingly independent of each 
other but existing papers are not so distinguishable, because these questions are, in 
fact, important components in a better understanding of asymptomatic PHPT. Thus, 
no matter how specific each question and how thorough the appraisal process is, 
overlap exists when attempting to address them individually (as shown in Figure 2.1, 
bottom two rows). For example, some studies investigating the symptoms associated 
with mild PHPT patients (Q1) often compare the findings with surgical outcomes 
(Q3).  It is, therefore, only appropriate to bear in mind that, ultimately, they are 
within an overall context. The results section addresses each question separately 
whenever it is appropriate and possible. 
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Table 2.1 Summaries of key study findings 
First author Year / 
Setting 
Design Objectives / endpoints Subjects  Main findings / Key messages Question 
addressed 
Wilson54 1988 
US 
Prospective 
observational  
Prevalence of vertebral  
fractures 
Mild PHPT (n=174) vs. 
historical controls (n=200) 
No increased risk of vertebral fracture 
compared to the controls, thus should not be 
used as surgical criteria. 
Q1 
Q2 
Rao55 1988 
US 
Prospective 
observational  
Natural history of PHPT Mild PHPT with 1-11 years of 
follow up (n=80)  
No progression in biochemical measurements 
associated with PHPT. Patients with a 
substantially reduced BMD at the time of 
diagnosis but no further acceleration in bone 
loss. Thus, suggest withhold PTX in mild PHPT 
patients due to lack to progression. 
Q1 
Q2 
Harrison56 1991 
UK 
Retrospective 
cohort with 
review of existing 
literature  
Clinical and biochemical 
features 
111 surgically treated PHPT 
patients (asy.=28, sym.=83) 
No observed difference between subgroups 
of asy. and sym. patients. Suggest liberal 
surgical approach, as clinical assessment may 
not detect subtle signs in asy. patients. 
Q1 
Q2 
Birkenhanger5
7 
1995 
Euro 
Review Surgical approach in 
association with 
outcomes 
NA Recommend surgery to those with life 
expectancy exceeds 10 years, due to the high 
success and low complication rates. 
Q2 
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Grey58 1996 
NZ 
Prospective 
cohort 
Bone loss observed in 2 
years at 6 month interval 
Post-menopausal asy PHPT 
women (n=17) vs. age 
matched controls (n=48) 
Significant increased bone loss in patients 
compared to the controls at total body, 
lumbar spine, thus suggested PTX for those 
with initial low, or rapid losing BMD. 
Q1 
Q2 
Roche59 2000 
UK 
Review Surgery in the elderly 
asy. PHPT patients 
NA PTX is a safe and definite treatment, but its 
exact benefits in the elderly is unclear, truly 
asy. patients can be safely followed. 
Q1 
Q2 
Bergenfelz60 2003 
Sweden 
Prospective 
cohort 
Differences between  
subgroups of mild PHPT  
211 surgically treated 
patients, four subgroups 
according to pre-op Ca and 
PTX (n=162,25,20,4) 
Normal PTH group indicate mild PHPT (better 
renal function and low bone turnover) but 
still benefit from PTX. Poor correlation 
between bio and clinical features. Ca level 
not distinguish disease severity, thus hint 
may not be used solely as surgery criteria. 
Q2 
Kaplan61 1976 
US 
Cohort Symptomatic vs. 
asymptomatic PHPT 
13 patients (asy.=6, sym.=7) Biochemical evidence of adverse effects in 
asy. group. PTX improve the condition safely 
in both groups. 
Q1 
Q3 
Erlichman62 1995 
US 
Review NA NA Evidence on fractures in mild PHPT varied by 
studies; PTX improves BMD, but some only 
shown in short-term, effects of PTX in the 
mild needs further elucidation. 
Q1 
Q3  
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Valdemarsson
63 
1998 
Sweden 
Longitudinal 
cohort 
Bone formation and 
resorption 
40 surgically treated 
patients, 30 mild 
Significant post-op improvement in bone 
turnover was seen in mild PHPT as indicated 
by the bio-markers. 
Q3 
Okamoto64 2002 
Japan 
2-year before-
after study 
Psychological symptoms 
before and after PTX 
26 surgically treated mild 
PHPT patients 
Patients with mild PHPT was associated with 
psychological distress which was ameliorated 
after PTX (GHQ score). 
Q1  
Q3 
Almqvist65 2002 
Sweden 
Randomised 
before-after study 
Effects of PTX on cardiac 
function 
50 mild PHPT patients (25 
prompt and 25 delayed PTX) 
Early PTX was suggested in mild PHPT 
patients, as it improved cardiac function. PTH 
rather than Ca was associated with cardiac 
dysfunction. 
Q2 
Q3 
Almqvist66 2004 
Sweden 
Randomised 
before-after study 
Effects of PTX on BMD 50 mild PHPT patients (25 
prompt and 25 delayed PTX) 
Mild PHPT is a risk factor of hip fractures. PTX 
improved BMD and is suggested at baseline 
regardless of calcium. 
Q2 
Q3 
Hagstrom67 2006 
Sweden 
Population-based 
cohort 
Effects of PTX on BMD 87 asy. PHPT patients with 
matched controls 
Lower BMD in patients compared to the 
controls. Positive PTX effects on lumbar 
spine; PTX also increased femoral neck BMD 
in patients <67 years. 
Q1 
Q3 
Bollerslev37 2007 
Europe 
Prospective 
randomised trial 
PTX effects on QoL and 
BMD 
191 asy. PHPT patients 
randomised into PTX or obs. 
Lower QoL (SF-36) observed in patients 
compared to the matched controls. PTX 
normalised Ca and PTH, increased BMD, but 
no significant benefit of PTX compared to the 
outcomes in the observed group. 
Q1 
Q3 
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Jarhult68 2008 
Sweden 
Before-after 
study 
PTX effects on self-
reported symptoms 
44 mild PHPT patients with 
matched thyroid controls 
Patients suffered more symptoms compared 
to the matched controls. PTX improved most 
of the symptoms but its effects were 
transient and varied by individual. 
Q1 
Q3 
Rubin69 2008 
US 
Observational BMD 
Natural history 
116 PHPT patients (PTX=59, 
Obs=57) 
Stable BMD in the lumbar spine, but 
decreased BMD in the cortical bone in 
majority patients. PTX improved BMD. 37% 
asy. patients showed progression, surgical 
criteria did not predict such progression. 
Q1 
Q2 
Q3 
Sankaran70 2009 
NZ 
Review 
Meta-analysis 
BMD in treated and 
untreated patients 
NA PTX improves BMD in mild PHPT, bone loss in 
the untreated is insignificant and slow. 
Q1 
Q3 
Farahnak71 2010 
Sweden 
Prospective case-
control 
Cardiac structure and 
function 
51 mild PHPT patients with 
51 healthy controls 
Compared to the controls, patients with mild 
PHPT had overall normal cardiac function and 
morphology. At baseline, patients had slightly 
higher systolic myocardial performance, 
suggesting disease-related inotropic BMD in 
treated and untreated patients BMD in 
treated and untreated patients effect, which 
was reduced after PTX. 
Q1 
Q3 
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Mitlak72 1991 
US 
Cohort Silent complications 85 mild PHPT patients (17 
with renal stones) 
Premature osteopenia and/or renal 
complications are shown in nearly 1/3 of 
cases, but their progression rate and surgery 
reversibility are uncertain. 
Q1 
Silverberg73 1995 
US 
Longitudinal 
cohort  
BMD and biochemical 
indices 
128 mild PHPT patients with 
62 being surgically treated 
Both biochemical indices and BMD were 
stable in the 7-year of follow up in untreated 
patients, but patients had lower BMD at the 
baseline. 
Q1 
Lundgren74 1998 
Sweden 
Case-control Symptoms and signs 102 mild PHPT with matched 
controls 
Mild, asy. PHPT patients had significant more 
psychic symptoms, bone loss and risk factors 
of CVD compared to the controls. 
Q1 
Wermers50 1998 
US 
Population-based 
cohort  
Mortality 435 PHPT patients with 126 
being surgically treated 
Overall survival in patients was better than 
expected, higher maximal calcium was an 
independent predictor of mortality as shown 
from adjusted model. 
Q1 
Barletta75 2000 
Italy 
Case-control Cardiovascular function 14 mild asy. PHPT patients 
who underwent PTX with 
matched healthy controls 
(n=20) 
Substantially normal cardiovascular 
morphology and function observed in 
patients compared to the healthy controls.  
Q1 
Smith76 2000 
UK 
Case-control Arterial stiffness (as a 
surrogate for CVD) 
21 mild PHPT with 21 
matched healthy controls 
Increased arterial stiffness were found in 
patients, which may partially account for the 
increased risk of CVD. 
Q1 
31 
Lundgren51 2001 
Sweden 
Longitudinal 
cohort 
CVD mortality 172 hypercalcaemic patients 
with a subgroup of 55 mild 
untreated cases with 
matched pairs 
Increased mortality was observed in patients, 
mainly due to CVD; Despite the majority had 
regressed calcium, age and hypercalcaemic 
were found to be significant risk factors in 
mortality. 
Q1 
Rao36 2004 
US 
RCT Surgery benefits vs. no 
surgery effects 
52 asy. patients randomised 
into surgery (n=25) and 
follow up (n=28) 
PTX improved BMD, some social and 
psychological domains; majority untreated 
patients were stable. 
Q3 
Rubin77 2005 
US 
Cases Arterial stiffness 39 mild PHPT patients with 
134 controls 
PHPT was a significant risk factor of arterial 
stiffness, which is a strong predictor of CVD; 
PTH, but not calcium, was associated with 
the stiffness. 
Q1 
Ayturk78 2006 
Turkey 
Prospective 
observational 
BMD, calcium and 
glucose metabolism 
61 asy. PHPT patients with 
80 healthy controls 
No progression of calcium metabolism 
abnormalities, loss of BMD, insulin sensitivity 
was found in asy. PHPT patients during 18-
month follow up. 
Q1 
Bolland79 2008 
NZ 
Prospective 
longitudinal 
Progression 23 postmenopausal women 
with asy. PHPT 
Many women with asy. PHPT could be 
followed up without surgery as they did not 
develop signs of progression or complications 
in the long-term. 
Q1 
32 
Kepez80 2009 
Turkey 
Case-control Coronary atherosclerosis 
burden 
31 asy. PHPT patients with 
19 matched normotensive 
controls 
PHPT itself was not a risk factor for coronary 
calcification; co-existing CVD risk factors 
might contribute to the risk 
Q1 
Walker81 2010 
US 
Case-control Cardiac structure and 
diastolic function 
54 mild PHPT with 76 
controls 
No evidence of cardiovascular abnormalities 
in patients with mild PHPT compared to the 
controls, but results suggested an association 
between severe hypercalcaemia and/or PTH 
elevation and diastolic dysfunction  
Q1 
Silverberg82 1996 
US 
Prospective 
cohort 
Vertebral bone loss 22 PHPT patients with low 
lumbar spine BMD, 14 were 
surgically treated 
PTX significantly increased the BMD in the 
lumbar spine; Stable BMD in those un-
operated during the 4-year observation. 
Suggested vertebral osteopenia as an 
additional PTX criterion based on the great 
gain after surgery. 
Q1 
Q2 
Q3 
McDermott83 1994 
US 
Cross-sectional BMD 59 mild PHPT patients (16 on 
estrogen replacement 
therapy (ERT)) and 129 
controls (45 on ERT) 
Patients with mild PHPT resulted in bone loss 
in lumbar spine and femoral neck; ERT 
ameliorated the loss. 
Q1 
Asy.: asymptomatic; sym.: symptomatic 
33 
Q1. Adverse outcomes associated with mild/asymptomatic PHPT, including disease 
progression, mortality and co-morbidities. 
 
The majority of PHPT patients are now categorised as “mild” cases, with no 
apparent symptoms as shown in the traditional form, although some signs or 
symptoms that may be attributable to the condition are usually uncovered in a 
detailed clinical history review.
84
 Non-specific symptoms often include patients‟ 
reported weakness, fatigue, muscle and bone aches, intellectual weariness, and 
sometimes even depression, but such symptoms are common in the general 
population. Existing evidence of the long term outcomes associated with mild PHPT 
is, however, conflicting (Table 2.1). A recent review (Mihai, 2008) of asymptomatic 
PHPT which covered long-term outcomes associated with PHPT, including CVD, 
mortality, fractures and QoL, concluded that due to the variations in study designs, 
small numbers and limited scopes, large multi-centred observational studies are 
needed before definite associations between asymptomatic PHPT and adverse 
outcomes, as shown in the severe type, can be drawn.
85
  
 
Progression 
Asymptomatic PHPT has been recognised since the 1970s. In an early study 
assessing the metabolic effects of PTX, Kaplan et al. (1976, US) evaluated the bio-
markers pre- and post- operatively in patients with asymptomatic and symptomatic 
groups separately.
61
 They disclosed biochemical evidence of low BMD (67%), high 
bone turnover (67%) and impaired renal function (33%) in the asymptomatic group, 
34 
who were patients free from nephrolithiasis or metabolic bone symptoms, 
comparable to the symptomatic group. PTX improved the condition in both groups. 
The small number (six asymptomatic and seven symptomatic patients only) limited a 
definite conclusion, but their results suggested the possible existence of adverse 
effects, which could be largely reversed by PTX, in asymptomatic PHPT patients. 
Another 10-year study (Scholz, 1981, US) that followed up 147 asymptomatic PHPT 
found 23% required PTX due to disease progression, including signs of bone mass 
loss and hypercalciuria, and 12% had an increased calcium level.
15
 Age was found to 
be the only predictor of progression.
86
 Evidence also found that these patients tended 
to have lower quality of life (QoL) and more psychological symptoms compared to 
healthy subjects.
74, 87
 A case-control study (Lundgren, 1998, Sweden), which 
evaluated the signs and symptoms in 102 mild PHPT with comparison to matched 
controls, found substantially lower bone mass content (BMC) at all measured sites 
(total body, lumbar spine, cervical neck, Ward‟s triangle and trochanter region) in 
patients.
74
 Despite the majority reporting no symptoms and having a similar overall 
score as reflected by the Comprehensive Psychopathological Rating Scale (CPRS), 
patients did have more complaints of fatigue and weakness and their bio-markers 
showed increased risk factors of CVD, as compared to the controls. 
 
Some studies, however, showed that most patients with mild PHPT nowadays do not 
progress adversely in the long-term.
10, 36, 37, 51, 88-90
 Rohl et al. (1981, US) followed 
30 older patients who did not undergo PTX because of age or lack of symptoms for 
three years and found no deterioration in clinical or biochemical status.
90
 Bollerslev 
35 
et al. (2007) observed patients with mild PHPT for a decade and found their calcium 
and PTH levels remained stable with no obvious deterioration in bone mass.
37
 
Another long-term study (Bolland, 2008, NZ), which followed 23 postmenopausal 
women with asymptomatic PHPT for up to 10 years, found that most patients were 
stable with no signs of progression for up to 8.5 years, although a few had some 
complications.
79
 This lack of progression was also confirmed in other studies.
55, 73, 90-
94
 These results suggested that patients can be successfully managed by clinical 
observation rather than PTX. If, however, the 2002 NIH criteria had been applied to 
Bolland‟s cohort, the majority (82.6%) would have met the surgical criteria. Thus, 
Bolland et al. concluded that such criteria might cause unnecessary intervention in 
these asymptomatic patients.
79
 
 
Cardiac function 
Hypercalcaemia has been shown to be associated with hypertension, left ventricular 
hypertrophy (LVH), arrhythmias, myocardial infarction (MI) and calcification of the 
myocardium, heart valves and coronary arteries.
51, 95-97
 PTH has direct positive 
chronotropic and medicated inotropic effects on the heart and increased PTH levels 
also have shown to be associated with the development of LVH.
50, 98-100
 Thus, the 
nature of PHPT, i.e. raised serum calcium with inappropriately elevated PTH, makes 
a potential effect of PHPT on the cardiovascular system a reasonable hypothesis. In 
fact, in a review in 2004, Andersson et al. has summarised that several forms of 
heart disease appeared to be associated with PHPT.
101
 But studies showed PHPT 
increased risk of mortality due to CVD and malignancy were mainly in patients with 
36 
higher quartile of calcium level, and no causal relationship could be established with 
calcium concentrations
51, 95, 97, 99, 102-109
 Such association was unclear in patients with 
only slightly elevated calcium levels. 
 
A case-control study (Barletta, 2000, Italy) observed the cardiac function in mild 
asymptomatic PHPT patients (n=14) in comparison to matched healthy controls.
75
 
He assessed cardiovascular function by echocardiography, heart rate variability 
(HRV) and QR intervals in the two groups and found the cardiovascular system was 
substantially normal in the patient group, in terms of LV diastolic/systolic diameters, 
LV mass index (LVMI), heart rate, power indices of HRV and QT intervals.
75
 Kepez 
et al. (2009, Turkey) examined the coronary atherosclerosis in 31 mild 
asymptomatic PHPT patients in comparison to 19 matched normotensive controls 
and found no association between hypercalcaemia and the risk of coronary 
calcification.
80
 These authors indicated that the cardiovascular abnormalities 
reported in previous studies might be related to higher calcium levels, the 
coexistence of hypertension, and/or other unknown associated factors. They 
suggested further research in the long-term outcome of cardiovascular function in 
asymptomatic PHPT taking these associated risk factors into account.
75, 80
 Similar 
conclusions were derived by Walker et al. (2010, US), who observed the cardiac 
structure and function in 54 mild PHPT patients in comparison to matched controls 
and found no evidence of cardiovascular abnormalities.
81
 A prospective case-control 
study (Farahnak, 2010, Sweden) observed cardiac structure and function in 51 mild 
PHPT patients with 51 healthy matched controls, and also found normal cardiac 
37 
function and morphology in the patients.
71
 Their results, however, showed 
marginally higher systolic myocardial performance in patients at the baseline, 
suggesting a disease-related inotropic effect, which was reduced after PTX. It is 
worth noting that these studies were either cross-sectional snap-shot
80, 81
 or a single 
post-operative measure made within 6-months to 2-years after surgery;
71, 75
 
therefore, the duration of PHPT in these studies might be too short to show an effect. 
 
Another case-control study undertaken in the UK population (Smith, 2000, UK), 
however, found increased vascular stiffness and indicated this could in part explain 
the risk of CVD, suggesting rigorous management of CVD risk factors in mild 
asymptomatic patients.
76
 A similar study carried out by Rubin et al. (2005, US) 
measured arterial stiffness as a predictor of CVD in 38 mild PHPT patients in 
comparison to 134 controls. The authors found the condition of PHPT itself was an 
independent risk factor of arterial stiffness.
77
 Only serum PTH, but not calcium, 
however, was positively associated with increased stiffness.
77
  
 
Mortality  
Increased mortality has been reported in symptomatic PHPT, mainly due to the 
increased risk of cardiovascular disease, but conflicting results are derived from the 
rising number of studies of the survival and mortality in mild PHPT patients.
23, 24, 26, 
51, 52, 102, 110-114
 Research from Scandinavian systems reported higher mortality in 
patients with PHPT,
24, 26, 113, 115
 but no increased mortality was found in US 
studies.
27, 50
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Hedback et al. (1998, Sweden)
102
 observed  4461 patients who underwent PTX 
between 1987-1994. The authors found a significant increase risk of cardiovascular 
death, compared to the general Swedish population, (relative risk (RR): men 1.71, 
95% confidence interval (CI) 1.34-2.15; women 1.85, 95% CI 1.62-2.11) 
independent of age and gender; but their study did not present calcium level. A 
population-based longitudinal study observed survival in 172 hypercalcaemic 
patients, in whom PHPT was believed to be the main cause of the condition, and 
found an increased risk of mortality, mainly caused by CVD deaths, in patients 
compared to matched controls.
51
 Such increased mortality persisted in a subgroup of 
patients who were followed up to 23 years, greater risk was observed in patients who 
were 70 years or younger at the time of diagnosis (hazard ratio (HR) hypercalcaemia 
1.72, p=0.001; age 1.12, p<0.0001). Based on the findings, the authors were strongly 
against conservative management of even mildly hypercalcaemia patients, 
particularly those younger than 70 years old.  These were however observational, 
and not intervention, studies. 
 
Contrary to the European studies, Wermers et al. (1998, US) studied an inception 
cohort of 435 PHPT over 28 years and found that the overall survival was not 
adversely affected in patients with mild PHPT. They found risk was higher in those 
with more severe disease (as higher calcium), and only age and maximum serum 
calcium were risk factors of mortality.
50
 Such discrepant results were believed to be 
due to the variations in the study populations: patients included in those European 
39 
studies
24, 26, 113, 115
 were often patients with higher calcium concentrations than those 
in the US studies
27, 50
. Over the past four decades, given the clinical scenario of 
PHPT changing towards a mild and asymptomatic form, the connection of mild 
PHPT and increased risk of death including CVD disease is no longer evident. Thus, 
Andersson et al. concluded in their review that proof was lacking to demonstrate an 
association between asymptomatic disease and increased mortality.
101
  
 
BMD and fractures 
Chronic PTH excess increases the rate of bone turnover; its effects on bone may be 
catabolic or anabolic, depending on the age of the patient, the skeletal site, and the 
pattern of serum concentrations of the hormone over time.
116, 117
 Studies have 
suggested an accelerating loss of BMD in PHPT patients, which may lead to 
osteopenia, in particular at cortical sites such as the forearm. This is probably 
associated with a relatively small increased risk of forearm and spine fractures but 
not all studies agree on this.
54, 118-120
 In general, persistently high PTH has catabolic 
effects on bone, whereas intermittent pulsatile release of PTH has anabolic effects.
50, 
121
 However, conflicting results are shown regarding the incidence of fractures 
among these patients.
122
 Most studies showed no significant difference in BMD loss 
or overall risk of bone fractures in patients with untreated mild PHPT.
73, 89, 119
 
 
A longitudinal study (Silverberg, 1995, US) following 128 patients for up to 7 years 
found that patients had low BMD at baseline, but both biochemical indices and 
BMD (in lumbar spine, femoral neck, and radial bone) measurements were stable in 
40 
the untreated group (n=66).
73
 A third (n=24) of the untreated patients developed 
signs that met the NIH criteria for PTX but the majority met only the age or calcium 
criterion. The authors concluded that untreated mild PHPT did not lead to 
progressive bone loss, as reflected by the BMD measurements. Ayturk et al. (2006, 
Turkey) examined the calcium metabolism and BMD in 61 asymptomatic PHPT 
patients at six-month intervals for 18 months and also found no progression in 
patients during the study period in comparison to the matched controls.
78
 
 
Studies that did show adverse bone involvement in mild PHPT often reported low 
BMD at the baseline. Bilezikian et al. (1991, US) and Zoehrer et al. (2008, US) 
showed high bone turnover and low bone mineralisation.
123
 
124
 McDermott et al. 
(1994, US)
83
  found bone loss in the lumbar spine and femoral neck compared to the 
controls in a cross-sectional study. Hasgtrom et al. (2006, Sweden)
67
 demonstrated 
significantly lower BMD in patients with truly mild and asymptomatic PHPT 
compared to age and sex matched controls. In another longitudinal study, Rubin et 
al. (2008, US) followed a group of 116 mild PHPT patients for up to 15 years (n=51 
(51%) being surgically treated).
69
 Lumbar spine BMD remained stable but decreased 
BMD were observed at all cortical sites. The majority (85%) of patients were 
asymptomatic, 37% showed progression, but the surgical criteria did not predict 
such progression. Although no significant BMD change was found in most 
asymptomatic PHPT without PTX, Silverberg et al. (1999, US)
89
 indicated a 
tendency of bone loss in menopausal women if left untreated. This seems to suggest 
that a biphasic bone effect is more appropriate in describing the bone involvement in 
41 
patients with mild PHPT, i.e. an initial low BMD at the baseline with no further 
deterioration. Thus, in a recent review, Sankaran et al. (2010, NZ) suggested that 
immediate intervention was not required in patients with mild PHPT, as the decrease 
in BMD was slow or stable in these patients, despite the fact that low BMD in the 
lumbar spine, femoral neck and forearm were repeatedly present at baseline.
70
 
 
BMD has been used for the assessment of fracture risk
122, 125
 but the varying findings 
from existing studies have made a true association between risk of fracture and 
PHPT uncertain.
55, 126-133
 Erlichman et al. (1996, US) specifically reviewed evidence 
on fractures and PHPT and concluded that existing studies provided controversial 
results
62
: some showed increase in fractures in patients with PHPT
27, 119, 120
, while 
others did not
54, 93, 134
. Such discrepancies were summarised as due to the variation in 
patient selection criteria and nutritional status.
129, 135, 136
 
 
In a population-based study, Khosla et al. (1999, US) evaluated the risk of fractures 
among 407 patients diagnosed with PHPT during a 28-year period (1965-1992).
119
 
Patients were relatively mild with a mean of the maximum calcium at baseline of 
2.725 +/- 0.15 mmol/l and a mean age of 58.5 years (range 18.5-89.4). In total, there 
were 471 fracture events observed during 5766 person-years. Overall, they found the 
risk of bone fractures in patients with mild PHPT was similar to matched normal 
subjects, but a significantly increased risk in the vertebral bone. The standardised 
incidence ratios (SIRs) of fractures at the sites of vertebral, distal forearm and 
proximal femur were significantly higher compared to that of the general population, 
42 
as well as to that of the total fractures (SIR (95% CI) = 3.2 (2.5-4.0); 2.2 (1.6-2.9); 
1.4 (1.0-2.0); 1.3 (1.1-1.5) respectively). In a multivariate Cox proportional analysis, 
only age and female gender were significant risk factors. The authors suggested 
careful evaluation of the skeletal involvement in patients with mild PHPT and 
recommended early surgical treatment in those with significant bone loss.  
 
Interventional studies have demonstrated sustained effects of PTX on increasing 
BMD in patients with PHPT
69, 82, 89
 and some demonstrated a decline in fracture rate 
after PTX.
119, 120, 137
 In these studies PTH is given therapeutically in a daily bolus 
and not with a sustained increased plasma PTH level as happens in PHPT.  It 
remains unclear whether surgery will reduce the risk of fracture compared to 
medical observation.
37
 
 
Renal stones  
Impaired renal function is another adverse endpoint which has been shown to 
deteriorate in patients with symptomatic PHPT. Its association with mild PHPT has 
not been ascertained. A mild decrease in renal function has been reported, from 0%-
11% of the asymptomatic PHPT patients.
90-94, 138
 Mollerup et al. (2002, Denmark) 
followed up 674 surgically verified PHPT patients, each of whom was matched with 
3 age- and sex- adjusted controls at a tertiary hospital setting in Denmark. An 
increased risk of renal stone episodes was found in PHPT patients pre-operatively 
compared with post surgery (Before: RR=40 95% CI, 31 - 53; After: RR=16, 95% 
43 
CI, 12 - 23). Preoperative stone event is the most significant predictive risk of 
postoperative stones. The authors concluded that the risk of renal stones is increased 
in PHPT patients, decreased after surgery, and normalised 10 years after surgery.
139, 
140
 Their findings were in accordance with previous studies, which showed a mild 
decrease in renal function in up to 10% of asymptomatic PHPT patients.
90-93, 138, 141
 
Other studies, on the other hand, showed little deterioration of renal function in 
patients with mild to moderate symptomatic PHPT, when the renal function is 
initially normal.
90, 91, 94, 142, 143
 Whether cases are representative of PHPT or selective, 
and what the controls are, are key questions to explain this discrepancy 
 
Other endpoints 
In the process of this literature review, some other endpoints also appeared to be 
associated with mild PHPT, these being QoL and neuropsychological features, 
diabetes and thyroid disease, and breast cancer. 
 
QoL and neuropsychological features 
Health related QoL was often lower in patients with mild PHPT compared with 
healthy subjects;
87
 in addition, PHPT patients also reported more psychological 
symptoms and subtle neurological components compared to the matched controls.
68, 
74, 144
 Okamoto et al. (2002, Japan) followed 26 mild PHPT patients for 2 years and 
found psychological distress as shown by the General Health Questionnaire (GHQ) 
score in comparison with a non-case group.
64
 In a randomised trial (Bollerslev, 
44 
2007, Sweden), patients with mild asymptomatic PHPT showed more psychological 
symptoms compared to the normal matched controls.
37
 These features, however, 
were often subtle and subjective, and solid evidence was lacking. 
 
Diabetes and thyroid disease in PHPT 
Taylor et al.(1991, UK) looked at the prevalence of diabetes in 205 PHPT patients 
and found significantly greater prevalence of known diabetes than in a series of 200 
consecutive non-PHPT outpatients from the same unit.
145
 A higher prevalence of 
PHPT in patients with Type 2 diabetes and/or thyroid disease was also found in 
some other studies.
146-148
 Whether or not these are just co-existing conditions is 
unclear, as there is no established causal relationship. 
 
Breast cancer 
Michels et al. (2004, Sweden) conducted a follow-up study using Swedish Cancer 
Registry data (1958-1997) to examine the coexistence of PHPT and breast 
carcinoma.
149
  A greater incidence rate of breast cancer was found in the 9835 
women (99,929 person year) who underwent PTX compared to the standard 
population (SIR=1.27 95% CI, 1.14-1.41). 
 
Section summary 
Over the past four decades, given the clinical presentation of PHPT changing 
towards the mild and asymptomatic form, the connection between mild PHPT and 
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increased mortality and co-morbidities is not clearly apparent. Although this chapter 
has sought literature from the 1970s till 2010, solid proof is still lacking to 
demonstrate any increased risk associated with mild PHPT. As suggested at the third 
NIH consensus workshop, large long-term population-based studies are needed to 
address these issues pertinent to the condition of mild PHPT.
150
 
 
Q2. Existing surgical criteria on mild/asymptomatic PHPT – how they are formed 
what are the views about them? 
 
As described in Chapter 1, the entry criteria for PTX were recommended by the NIH 
consensus panel in 1990 and have been subsequently updated in 2002 and 2009. The 
adequacy of such criteria depends on sufficient evidence of the frequency of disease 
progression in mild PHPT, the risk and success rate associated with PTX, and the 
availability and efficiency of alternative treatments.
57
 This section reviews the 
evolution of these guidelines with the intention of evaluating the appropriateness of 
these set indications based on existing literature. 
 
In the emergence of increasing number of patients with mild to moderate PHPT 
discovered incidentally during biochemical screening, Scholz et al. (1981, US) 
initiated a 10-year prospective study in 1968 at the Mayo Clinic, with the hope of 
formulating surgical criteria through long-term observation.
86
 During the period 
from January 1968 to July 1970, a total of 142 uncomplicated „biochemical‟, or 
mild, PHPT patients (baseline serum calcium <2.75 mmol/l) were selected for the 
46 
study with up to 12 years of follow up. With the absence of standard criteria, the 
authors proposed and used a set of surgical indications (Table 2.2). During the study 
period, 19 (13.4%) patients were subsequently removed from the cohort because 
they either declined further study (n=10) or could not be traced (n=9). Of the 
remaining 123 patients, 32 (26.0%) were deceased, 16 had negative neck exploration 
during the recruiting period, and 33 (26.8%) had undergone PTX by the end of June 
1980, approximately half of them being operated within the first 30 months (n=16).  
The majority of the operated cases either had increased serum calcium (n=8, 24%) or 
presented with renal complications (n=12, 36%). Nearly a third of the unoperated 
(n=12, 28.6%) patients had subsequently decreased calcium during the follow up, 
thus were categorised as indeterminate cases. Scholz et al.‟s work provided probably 
the earliest long-term study on the natural history of asymptomatic PHPT. Their 
results suggested that the signs of surgical indication varied by patients and the 
persistent disease existed only in a sub-proportion of patients, if left untreated. They 
recommended delaying the surgical decision for at least 1 year in uncomplicated and 
asymptomatic PHPT patients and concluded that such patients could be followed 
safely without operation subject to close medical observation. Although Scholz et al. 
have defined rudimentary surgical criteria, they considered formulation of such 
criteria among asymptomatic patients as not possible. 
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Since the symptoms that are associated with mild PHPT are often nonspecific and it 
is difficult to establish the causal relationship, they are not considered as clear 
criteria for surgery, or as providing a definition of the symptomatic condition.
10
 
 
Table 2.2 Criteria for surgical treatment used in Scholz‟s study86 
1. Mean serum calcium > 2.75 mmol/l 
2. Roentgenographic evidence of bone disease 
a. Subperiosteal resorption of phalanges, distal clavicles, or other bones 
b. Fraying, distal phalangeal tufts 
c. Bone cyst (brown tumour) 
d. Osteoporosis with vertebral compression or other bone disease 
3. Decreased renal function 
4. Metabolically active or infected renal lithiasis * 
5. Prolonged observation impractical 
a. Patient cooperation unsatisfactory 
b. Geographic remoteness 
c. Psychiatric complications 
6. Gastrointestinal complications 
a. Peptic ulcer not controlled by medical management 
b. Recurrent or chronic pancreatitis 
*Metabolic activity of renal lithiasis refers to Roentgenographic evidence of new stone formation, 
enlargement of existing stones, or the passage of documented gravel from the urinary tract within 
the previous year. Metabolic activity of renal lithiasis is classified as ‘indeterminate’ if inadequate 
data are available to assess activity and the patient is observed until activity can be established. 
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Subsequent to Scholz‟s work, subsequent studies on asymptomatic PHPT have also 
shed light on the formation of surgical criteria. Van‟t Hoff et al. (1983, UK) 
medically followed up 32 PHPT patients for a mean of 4.2 year and compared their 
outcome with 60 surgically treated PHPT patients (mean follow up 5.9 years).  No 
significant difference was found between the two groups, in terms of BP and renal 
function (as measured by creatinine). Patients who were followed up medically had 
stable BP, renal function and no deterioration of serum calcium. Thus the authors 
suggested asymptomatic PHPT patients could be safely followed, in particular 
patients over 60 years of age, but recommended surgery for those with calcium 
greater than 3 mmol/l or aged 50 years or less. In 1984, a review by Pearson (1984, 
UK) also recommended observation as adequate management in elderly patients 
with asymptomatic PHPT.
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About a decade prior to the first NIH criteria, Russell et al. (1982, US) evaluated 
surgical outcomes in patients with PHPT. The authors compared the surgical results 
in two sub-groups: those with symptomatic PHPT (serum calcium >2.75 mmol/l, 
n=311) and those with „biochemical‟ PHPT (serum calcium < 2.75, n=84), whom 
they assumed to be asymptomatic.
152
 They concluded that PTX is safe and effective 
with over 90% success rate and recommended surgery for these asymptomatic 
patients. 
 
An update to Rao‟s55 study (1988, US), which added additional 26 asymptomatic 
PHPT patients (baseline serum calcium 2.75 mmol/l) to the original cohort (n=86) 
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for up to 11 years of follow up, revealed almost identical results to previous 
findings.
153
 All observed biochemical measurements, such as serum calcium, PTH 
and creatinine, appeared to be stable during the course of the study. Although BMD 
was significantly reduced at the time of diagnosis, no further acceleration of bone 
loss was observed. Parfitt et al. indicated that their study data had not supported the 
common reasons for advising PTX in asymptomatic patients. Instead of favouring 
definite surgical criteria, they reinforced their specific criteria, set in 1975, for 
withholding surgery in asymptomatic patients, as little progression was seen. Their 
criteria for withholding surgery were: 
 
Absence of relevant symptoms, current stone disease and radiographic osteitis 
fibrosa cystica; 
Plasma calcium < 3.0 mmol/l; 
Plasma creatinine < 133 umol/l and 
Forearm BMD not more than 2.5 SD below the age and sex specific mean value. 
 
By the end of 1990, however, the urge for developing standard surgical criteria was 
increased as studies were offering discrepant opinions. Potts (1990, US) reviewed 
existing evidence regarding asymptomatic PHPT and summarised that hypertension 
and psychiatric symptoms should not be used as indications due to the limited scope 
of the then current findings. He suggested premenopausal women and patients with 
serum calcium greater than 3 mmol/l should be treated for PHPT and agreed that 
50 
younger patients should also be treated surgically. In addition, regarding the possible 
bone involvement and renal features, he listed the following as probable indications: 
 
1. Low cortical or trabecular bone mass (<2-2.5 SD below mean adjusted for 
age); 
2. Kidney stones (recurrent); 
3. Pancreatitis. 
 
With the implications that asymptomatic PHPT may differ from its classic form and 
thus not be prone to the same adverse outcomes or subject to non-traditional 
complications, treatment policies derived from the traditional form could not be 
assumed without proof.
153
 The first NIH consensus conference on the management 
of asymptomatic PHPT was convened in 1990 with the aim of formulating optimal 
management of this non-traditional form.
154, 155
 Based on pre-existing evidence from 
observational studies and the experiences and expertise from the multi-disciplinary 
panel, the first NIH criteria for surgical recommendation in patients with 
asymptomatic PHPT were developed. These were viewed as reasonable but 
conservative indications. At the conference, the panel agreed that a sub-group of 
patients with PHPT could be safely followed, but indicated that all patients should 
be considered as candidates for surgery.
155
 They suggested that asymptomatic 
patients who had markedly elevated serum calcium, presentation of potential renal 
complications, or substantial loss in bone mass or young patients, should be 
recommended for surgery. The panel acknowledged that existing data were 
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insufficient to quantify the thresholds for surgery and required that any surgical 
decisions should be made on a case-by-case basis; however, they provided 
quantified recommendations which should be subject to further justification (Table 
2.3). These criteria formed the first NIH guidelines to aid medical decision making 
in the face of asymptomatic PHPT patients. 
 
Table 2.3 1990 NIH criteria for surgical treatment 
An elevation of serum calcium of 0.25 to 0.4 mmol/l above the upper limit of normal range; 
A creatinine clearance reduced by 30% compared with age-matched normal persons; 
A confirmed 24-hour total urine calcium excretion of more than 400 mg; 
A bone mass of more than 2 SDs less than those matched persons; 
Age younger than 50 years 
In addition, surgery should be considered when medical surveillance is not desirable or suitable, or 
when patients request surgery, or when co-existing illness complicates medical management. 
 
 
In 1995, Strewler reviewed these indications and summarised that
156
: 
 
Serum calcium alone should not be used as a surgical indication as most minimally 
symptomatic patients did not have increasing calcium during long-term follow-ups.  
 
Renal insufficiency as presented by an increased serum creatinine level or decreased 
creatinine clearance is generally an indication, as it was shown to be more prevalent 
in PHPT patients than in controls and such patients were more prone to having 
progression of renal dysfunction; 
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Regarding the risk of osteoporosis, the author agreed with a biphasic course of bone 
loss in mild PHPT patients, with substantial bone loss prior to diagnosis, particularly 
in cortical and cancellous bones, but no detectable tendency of worsening after 
diagnosis. Despite this as a possible comfort for surgeons in deciding not to operate 
on these patients, the author also identified significant beneficial effects on bone 
mass in these patients post-operatively. Thus, he recommended the relationship 
between bone density and fracture risk should be further studied before deriving any 
decision; 
 
Hypertension should not be used as an indication, as, although common, the 
reversibility after PTX was not clear; 
 
Although improved survival after successful PTX has been demonstrated, the 
possibility of increased mortality cannot be used as an indication. Age under 50 
years is a transformed criterion to reflect the possible survival benefits of surgery, as 
younger patients have a longer life-expectancy; 
 
Other neuromuscular and psychiatric signs, which have shown in patients with mild 
PHPT, can also not be used as indications, unless the placebo effects of surgery can 
definitely be removed. 
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In addition to the NIH criteria, the author considered the experience and expertise of 
the parathyroid surgeon as being the paramount and key factor in making the 
decision for surgical treatment, as both the success and the complication rates varied 
substantially between experienced and inexperienced surgeons. 
 
In a four year prospective study, Silverberg et al. (1996, US) followed 22 PHPT 
patients with low lumbar spine BMD at the baseline and found a remarkable 
increase in lumbar spine BMD in the 14 patients who had been surgically treated.
82
 
Thus, in addition to the 1990 NIH guidelines for surgery, the authors proposed 
markedly reduced cancellous bone density as another criterion to be considered. 
 
Another subsequent review of the first NIH criteria was carried out by Sliverberg et 
al. (1999, US) summarising data arising between 1990 and 1999.
157
 They suggested 
three potential groups who may benefit from surgery: patients with vertebral 
osteopenia, patients with vitamin D deficiency, and perimenopausal women. 
Regarding the increased mortality risk, the authors stated that Swedish studies 
showed a 1.5 times risk of death compared to that of matched controls
52, 115
 but as 
over half of the survivors did not show consistent hypercalcaemia they concluded 
that such risk might have been under-estimated due to over-diagnosis. Another large 
study showed gradually declining mortality after PTX
23
 and demonstrated a 
statistically significant reduction in mild hypercalcaemic patients, suggesting greater 
benefits might exist for these mild cases than for those with classic hypercalcaemia. 
The authors, however, acknowledged the existence of over-diagnosis and 
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recommended at least a one-year follow up in mild patients before choosing surgery, 
to remove confounding diagnoses. Although the 1990 NIH consensus conference 
justified conscientious surveillance in a sub-proportion of mild PHPT patients who 
did not meet the proposed criteria, the authors recommended PTX for all patients 
with a definite diagnosis of PHPT, as they considered the benefits of experienced 
surgeons overweighed both the risks and the expense involved in rigorous follow-up. 
 
In a prospective study, to evaluate the appropriateness of including age as a surgical 
criterion, Silverberg et al. (2002, US) observed disease progression in patients aged 
under 50 years compared to those over 50.
158
 Of the 121 patients enrolled in their 
study, 37 (30.6%) were younger than 50 years at the time of diagnosis. Over half of 
the asymptomatic patients who were under 50 years of age developed further 
indications for surgery other than age and the percentage of asymptomatic patients 
who had progressive disease was significantly higher in the younger patients, 
compared with older. These results indicated that asymptomatic PHPT is a disorder 
that is „worse‟ and more likely to progress in younger patients and supported the 
inclusion of age as a criterion for surgery. 
 
In a comprehensive review of the 1990 NIH statement incorporating evidence from 
subsequent studies, Bilezikian et al. (2002, US) proposed areas for further research 
and for modification of the original guidelines, which formed the basis of the second 
NIH workshop on the topic.
48
 In April 2002, the 1990 Consensus Development 
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Panel convened the second conference, during which the existing surgical criteria 
were reviewed item by item.
5
 Changes were made as follows: 
 
1. Serum calcium concentration criterion was lowered from 0.25-0.4mmol/l to 
0.25mmol/l above the upper limit of the normal range. The panel agreed that 
patients might still remain asymptomatic when calcium is greater than 0.25 
above normal, but believed these patients would be at greater risk of 
progression and complications. 
 
2. The bone density criterion was changed to a greater than 2.5 SD reduction in 
bone mass at the lumbar, spine, hip, or distal radius, compared to sex- and 
race- matched reference, using the t-score. This was to reflect newer data 
indicating that the BMD reduction predicts fracture risk in PHPT patients 
and t-score, which reflects frank departure from peak bone mass, and was 
consistent with the newer WHO definition of osteoporosis. 
 
Other criteria remained unchanged. A 24-h total urinary calcium excretion of greater 
than 400 mg stayed unchanged as an index for the risk of renal stone formation. 
Creatinine clearance reduced by 30% compared with age-matched normal person as 
a surrogate measurement for renal function was also unchanged. In addition, 
possible factors, such as neuropsychological dysfunction, menopausal status, CV 
abnormalities, gastrointestinal symptoms, and serum or urinary indices of bone 
metabolism, which had been suggested from studies, were also considered. Due to 
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the inherent uncertainty, however, the panel recommended these should NOT be 
used as sole criteria, but could be used to support decision-making. 
 
Although the second NIH criteria had incorporated the newer evidence from 
literature, they were still challenged. In a prospective study, Eigelberger et al. 
demonstrated that patients who did not meet the NIH criteria benefitted equally from 
PTX as those who met the criteria and concluded all patients with PHPT, regardless 
of the NIH criteria, will achieve improved survival and symptomatically and 
metabolically benefits.
159
 
 
When the NIH surgical criteria were reviewed by a survey study of the American 
Association of Endocrine Surgeons (AAES), Kouvaraki et al. (2006, US) concluded 
that over 80% of the surgeons would operate on asymptomatic patients who did not 
meet the NIH criteria but had shown subjective symptoms.
160
 Surgeons who would 
operate on all patients, regardless of the objective parameters, were those with high-
volume practices (>30 PTXs per year). This, to an extent, reflects Strewler‟s156 view 
that surgeons‟ experience is another key component in decision making.  
 
Based on the 2002 NIH criteria, Zanocco et al. (2006, US) built a hypothetical 
decision-tree model to assess the cost-effectiveness of PTX, medical observation and 
pharmacologic therapy in asymptomatic PHPT patients.
161
 They found that, using 
the incremental cost-effectiveness ratio (ICER) per quality adjusted life year (QALY) 
gained, PTX was the most cost-effective strategy and recommended PTX as an 
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effective treatment in these patients, even when the NIH criteria were not met. A 
further Markov decision model was established by Zanocco et al. using 50-years of 
age as the cut-off for surgery.
162
 The authors found surgery to be effective for life 
expectancies between 6.5 and 75 years for inpatient PTX and 5 to 75 years for 
outpatient PTX, and concluded that surgery might not be a cost-effective option for 
patients who are aged over 80. 
 
In order to determine if patients differ pre-operatively or post-operatively between 
those who meet the NIH criteria and those who fail to meet them, Eigelberger et al. 
(2004, US) carried out a prospective study.
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 During the period of September 1996 
to December 1999, 178 PHPT patients who underwent PTX and 63 thyroid controls 
who had non-parathyroid neck surgery were followed up to 3 years.  Of the total 
PHPT patients, 103 (57.9%) met the 1990 NIH criteria. For all participants, 
complete questionnaires comprising of 14 symptoms and 9 conditions that were 
viewed to be associated with PHPT were collected pre- and post- operatively.  
Compared to the thyroid controls, patients with PHPT, in general, had more self-
reported symptoms and conditions pre-operatively, which were significantly 
improved after surgery. In the subgroup analysis, apart from being significantly 
older with a higher percentage of self-reported pruritus, the non-NIH patients did not 
differ from the NIH patients in all other baseline characteristics and symptoms. The 
two groups were also similar in 4 of the 6 conditions at the baseline. The higher 
percentage of hypertension in the non-NIH group could be explained by the older 
age, and nephrolithiasis as one of the NIH criteria accounted for its higher incidence 
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in the NIH group. The two sub-groups had similar improvements in all symptoms 
post-operatively. The authors also applied the 2002 NIH criteria to the cohort and 
found similar results, thus they concluded that virtually all patients with PHPT, 
regardless whether they met the NIH criteria or not, should be recommended for 
surgery because of the equal benefits consistently demonstrated from the two-
subgroup analyses. 
 
In response to the first two NIH guidelines, Walker et al. reviewed existing evidence 
on the neuropsychiatric features in comparison to bone involvement.
163
 They stated 
that, unlike BMD, the current surgical findings on QoL and psychiatric symptoms in 
patients with mild PHPT should not be used as indications for PTX, as the clinical 
relevance of such changes was unclear due to the limitations of their study designs, 
sample sizes and inclusion criteria. 
 
Since 1990, a rising number of studies have been carried out in line with the further 
research area recommended by the Consensus Development Panel and an immense 
amount has been learned on the nature of asymptomatic PHPT. In May 2008, the 
third NIH conference was convened and the entry criteria for PTX were reviewed to 
more accurately reflect the modern PHPT.
43
 Although some evidence has shown 
calcium as not reflecting disease severity
60
 and some showing no adverse effects on 
mortality in PHPT patients
50, 164
, the calcium remained as a surgical criterion. The 
panel, accepting that the increased mortality shown in several European studies
23, 24, 
52, 98, 102, 115
 was as a result of higher calcium in their patients than that in the US 
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population
50, 164
, believed an elevation of 0.25 mmol/l in calcium indicated greater 
risk. Age limit also remained unchanged in the new guidelines but hypercalciuria 
was no longer an indication for surgery and the threshold for creatinine clearance 
was changed to 69ml/min. The panel acknowledged the primacy and increasing 
favour for surgery because new data demonstrates that bone density is not 
indefinitely stable with up to one third of the untreated patients having progressive 
bone loss and consistent increases in BMD after PTX had been well documented.
36-
38, 63, 67, 69, 70
 Thus, in addition to the existing criterion on BMD, previous fracture 
fragility was also included as a surgical indication. Well-controlled randomised 
prospective studies are, however, needed regarding the CVD presentations and other 
reversible neurocognitive elements, before they are used in decision-making.
165
  
 
Despite the fact that NIH guidelines have been updated twice to encompass new 
knowledge gained in the past 4 decades, controversy remained as to how the 
condition should be managed. Although surgery is the absolute cure for PHPT with a 
high success rate if excised by an experienced surgeon, decisions on the need for 
surgery still differ: some advocate PTX being generally offered to all patients, even 
in the absence of classic symptoms; others think truly asymptomatic patients can, 
however, be safely followed as recent data has suggested.
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To 
illustrate this variation, Appendix 2 summarises surgical indications (or baseline 
characteristics of surgically treated patients) from existing studies. To what extent 
the post operative improvements are worth the risk of surgery in mild PHPT 
patients, who are apparently healthy subjects, remains to be established, this section, 
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however, concludes that surgical decisions should primarily lie on an optimal 
balance between individual patient‟s potential health outcome gain and the effects of 
alternative treatment, as summarised by Gittoes et al. (2010, UK). (Figure 2.2) 
 
Figure 2.2 A balanced overview of factors influencing the management of mild 
PHPT 
 
Note. The figure is adapted from Gittoes et al. (2010, UK).
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PTX No PTX 
 Old age 
 Short life expectancy 
 High operation risk 
 Patient’s preference 
 Low fracture risk 
Surgical experience 
? Risk of CVD  
? Risk of malignancy 
 Young age 
 Long life expectancy 
 Low operation risk 
 Patient’s preference 
 Risk of bone disease 
 Risk of renal complications 
 Neuropsychiatric worsening 
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Q3. Surgical outcomes – are the adverse endpoints, if any, reversible after surgery? 
An obvious benefit of the operative management is that it instantly lowers the 
biochemistry indices compared to other options and relieves symptoms.
38, 75
 Another 
significant outcome of PTX, as mentioned previously, is its sustained effect on 
increasing BMD. Nonetheless, studies have reported that such an effect is limited to 
certain sites.
36, 73, 120, 168
 Other expected benefits in renal function, cardiovascular 
disease and psychological function have also been shown from different studies. 
These, however, may be biased due to the study design, small sample size or limited 
follow-up period as an invasive intervention needed to be applied to generally 
healthy subjects. In addition, these impacts of surgery are diminished to some extent, 
due to the fact that most untreated mild asymptomatic patients remained stable in 
prolonged follow-up studies. Observational studies to date have provided valuable 
information to help in understanding the condition of mild PHPT, such as its natural 
history but RCT is the gold standard design in detecting any causal-relationship, 
which is particularly useful in assessing surgical outcomes and associated 
symptoms. There have been five such RCTs, to date, investigating the surgical 
outcomes in patients with mild PHPT compared to those who were followed up 
without surgery, which are firstly described in detail. The second part of this section 
summarises key findings from other studies which addressed PTX outcomes by 
specific endpoint. 
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RCTs 
Talpos et al. (2000 US) undertook an RCT to evaluate the surgical effects on 
patients‟ QoL, using an SF-36 questionnaire. Using extensive measures, 53 eligible 
patients with asymptomatic PHPT (baseline serum calcium 2.58 SD=0.14) were 
selected, between April 1994 and March 1997, to participate in this 2-year follow up 
study.
169
 Of these, 25 were randomised to surgery and 28 to observation. They found 
favourable surgical effects in 2 out of the 9 domains and approximately 10% of 
patients in the observation group showed evidence of progression. Based on the 
study results, they recommended surgery to be performed at the time of diagnosis for 
all asymptomatic patients. Such a conclusion is, however, subject to further 
investigation, as their results also suggested that both groups had a negative change 
in most of the other domains that were measured.  
 
Rao et al. (2004, US) undertook an RCT, in order to evaluate the role of PTX in 
patients with mild asymptomatic PHPT.
36
 They followed 53 patients, who were 
randomised to either having PTX (n=25) or being followed up without surgery 
(n=28), for 2-4 years with BMD and biochemical indices being measured at baseline 
and subsequently, at 6-month intervals. Quality of life, both physical and 
psychological well-being, was assessed using a standardised form (SF-36 and SCL-
90R). At baseline, there was no significant difference between the two groups 
(demographic, BMD and biochemical records), except for an obvious but not 
significant older mean age in the PTX group. Serum calcium and PTH were both 
significantly decreased in the PTX group after surgery. Changes in BMD were 
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significant in total hip and forearm sites but not in spine or femoral neck (for which 
gain in BMD at those sites was found in both groups). Surgical benefits were also 
shown as regards quality of life in the PTX group, plus significant improvements 
found in social functioning, emotional problem, anxiety scale and the phobic anxiety 
scale. In summary, they confirmed the feasibility of conducting RCTs of surgery in 
mild PHPT patients. Outcome measures showed significant increase in BMD in the 
surgery group only at the femoral neck and total hip. They also revealed benefits in 
favour of surgery in patients‟ social, emotional and psychological functions. 
Nonetheless, some limitations existed in their study: firstly, due to the un-blinded 
nature of the study, the placebo effect could not be precluded; secondly, the majority 
of untreated patients showed no signs of disease progression; thirdly, the 
cardiovascular issue was not addressed in the study. 
 
Bollerslev et al. (2007 Sweden) performed a 2-year RCT evaluating outcomes in 
116 mild PHPT patients (baseline serum calcium 2.69+/- 0.11 mM) who were 
randomised to either observation or PTX treatment.
37
 They measured serum calcium, 
PTH, BMD, a panel of bio-markers for bone turnover and a variety of measures of 
the metabolic syndrome, adipokines and CV risk factors, at both baseline and 
follow-up period. At baseline, there was no significant difference between groups; 
after PTX, calcium and PTH level were decreased as expected in the surgical group. 
A significant BMD increase in the lumbar spine and a borderline increase in the 
femoral neck were found in the surgical group. The changes were even more 
significant when analysing women separately or excluding patients on 
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bisphosphonates, whereas in the medical group BMD remained stable. No change in 
kidney function (serum creatinine) or blood pressure was observed longitudinally or 
between the groups. They did not find significant alterations regarding patients‟ SF-
36 or CPRS score, nor detectable differences in the metabolic and CV surrogates. In 
the observed group, no deterioration was observed in the parameters measured. 
Based on their findings, PTX was not favoured by the authors, as no disease 
deterioration was noted in the medical observed group. The authors were not 
convinced by these moderate changes, as these might well be because of the placebo 
effect or the non-specific designed nature of the questionnaires and thus, suggested 
further research. 
 
Ambrogini et al. (2007 US) carried out an RCT involving 50 mild PHPT patients 
being randomised to either receive PTX treatment or be followed-up 
conservatively.
38
 The primary outcome was the changes in lumbar spine BMD and 
the secondary outcomes included the changes in total hip and forearm BMD and in 
the quality of life (SF-36). They found that, in patients who did not undergo PTX, 
apart from a small decrease in the BMD at the total hip (-0.015+/-0.005 g/cm2 
P=0.0044), the biochemical profile and the BMD at other sites were stable during 
the 1 year follow up. PTX significantly increased the BMD at lumbar and hip sites, 
however, in the surgical group. Small increases at the femoral neck and trochanter 
were also found in the surgical group but no difference at the distal third radius. In 
addition, improvements in patients‟ general health, vitality, mental health and bodily 
pain were also found in the surgical group. They concluded that PTX might benefit 
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patients with asymptomatic PHPT who did not meet the NIH (the 1990 criteria were 
used) criteria as the results demonstrated improvements in BMD and in some 
parameters of quality of life as reflected in the SF-36 measurements. The study was, 
however, only powered to compare lumbar spine BMD. Its short-term follow up also 
limited the findings of any adverse events for untreated patients.  
 
A recent RCT carried out by Morris et al. (2010, US) examined the effects of 
surgery on physical function in 18 older asymptomatic patients (baseline serum 
calcium =2.59 mmol/l).
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 They found significant a decrease in serum calcium and 
PTH after PTX but no progression on these biomarkers in the group who were 
observed without surgery was found. Using a battery-run physical performance test 
as a surrogate for functional capacity, patients in the PTX group walked for 
significantly longer than the control group (11% further within the tested 6 minutes) 
and a higher percentage of patients in the PTX group achieved clinical significant 
improvement in walking-distance than did the control group. The small sample size, 
however, failed to detect any significant difference in the other two measurements; 
nevertheless, they concluded that surgery improved physical function in older 
patients with asymptomatic PHPT and recommended such patients with serious 
functional deficits to undergo PTX. 
 
Mortality 
The association between mortality and PTX is unclear, especially in mild 
asymptomatic PHPT. Some studies suggested that PTX lowered the overall death 
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rate,
23, 120
 whilst others thought PTX had no effect on overall mortality.
26, 50, 102
 
Nilsson et al. (2002)
110
 examined 10,995 Swedish patients (102,515 patient year) 
who underwent PTX between 1958-1997 using linked Cancer and Causes of Death 
Registries. By the use of the Swedish population as controls, an increased risk of 
postoperative mortality was verified for PHPT patients (SMR=1.2, 95% CI, 1.19 to 
1.27) in both sexes and all age interested groups, where the principle causes were 
cardiovascular disease, diabetes mellitus, and urogenital diseases.  
 
Cardiac function 
Positive effects of PTX on cardiac dysfunction have been indicated in some studies 
but not all. Almqvist et al. (2002, Sweden) randomised 50 patients into PTX at 
baseline (n=25) and PTX after one-year‟s observation and assessed the effects of 
PTX on cardiac function using a combined assessment of equilibrium radionuclide 
angiography at rest and during exercise, plus echocardiography.
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 They found that 
PTX significantly improved cardiac function in both groups and suggested early 
PTX in prevention of left ventricular hypertrophy. A prospective study which 
measured N-terminal pro-B-type natriuretic peptide in patients with mild PHPT, also 
indicated an improvement in heart function post-operatively.
171
 Other studies 
assessing the effects of PTX on blood pressure (BP), however, found no 
improvement in BP post-operatively.
172-176
 Such conflicting findings can also be 
seen in Andersson et al.‟s review, where the authors opined that PTX seemed to 
reduce left ventricular hypertrophy but the process of regression-to-normal took 
years to complete in these patients. 
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BMD and fractures 
A sustained increase in BMD after PTX was seen in a longitudinal study (Rubin, 
2008, US), which followed 116 mild PHPT patients for up to 15 years.
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Valdemarsson et al. (1998, Sweden) performed a longitudinal cohort study to 
evaluate the impact of PTX on bone turnover and found significant improvement in 
those with mild PHPT after surgery.
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 Hagstrom et al. (2006, Sweden) found PTX 
significantly increased BMD in the lumbar spine and also a significant increase in 
the femoral neck for those aged 67 years and under.
67
 A prospective randomised 
study (Almqvist, 2004, Sweden), followed 50 patients with mild PHPT who were 
randomised into PTX at baseline or PTX after one-year operation and found PTX 
increased BMD.
66
 In addition, their results showed an increase in BMD in those 
without evidence of osteoporosis and hip BMD was only increased in the early 
operation group, thus they recommended PTX at baseline regardless of serum 
calcium level. In a recent review (Sankaran, 2010, NZ), the meta-analysis showed 
significant increases in BMD for the lumbar spine and femoral neck.
70
  
 
Although BMD has been reported as increasing in some sites after successful PTX 
repeatedly, it was also pointed out that PTX could not repair the entire bone deficit 
that had already been caused prior to surgery.
49, 89, 157
 In addition, it remains unclear 
whether a benefit in terms of fracture risk reduction is likely to occur after PTX. 
 
68 
Psychological and QoL benefits  
Several studies showed post operative benefits on neuropsychiatric manifestations.
36
 
169, 177, 178
 A modest but significant post-operative beneficial effect on the QoL was 
observed in Ambrogini‟s study.38 A similar finding was also reported by Rao36 in the 
social and emotional domains, as well as in psychological functions. Bollersleve did 
not find any significant benefit from surgery in terms of the emotional role and 
mental health domains.
37
 A potential placebo effect of surgery cannot be excluded, 
since it is reasonable to believe that patients would be expected to feel better after 
operation. Nonetheless, a persistent quality of life improvement 2 years after PTX , 
would appear to diminish the likely placebo effect.
178
  
 
Okamoto et al. (2002, Japan) followed 26 mild PHPT patients for two years and 
found improvement in their psychological distress as measured by the GHQ score 
after PTX.
64
 Tsukahara et al. (2008 Japan) evaluated subjective symptoms and QoL 
in 25 asymptomatic PHPT patients who underwent PTX during October 1995 and 
March 2004.
179
 A non-standard questionnaire, which contains patients‟ perceived 
general health status and 7 neuropsychological aspects, was given to all patients 
before and 1 year after the operation. They found no post-operative changes in all 7 
neuropsychological symptoms, although 52% of the total patient group felt an 
improvement in their general health. It should, however, be noted that because of the 
non-standard questionnaire and scoring system they used, the generlisability and 
comparability of their results were limited. 
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Ljunghall et al. carried out a longitudinal study of patients with mild PHPT 
identified from a nation-wide screening in Sweden prior to the first NIH consensus 
meeting. In a subgroup of 59 patients who were subsequently operated on, patients 
showed significantly more psychiatric symptoms as measured by the Hopkins 
symptoms checklist (HSCL-56), such as fatigue, sadness, anxiety and 
aggressiveness, pre-operatively, which were all improved post-operatively.
115
 
Another prospective cohort study (Jarhult, 2008, Sweden) evaluated self-reported 
symptoms relating to QoL in patients with mild PHPT before and after PTX, as well 
as before and after neck surgery in matched thyroid controls, found significantly 
more subjective symptoms in patients with mild PHPT compared to the controls but 
PTX improved most of them.
68
  
 
Although most of these studies have suggested improvements in a number of 
psychological and QoL symptoms post-operatively, a true demonstration of the 
effects of PTX on these subtle subjective variables would require more rigorously 
controlled studies. 
180, 181
 
 
Section summary 
The findings of this section suggested that although surgical complications can be 
minimised when excised by an experienced surgeon, the extent to which the benefits 
in QoL, psychological function, BMD and other non specific symptoms, outweigh 
the possible risks of surgery still remains to be established. More rigorous 
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quantitative assessment of surgery outcome measures is needed, in order to resolve 
the current conflicting evidence.  
 
2.5 Conclusions 
The clinical manifestation of PHPT has changed dramatically over the last four 
decades. Whether asymptomatic PHPT has increased risk of the adverse endpoints, 
as seen in advanced PHPT, remains controversial. PTX is the only definite 
treatment; the value of this surgical option in mild or asymptomatic patients has 
been a matter of debate due to the equivocal causal relationship between adverse 
endpoints and this mild asymptomatic form. Existing literature have been consulted 
in order to try to  reveal an accurate presentation of PHPT nowadays and also to try 
to identify to what extent patients with asymptomatic PHPT should contemplate the 
risk of undergoing surgical treatment.  The results are, however, conflicting and 
confusing. It is, therefore, a challenge for this thesis to provide an up-to-date and 
accurate understanding of contemporary PHPT, using large population-based data, 
which covers the past decade. 
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CHAPTER 3  
DESCRIPTION OF DATABASES AND METHODS 
 
3.1 Overview 
This chapter will describe the various databases required in this project and give an 
overview of the methods used in analyses. A brief introduction of the data provider, 
HIC, the data available in Tayside and the principle of record-linkage, will firstly be 
described. The databases will be described individually in terms of what they are and 
how they will serve this project. The latter part of the chapter will discuss the 
methods adopted for the project.  
 
3.2 Tayside healthcare data and record linkage 
3.2.1 Health Informatics Centre (HIC) 
HIC is a partnership between the University of Dundee, National Health Service 
(NHS) Tayside and the Information and Statistics Division Scotland (ISD) (part of 
NHS National Services Scotland).
182
 HIC provides researchers with anonymised 
health information derived from person-specific data sets, sourced from the NHS, 
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the University of Dundee and others, to help in the answering of research questions. 
It is at the heart of this pioneering work and provides a valued national resource.  
 
3.2.2 Community Health Index (CHI) 
Each patient registered with a general practice (family doctor) in Tayside is given a 
unique health index, known as a CHI. This is a unique 10 digit number, consisting of 
patient date of birth (6 digits, in ddmmyy format), a three digit unique code 
containing patient gender (last digit indicates gender, with odd numbers being male 
and even being female) and an additional check number (1 digit) (Figure 3.1). This 
number has been used universally across Tayside since 1979 and is the key to 
linking each resident‟s health records and activities across many health related 
datasets. It is the foundation of enabling electronic linkage of cross-sectional 
datasets and providing a fully integrated information system. The CHI is also used in 
the rest of Scotland but is only now beginning to be used consistently. Hence, this 
study looking back over 15 years could not have been conducted for the whole of 
Scotland. 
Figure 3.1 Sample of Community Health Index (CHI) used in Tayside 
 
 
Note, this figure is adapted from the HIC website: http://www.dundee.ac.uk/hic/data/tayside/ 
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3.2.3 Record Linkage of Clinical Dataset for Research 
Record linkage of the original datasets takes place in the Clinical Information 
Bureau (CIB), where the data has all personal identifiers removed and is pseudo-
anonymised using software called CLAM (CLeaning and AnonyMisation). These 
data are then transferred to HIC where they are made available for approved projects 
registered with the Project Management System (PMS) (Figure 3.2). The processes 
from raw NHS data to anonymised pre-analysis dataset are governed by Standard 
Operating Procedures (SOPs) and externally audited annually. 
183
 
Figure 3.2 Data linkage in HIC 
 
Researchers are provided with an anonymised datasets that include only the data 
required for their project, as documented in the protocol approved by Tayside's 
Committee on Medical Research Ethics, which is registered with Tayside's NHS 
Research and Development office and Caldicott Guardians. All individual data 
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released to researchers are subject to rigorous anonymisation and are linkable only 
through the anonymised patient index, which is unique to individual studies. All 
analyses carried out operate under approved SOPs.
183
 The data linkage approach 
used in this study has also been applied previously to diabetes mellitus 
184
 and 
thyroid disease.
185-187
 The unique anonymised patient identifier, known as PROCHI 
in this PhD study, enabled researchers to link all necessary information across 
regional and national databases. Figure 3.2 illustrates the Tayside data model held by 
HIC, which is made available through record linkage for research purposes. 
 
3.2.4 Tayside Data 
The region of Tayside consists of the City of Dundee, Perthshire, Angus and Kinross 
and encompasses approximately 400,000 people, including those in both rural and 
urban areas. The demography of the Tayside population is representative, in terms of 
age, sex and social class, to that for the United Kingdom, as well that of as Europe. 
(Figure 3.3) Tayside does, however, have a relatively low proportion of people from 
ethnic minorities (less than 2%). 
188
 Tayside Health Board introduced the Tayside 
Master Patient Index (MPI) in 1972, with the aim of integrating patient health 
records, in primary and secondary care. Tayside is now a pioneer region within the 
NHS in Scotland (NHSiS), which actively uses the CHI number in all healthcare 
activities, from cradle to grave. The actual population, who are all registered with a 
general practitioner, i.e. is covered by the datasets, is essentially 100% of the 
population, as the NHS is free at the point of care delivery (Figure 3.3) and there is 
very little private care in Tayside. 
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Figure 3.3 Representativeness of the Tayside population, in comparison with   
Scotland and the entire UK 
 
Note, this figure is taken from the HIC website http://www.dundee.ac.uk/hic/data/tayside/ 
 
3.2.5 Anonymisation and confidentiality in HIC 
All the datasets held at HIC are registered under the Data Protection Act for the 
purposes of research and audit and being rigorously rendered anonymisation before 
release. CHI is the only identifiable information as mentioned, but it is anonymised 
by a unique but unidentifiable ID before any data is released to researchers. All the 
anonymisation takes place within a secure environment within the Clinical 
Technology Centre (CTC) (based at Ninewells Hospital), where both physical access 
and electronic access are securely restricted and secure password protection is 
employed in relation to all the devices that hold any identifiable data.  
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All projects requiring access to data via HIC are documented on the PMS, which is a 
separate database containing full details of each project and electronic copies of all 
relevant documentation  (e.g. Ethics, Caldicott, NHS R&D Governance) and this has 
to be completed before any data is released to an approved researcher. The PMS can 
also keep track of the progress of projects and ensures all data are removed from 
researcher‟s local PCs at the end of each project. Each project has to comply with 
the HIC SOP, in order to enable internal and external audit. 
183
 This SOP contains 
the management of all HIC Datasets, including arrival of new datasets, 
anonymisation, data releases and archiving.  As a result, although data linkage is the 
key to this PhD study, all cross linkage is made with anonymised data, as well as the 
performance of all statistical analyses. At all times, confidentiality of individual 
patients was maintained in accordance with the HIC SOP. 
183
 
 
3.2.6 Ethical approval  
The study was approved by the Tayside Research Ethics Committee which gives 
standard approval for all HIC anonymised electronic datasets without having to 
complete the IRAS form and permission for the case record validation audit was 
obtained from Tayside Caldicott Guardians.  
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3.3 Description of databases 
Seven principal datasets, which are available from HIC, have been used for this PhD. 
Details of these data are discussed below.  
 
3.3.1 Tayside Master Patient Index 
This dataset serves as a master index to provide detailed demographic information of 
every person residing in Tayside, who has registered with a general practice. It 
contains information on patient name, address (current and previous), postcode, 
gender, date of birth, date of death (if applicable), date moved in/out of Tayside (if 
applicable) and the information of their registered General practitioner (GP) and GP 
practices, as well as the unique CHI number.  Data released for research contains 
anonymised CHI number, which is unique to individual study to enable further 
linkage, approximated date of birth and date of death (if applicable). A social-
economic deprivation score, known as the Scottish Index of Multiple Deprivation 
(SIMD), is also attached to each person.
189
 The SIMD provides an index of multiple 
deprivation, identifying small area concentrations across of Scotland in a fair way.  
The estimate is made based on over 30 indicators across 7 domains, namely, income, 
employment, health, education, skills and training, housing, geographic access and 
crime. This allows further exploration of the relationship between deprivation and 
health, in epidemiological studies. In this PhD research, the Health Board SIMD 
decile is used, with 1 being the most deprived and 10 being the most affluent. A 
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dynamic population is used in this research to include all patients who are registered 
with a general practitioner and resided in Tayside between 1 January 1997 and 31 
December 2006. This population includes those who had died and who were born, 
migrate in or out during the study period.  
 
3.3.2 Biochemistry database 
This database contains all laboratory tests for Tayside since 1989 and is primarily 
archived in the Department of Biochemical Medicine at Ninewells Hospital, Dundee. 
HIC receives quarterly downloads of this data and each entry comprises the patient‟s 
anonymised CHI, tests performed, dates and results of the test. This is the core 
database used for establishing PHPT diagnosis in Tayside, as it holds all the 
electronically available serum calcium (mmol/l) (corrected for serum albumin) and 
PTH records in Tayside. The results of serum and urine creatinine concentrations 
(µmol/L and mmol/L respectively), alkaline phosphatase, cholesterol, vitamin D and 
urine calcium concentrations (mmol/L), are also extracted for this study.  Although 
the study covers the period of 1997 to 2006, the starting date of biochemistry data 
collection goes back to 1994, allowing a few years‟ screening period to more 
accurately distinguish prevalent and incident cases. It is, therefore, useful to identify 
methods and systems used in the blood sample testing, which obviously changed 
over the 13 year period.  Table 3.1 contains details of the various laboratory systems 
used and their corresponding codes. 
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Table 3.1 Laboratory systems and codes used in Tayside and their respective names 
and hospitals 
Codes Lab systems Hospitals 
1 Pinnacle system Ninewells Hospital, Dundee 
2 Pre-Pinnacle system Ninewells Hospital, Dundee 
3 Llims system Perth Royal Infirmary, Perth 
6 MasterLab system Ninewells Hospital & Stracathro Hospital 
8 MasterLab 1 system Stracathro Hospital, Angus 
12 MasterLab system Perth Royal Infirmary, Perth 
13 MasterLab 2 system Stracathro Hospital, Angus 
 
Apart from the PTH concentration, the reference ranges for all other relevant tests 
used in this study are consistent during the study period. There are three assays used 
in measuring PTH concentration, namely the DPC IMMULITE (before 2003), the 
subsequently Roche Elecsys 2010 (until November 2005) and then the Roche 
Modular E170 assay (until the present). The last two assays both have a reference 
range of 1.0-6.9 pmol/l and the former had a reference range of 1.2-7.6 pmol/l. 
Although there is a slight difference in the reference ranges for the PTH, this is 
unlikely to affect the study results, as we only used the upper reference range in 
patients with one raised calcium reading. Any patient with two or more raised 
calcium concentrations was labelled as having PHPT, if the PTH concentration was 
greater than 3pmol/l (i.e. inappropriately “normal”). Patients with one raised calcium 
and a raised PTH concentration were also labelled as PHPT. Patients who may have 
been included as having PHPT inappropriately are those who had a single raised 
serum calcium concentration and a PTH concentration of between 6.9 and 7.6pmol/l 
before 2003.  We have checked our data and the number of patients meeting these 
80 
criteria are only seven in number out of the total of 2709 (0.3%) and therefore its 
adverse effect to the results is small. 
 
3.3.3 GRO death registration 
General Registry Office (GRO) is the department of the devolved Scottish 
Administration responsible for the registration of births, marriages and deaths.
190
 It 
holds all information on deaths of Scottish residents, with date of death and details 
of causes. All underlying causes of death are recorded in the International 
Classification of Disease (ICD) codes, the Tenth Revision (ICD-10) from 2000 and 
the ninth edition (ICD-9) prior to 2000.
191, 192
 Other fields available include: sex, 
social class, occupation, place of birth, country of birth and residence. All the death 
data is in a format linkable via CHI.  
 
For this PhD, detailed information on date of death and the first four underlying 
causes of death, are extracted for all potential patients and matched cohorts. In 
addition to this complete death registration, HIC also holds death information 
obtained from the Tayside Master Patient Index (described previously), which 
records deaths intimated by GPs. This is also checked in the study, in order to 
capture a comprehensive record of deaths. In addition to all cause mortality, this 
PhD also considers two other disease-specific deaths, these being cardiovascular and 
cancer related deaths. Codes used for extracting this death information are listed in 
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Table 3.2 Aggregated mortality information classified by causes is derived for the 
total Tayside population over the study period by ten-year age group, sex and year of 
event. All information for the study is provided only by means of the anonymised 
patient identifier, the PROCHI.  
Table 3.2 ICD codes used in the study 
Conditions ICD-9 codes ICD-10 codes 
Cardiovascular disease 410-414, 427-428 I20-I25, I44-I50 
Cerebrovascular disease 431, 433-438 I61, I63-I69, G45 
Cancer 140-209 C00-C99 
Hypertension 401-404 I10-I14 
Renal failure 584-587 N17-N19 
Renal stones 592, 594 N20-N23 
Psychiatric disease 
293-298, 301, 307, 
311-312 F20-F29, F30-F39, F40-F48, F50-F52, F60-F63 
All fractures 800-829 
S02/12/22/32/42/52/62/72/82/92, T02, T08, 
T10, T12 
Diabetes
+
 250 E10/11/12/13/14 
Glaucoma 365 H40-H42 
Parkinson’s disease* 332 G20, F02.3 
*Also included patients who were on prescription of Dopaminergic drugs used in Parkinsonism (BNF 
4.9.1) 
+
SCI-DC dataset was used to capture all diabetic patients as well as the SMR01 data 
3.3.4 Hospital admission data 
The ISD, Scotland has been a valued supporting partner to NHS Scotland and the 
Scottish Government Health Department, by providing an essential service to 
improve the health and wellbeing of the people in Scotland for over 40 years.
193
 ISD 
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collects and holds various patient and health care data at individual level and 
annually provides HIC with a download of their Tayside data. The Scottish 
Morbidity Record schemes, which are patient morbidity information collected since 
1961 in Scotland, cover most of the clinical indicators produced by ISD. 
194
 Over the 
past forty years, these have been developed and collected focusing on key aspects of 
NHS activities, with different specialised areas. Two such datasets, namely SMR01 
for Acute Stay Hospital Admissions and SMR06 for Cancer Registry, are used in 
this PhD. They provide outcome measurements and previous co-morbidity 
information for Chapters 6, 7 and 8.  
 
SMR01 – Acute Stay Hospital Admissions 
SMR01 records all inpatient acute stay hospital admissions. Each SMR01 record 
represents a Finished Consultant Episode (FCE), i.e. a record is only generated when 
a patient completes an inpatient episode or day care case, with up to six diagnostic 
fields indicating possible conditions responsible for the admission. The first 
diagnosis field records the principle condition that caused the admission and other 
co-existing conditions are recorded in fields two to six. All diagnosis fields are 
coded using the ICD codes: ICD-9 is used where diagnoses and admissions are prior 
to 1996; subsequently both ICD-9 and ICD-10 were used simultaneously during the 
period of 1996 to 1997, with ICD-10 then being used from April 1997 onwards. Any 
operation or surgical procedure occurring during the hospital stay is recorded using 
corresponding operation and procedure codes (OPCS): OPCS-3 classification was 
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used up to the end of 1988 and OPCS-4, from 1989 onwards. In addition to  the 
dates of admission and discharge, an SMR01 episode also contains information on 
which hospital admitted the patient,  specialty involved, length of stay, details of 
transfer (if applicable) and data source. 
 
Table 3.2 lists a number of conditions that are investigated in this PhD. In addition 
to aforementioned purposes the SMRs datasets served, SMR01 is also used to 
identify all hospital diagnosed PHPT cases (ICD-9: 194.1 227.1 237.4 252.0; ICD-
10: C75.0 D35.1 D44.2 E21.0), and OPCS codes (OPCS3: 0722 0763 0764; OPCS4 
(1993 onwards): B14 B16 Z13.5) are employed to identify all surgically treated 
PHPT patients. 
 
SMR06 – Cancer Registry 
In a similar format to SMR01, SMR06 is a complete cancer registry containing 
cancer diagnosis and treatment at patient level. It contains information on date of 
incidence (as the first date of consultation for the cancer), sites of tumour, plus date 
and underlying causes of death (if applicable).  
 
84 
3.3.5 Scottish Care Information –Diabetes Collaboration (SCI-DC) 
The SCI-DC system is an up-to-date central repository containing detailed 
information for all people with diabetes in Scotland.
195
 Under secure management, it 
provides a clinical network allowing GPs, diabetes specialists, practitioner nurses 
and other diabetes members, to have privileged access to individual information on 
diabetic patients and is set up for clinical use to improve the quality of joint 
treatment and care of diabetes. HIC holds a subset of Tayside patients collected by 
the SCI-DC system, which is translated into a format suitable for research purposes. 
Information available to HIC includes type of diabetes, date of diagnosis, results of 
all laboratory tests (e.g. HbA1c, cholesterol, body mass index (BMI), blood pressure 
(BP)), eye clinic data and podiatry clinic data.  
 
3.3.6 Tayside Community Dispensed Prescribing 
This database contains every prescription presented at a community pharmacist in 
Tayside. Using the unique identifier, CHI, HIC has been recording prescriptions 
since 1989. 
196
 From 1989 to 1992, however, only certain drugs that were felt 
important or useful to research were collected manually, using scanned paper 
prescriptions. Data on all British National Formulary (BNF) categories are available 
from 1993 to the present but electronically obtaining prescription data has only been 
made available since late 2004, from the Practitioner Services Division (PSD). The 
file contains the CHI number, details of the actual drug dispensed (brand or generic), 
date of prescription, GP, pharmacy, dose, details and amount.  
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For this study, thiazide diuretics (BNF 2.2.1) and lithium (BNF 4.2.3) prescription 
data for the selected patient cohort are retrieved, in order to create a marker for 
patients whose biochemistry might reflect the effects of these drugs. Other drugs 
extracted include bisphosphonates (BNF 6.6.2), which are used as an adjusting 
factor in Chapters 6 and 7, prescriptions for  Dopaminergic drugs used in 
Parkinsonism (BNF 4.9.1), for identifying patients with Parkinson‟s disease, as well 
as Cinacalcet prescription for distinguishing patients with secondary PHPT from 
patients with untreated PHPT (BNF 9.5.1.2). 
 
3.3.7 Other study data 
Four additional datasets obtained from hospital clinics are also used to aid patient 
identification, these being the histology database, the nuclear medicine, hospital 
renal registry data and some hospital letters. All these datasets are anonymised at 
HIC using the PROCHI which is unique to this study, before release. From the 
pathology records, details of all patients with proven parathyroid adenoma and/or for 
glandular hyperplasia histologically, are collected into the histology database and 
used to identify definite PHPT diagnosis. Sestamibi Tc-99 scans carried out for all 
Tayside patients are recorded in the nuclear medicine files,  positive scan results 
being  used to confirm definite cases. Additional hospital renal registry data and 
hospital letters are used to ascertain patients with tertiary and primary 
hyperparathyroidism, respectively. 
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3.4 Methods 
3.4.1 Epidemiological measurements 
3.4.1.1 Incidence and prevalence 
Incidence and prevalence are two important measures of the occurrence of disease. 
Incidence measures the frequency of a new event over time, whilst prevalence shows 
the frequency of an existing event at a particular point in time. An event can be the 
onset of a disease, death, remission or other outcomes, e.g. stage of growth or 
development. 
197
 
There are two measurements for incidence, namely cumulative incidence and 
incidence density (ID). Cumulative incidence measures the risk of an event, based 
on persons at risk.  The numerator of cumulative incidence is the number of new 
events in a certain defined period and the denominator is those of the population at 
risk, at the start of the period. Cumulative incidence is good over short periods of 
time, e.g. outbreak investigations, however, it appears to be problematic over long 
periods, due to loss of follow-up and competing risks. ID takes into account such 
problems by using an accumulated time that the population is at risk, known as 
person-time and is, therefore, adopted in this PhD study. ID can be express as  
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Prevalence describes the occurrence of disease from another angle: that is it 
estimates the burden of disease on the population. Point prevalence is a snapshot 
87 
measurement, with the numerator being the number of existing events at a certain 
time point and denominator being the total population at that certain time point. 
Period prevalence (PP), however, measures the burden of disease in the population 
over a certain time period, expressed as  
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This study uses PP for estimating the prevalence of PHPT in Tayside in Chapter 5. 
 
For each of these point estimates, such as ID or PP, a CI is also presented which is a 
constructed range, or interval, of likely values, with a specific degree of confidence 
and includes the true population parameter, i.e. true population ID or PP, being 
estimated.
198, 199
 In brief, a CI consists of two numerical values, based on the 
estimated parameter and standard error (SE) from the observed sample data, which 
give the upper and lower limits of the true (unknown) population parameter. In this 
thesis, a corresponding 95% CI, which is normally used in practice, is computed for 
each of the point estimate. For ID, the 95% CI is calculated assuming a Poisson 
distribution using the formula:  
ypnew TNIDCI  96.1%95 ; 
And, for PP, it is calculated assuming a Binomial distribution based on the formula: 
popTPPPPPPCI )1(96.1%95   
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3.4.1.2 Standardised Mortality Ratios 
Measurements of disease occurrence (incidence, prevalence, odds) are the basis for 
comparison between groups. When two such measurements are combined into a 
single summary measure, estimates of the association between exposure and 
outcome are made possible. 
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 This summary can be a ratio (or a relative measure), 
which indicates how much more likely one group is to develop the disease relative to 
another, or, a difference (or say an absolute measure), which indicates how much 
greater likelihood on an absolute scale is the frequency of disease in one group 
compared to another. In this PhD study, relative measures, RR – to be specific,  are 
used to summarise risks of outcomes in the study group compared to a reference 
population, as the nature of this study is  a population based cohort study, with 
person-time information available. The RR is a summary of two measures of ID and 
it is the ratio of the ID in the exposed, the patient cohort – in this study, to the ID in 
the unexposed, the reference cohort, i.e. RR=IDe/IDu.  
 
Without adjustments, however, such measure only gives a crude estimate of risk 
subject to confounding, which is an extraneous factor with a mixing effect on the 
exposure-outcome association. Thus, standardisation, as a common approach in 
epidemiological studies, is introduced to remove or minimise the influence of 
confounding factors. Take age as a confounding factor, for example: direct 
standardisation uses rates from the study population and weights from the standard 
population to calculate the expected age-specific rates in the standard population and 
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compare with the observed; indirect standardisation uses age-specific rates from the 
standard population to calculate the expected number of events in the study 
population and to compare the observed total to the expected total. The latter is 
called standardised mortality ratio (SMR) and is the method adopted in Chapter 6. 
SMR can be written in a formula as SMR = O/E, where O stands for observed and E 
denotes expected. SMR of 1 means the study population has same rate as expected 
and SMR of greater than 1 means the study population has an increased rate or risk, 
as expected. The 95% CIs are estimated assuming a Poisson distribution using an 
exact method.
201, 202
 
 
3.4.2 Statistical methods 
3.4.2.1 Multiple regression 
Multiple regression is a statistical method that allows testing the relationship 
between a dependent variable (DV) and several independent variables (IVs) 
simultaneously. 
203, 204
 A simple multiple regression can take the form of: 
Y = a + b1X1 + b2X2 + ... + bnXn + ε 
Where Y is the DV of interest measured on a continuous scale; Xs are the IVs; a is 
the intercept, bs are the “regression coefficients” for each corresponded X and ε is 
the error term. 
90 
 In order to give reliable results, however, a multiple model relies upon certain 
assumptions. A brief introduction of these and how they can be tested is described 
here, detailed information being available in Allison (1999) Chapter 6. 
203
 
1. Variables are normally distributed. The normality of distribution can be 
tested visually by using P-P plots or statistically, by computing the skew and 
kurtosis. Non-normally distributed variables can distort the relationship and 
significance tests. Nonetheless, sometimes, whilst transforming the variable 
(e.g. using square root, log, or inverse) can improve normality, it may also 
complicate reporting the results and should thus be interpreted with caution. 
2. Linear relationship between IVs and DV. This can be tested by using scatter 
plots examining the relationship between DV and each IV, as well as by 
examining residual plots of standardised predicted residuals against the DV. 
When this assumption is violated, the true relationship will be under-
estimated. Testing for different functional forms can rectify the non-linearity 
but this, as mentioned previously, can complicate the interpretation of the 
results. 
3. Homoscedasticity.  The assumption of homoscedasticity is that the variance 
of errors is the same across all levels of the IVs. This can be tested by using 
scatter plots, examining the standardised residuals (the error term) by the 
predicted Y. 
4. IVs are not correlated and this can be tested by examining the correlations 
between IVs. 
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Once the assumptions are met, how well a model is fit in terms of reliably and 
accurately predicting the DV, can be tested by the adjusted R Square statistics, 
which is the square of the correlation between the observed and predicted value of 
the DV, adjusted for the number of variables in the model and the number of 
observations (cases) the model is based on. How strongly each IV influences the DV 
can be assessed using the beta, which is a standardised correlation coefficient, i.e. b, 
allowing comparisons being made between each IV. 
In the cases when the DV is not an interval or ratio scale, other regression method 
needs to be applied. For example, logistic regression is a generalised linear model 
used when the Y is a dichotomous DV. It fits data into a logit transformation 
function, which is the natural log of the odds, expressed as: 
Log(odds)=logit(P)=ln(1/(1-P)).  
Here P is the probability or proportion of events. The impact of predictor variables is 
then often explained in terms of odds ratios. 
 
3.4.2.2 Missing data methods 
Missing data is an almost inevitable problem in all longitudinal studies involving 
health databases. 
205
 
206
 Without properly addressing this problem, this can result in 
producing biased results. In order to deal with missing data appropriately, it is 
important to know the types of missing data. 
206
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1. Missing completely at random (MCAR), is the scenario that the missing 
observation/data is unrelated to both the observed data and the data that 
would have been observed if it was not missing or the probability of being 
missing (missingness) is independent of, both observed and unobserved data. 
2. Missing at random (MAR) is the missing data being independent of the 
missing value itself but the probability of missing is dependent on and can be 
predicted by, observed data, thus it is a weaker version of MCAR. 
3. Missing not at random (MNAR) is when the missing data depend on both 
unobserved and observed data and is often referred to as non-ignorable 
missing mechanism or informative missing.  
There are several of existing methods for handling missing data and they are 
discussed below, with their advantages and disadvantages, taking the types of 
missingness into account. 
1. Complete case analysis (CC) is the simplest way to deal with missing data, 
by using only cases with complete data in the analysis. This method uses in 
fact only a subset of the collected data and is often assuming MCAR. 
Although a CC analysis can produce unbiased regression estimates, it inflates 
standard errors, which then affects the significance of the covariates in the 
model and this problem is exaggerated when there are more than 25% or 
more missingness, Furthermore, when MCAR assumption does not hold, that 
is, there are systematic differences between complete and incomplete cases, 
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CC analysis approach will produce biased inference because of the exclusion 
of potentially valuable information from the incomplete cases. 
2. The Missing indicator method is used to code all missing as unknown and to 
include all unknown categories in analysis. The advantage of this approach is 
that it is easy to perform and it includes all subjects, without exclusion.  The 
problem with this method, however, is that it is difficult to interpret the 
results and that it actually introduces bias, instead of dealing with bias. 
3. Single imputation (SI) is to impute the missing value with a, somehow, 
meaningful value derived from the complete cases. Using the mean is the 
most common SI approach. It is a method used to replace the missing values 
by the calculated mean from the complete data and thus, counts as a specific 
version of the missing indicator method.  This method, again, fails to explain 
the uncertainty of what could be predicted if there were no missing values. 
Moreover, it also tends to bias the variances of the parameter estimates and 
results in them being towards zero. 
207
 
4. Weighting is another alternative solution to missing data, which predicts the 
probability of being missing, say p, and then performing a CC analysis but 
weighting the data by the reciprocal of this probability, i.e. 1/p. A logistic 
regression is normally used to predict the p including both DV and IVs. 
Although this method omits missing cases, it gives more weight to the 
complete cases which have similar properties to those missing ones. It 
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requires the assumption of MAR and may still be subject to bias when a large 
proportion of data are missing. 
5. Multiple imputation (MI) analysis is a process that replaces missing values 
with a set of say n, plausible values that represent the uncertainty about the 
actual correct value that should exist. It does not require MCAR, however, it 
depends on the assumption of MAR. In this way, an n set of complete 
datasets are created. Proposed statistical analyses are subsequently performed 
on these n sets of data in a standard way, to generate a set of parameters 
estimates for each of the dataset. These n sets of results are then combined to 
produce an inferential result. 
206, 208
 The imputed values are estimated using 
all available and relevant information from the study data. There are many 
methods used to estimate the missing values depending on the patterns of 
missingness: regression method predicting missing values by regression 
models of previous values and covariates; propensity score (described in 
more detail in a later part of this chapter) introducing a propensity variable of 
being missing; and Monte Carlo Markov Chain (MCMC), using the 
conditional distribution method to draw imputations. 
Although there has not been consensus on which is the most appropriate approach to 
handle missing data, when MAR assumption is supported, the method of MI 
provides a means of valid inferences. 
209
 The relative efficiency of the model 
improves with the increase in the number of imputations performed but 
compromises with the increase in the proportion of missing data. (Table 3.3)  When, 
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however, there is the case of MNAR, all the standard methods mentioned earlier are 
invalid and other methods need to be considered. In this PhD study, different 
approaches of dealing the missing data are used, according to the property of the 
data under consideration and the specific research aims.  
 
Table 3.3 Relative efficiency of MIs by creating different set of estimators (n) 
against the percentage of missing data 
N Percentage of missing data 
10% 20% 30% 50% 70% 
3 0.9677 0.9375 0.9091 0.8571 0.8108 
5  0.9804 0.9615 0.9434 0.9091 0.8772 
10 0.9901 0.9804 0.9709 0.9524 0.9346 
20 0.9950 0.9901 0.9852 0.9756 0.9662 
The relative efficiency (RE) is calculated as RE = (1+λ/n)
-1
, where λ=percentage of missing data. 
(Rubin 1987, p114) 
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3.4.2.3 Mixed linear model 
Mixed linear model (MLM), also known as random effects model or multi-level 
model, is a regression model where the regression coefficients and intercept are 
allowed to vary across the subjects, that is, random effects.  It is often used in 
longitudinal studies when data are collected hierarchically, or when repeated data are 
collected over time on the same subject. There are two components of a MLM, these 
being within-individual component, which captures an individual‟s changes over 
time described as a intercept and slope at population level, and between-individual 
component, which is variation between individuals described as individual intercept 
and slope. MLM allows describing the trend over time taking account of the 
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correlations between successive measurements for each individual, which is the case 
of calcium measurements in this study. This method is used in Chapter 7 when 
examining the natural history of PHPT in terms of calcium progression, because 
both calcium and PTH are repeated measurements for each individual with both the 
number of measurements and the intervals between measurements being uneven 
between subjects. Any trend in calcium and PTH concentrations over time are 
estimated adjusting for age and gender as fixed effects, with both the slope and the 
intercept allowed varying across individuals. The best model in describing the trend 
is selected based on the Akaike‟s Information Criterion (AIC), which is a measure of 
goodness fit of a statistical model with smaller the AIC being the better fit model. 
AIC is generally denoted as: 
AIC=-2ln(L)+2k 
Where L is the maximized loglikelihood value for the estimated model which is 
directly produced within statistical software and k is the number of parameters 
included in the model. The smaller the AIC value the better the model fit. Normally, 
an reduction of 3 in AIC values is considered an improvement of a better model fit. 
 
3.4.2.4 Survival analysis 
Survival analysis uses the regression method to examine the independent effect of 
covariates on the hazard of a particular time-to-event outcome (e.g. deaths), with 
focus on the distribution of time it takes for events to occur, i.e. survival times. 
210, 
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 Survival data can be summarised in two functions, namely survival function and 
hazard function. The hazard function represents the risk or hazard of an event 
happening for an individual and is widely used in survival analysis. There are many 
methods in modelling survival data, in this PhD study, the Cox proportional-hazards 
regression is used, which is the most commonly used semi-parametric survival 
model. 
210
  
Supposing the hazard is associated with a single covariate, x, a simple hazard 
function model of time t for the i
th
 individual can be expressed as: 
).()()exp()( 00 thethxth
x
ii
   
Where exp (βx) is a function of the covariates in the model, h0(t) is generally termed 
as the baseline hazard, as it is the h(t) when x=0, i.e. exp(βx)=1.  211, 212 The hazard 
ratio for the covariate taking two different values, x0 and x1, can be denoted as: 
.)exp()(/)exp()( )01(0010
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This model is called the proportional hazards model because the proportional 
hazards assumption is crucial to the Cox regression model, which means the hazards 
need to be proportional over time for each covariate of interest. For categorical 
covariate of interest, this assumption can be tested by the log-cumulative hazard 
plot, that is, a plot of the logarithm of the negative log of the survival from the 
Kaplan-Meier estimate against the log of survival time, i.e. log(-log(S)) against 
log(t), and assumption is supported if the plots for each category are roughly 
parallel. For continuous covariate, the assumption can be tested by creating a time 
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dependent variable, say f(t)*x, where the f(t) is the function of time (e.g. logarithm, 
square, square root) and x is the tested covariate. This time-dependent variable is 
included in the Cox model and the assumption is supported if the score test for this 
variable is not significant. 
211, 212
 For continuous covariate, the assumption can also 
be tested using the log-cumulative hazard plot by categorising the covariate. 
 
3.4.2.5 Propensity score 
Propensity score is a statistical method describing a conditional probability that a 
subject will receive a “treatment” or be “tested”, based on a set of observed 
covariates. In the propensity score method, a propensity score is generated for each 
variable with missing values to indicate the probability of the observation being 
missing. The observations are then grouped based on these propensity scores, and an 
approximate Bayesian bootstrap imputation is applied to each group. It is used to 
reduce bias in observational studies when missing information or disease verification 
is subject to selection bias. In Chapter 7 and 9, the risk associated with the study 
population, that is, patients with PHPT, is measured by using a matched cohort 
selected from the general population, in order to adjust for more confounding factors. 
Although this is a closer match and offers a better estimate, there is an indisputable 
but often implicit, assumption that the effects of prognostic differences between 
groups are minimised by controlling for confounding factors. Any estimation on 
causal relationship or disease association can only be unbiased, when this 
assumption is met.
213-215
 In this PhD study, however, PHPT diagnosis is primarily 
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based on biochemical tests, in particular serum calcium measurements, which are 
not part of the routine screening of the population in Tayside, thus the disease 
verification is subject to some form of selection bias, where all the cases would have 
at least a calcium measurement but not necessarily for all the matched comparators. 
It is therefore critical to adjust for this systematic difference between groups, 
without which bias could result.  The propensity, or probability, of having a calcium 
check is predicted using multiple logistic regression including both covariates and 
other outcome measures. This propensity score is then included in the subsequent 
adjusted models as a covariate;  including such a balancing score taking the 
underlying reasons as being calcium tested into account, this can make direct 
comparisons more meaningful by reducing bias.  
  
3.5 Chapter summary 
This chapter has introduced the data provider, HIC and described the various 
datasets used in this study. It has also described both epidemiological and statistical 
methods used for the thesis.  
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CHAPTER 4  
PATIENT IDENTIFICATION 
4.1 Overview 
This chapter will describe the process undertaken to identify the base cohort, that is, 
all Tayside residents with diagnosed PHPT. This is a vital and fundamental element 
of the study, as all the subsequent analyses (detailed in later chapters) will be based 
on this group or specific sub-groups selected from this base population. The chapter 
will start by summarising the existing diagnosis followed by a description of the 
diagnostic method to be used in the thesis. The data collected for the project and the 
initial diagnosis, will then be explained. The derivation of the patient cohort and a 
possible group will be described. As a result of the patient cohort being primarily 
diagnosed using retrospective electronic data, it is essential to examine the accuracy 
and completeness of our patient identification, which will be described in the data 
validation section. Once the base cohort of study subjects have been derived, their 
baseline characteristics will be described and some comparisons among different 
groups will be presented. This chapter will guide the reader through the process of 
data management and patient identification. 
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4.2 Introduction 
The presentation of PHPT has changed radically over the last half century, from a 
symptomatic disease to a subtle condition in search of symptoms. Although the 
history and clinical examination can still be useful in establishing the diagnosis, with 
the majority (>80%) now being mild PHPT patients, hypercalcaemia with an 
inappropriate PTH concentration has become the most prevalent feature.
216
 As a 
result, the diagnosis is now made incidentally, when a mild elevation of serum 
calcium and parathyroid hormone concentrations is observed, or often when 
investigating non-specific symptoms. A real population level epidemiological study 
of the contemporary PHPT is, however, currently lacking. The recruitment of PHPT 
patients in the existing literature can be synthesised into two diagnostic modes, 
namely physician referrals and health surveys. The epidemiology of PHPT has been 
systematically studied since the mid 1960‟s, however, the majority of studies 
initiated prior to 1980 have depended on physician or hospital referrals to identify 
PHPT patients, thus, these studies are subject to small patient numbers and a lack of 
real asymptomatic patients. Large studies carried out under the Scandinavian system 
started to identify patients using biochemistry data, however, the primary database 
was established from national health screening initiatives and therefore, a potential 
selection bias co-exists with these studies, when participants volunteered to take 
part. 
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In brief, although greater understanding of mild asymptomatic PHPT has been 
achieved from recent studies, knowledge derived from a genuine population based 
study remains to be established. The access to the exhaustive biochemistry records 
in Tayside enables us to bridge such a gap by identifying a complete cohort of 
diagnosed PHPT primarily using biochemistry data, based on a large population. 
 
4.3  Summary of existing patient diagnosis 
4.3.1 Summary of guidelines 
Acknowledging the change in its clinical presentation, the NIH set up a multi-
disciplinary Task Force on PHPT in 1991, which brought together endocrinologists, 
surgeons, radiologists, epidemiologists and primary health care providers, as well as 
the public, to systematically address the diagnosis and management of asymptomatic 
PHPT.
42
 Supported by ten interested professional societies, the panel held two 
further consensus conferences in 2002 and 2008, respectively, to review advances 
and changes in light of the new available data.
5, 43, 150, 165, 217-219
 Pertaining to the 
diagnosis of PHPT, consensus has been reached in all three workshops, that the 
PHPT can be confirmed by demonstrating sustained hypercalcaemia and elevated or 
non-suppressed PTH levels, which are the two most characteristic biochemical 
features of PHPT. The rationale behind this is that, in a person free from PHPT, PTH 
is normally suppressed if serum calcium is increasing. Thus, if this suppression of 
PTH does not occur in the presence of increasing serum calcium concentration, the 
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presence of PHPT should be considered. This unique biochemical feature can 
capture many people with mild to moderate hypercalcaemia, without overt 
symptoms and is straightforward in identifying most PHPT cases. 
6, 57, 220
 
 
Total serum calcium concentration, corrected for albumin level, should be used for 
screening for hypercalcaemia, as it has the greatest uniformity among different 
laboratories. Resulting from it being common to have normal calcium concentration 
even in a confirmed PHPT patient and a small elevation in serum calcium 
concentration could indicate a clinical significance, the finding of hypercalcaemia 
should be confirmed by a repeat measurement, preferably with venous occlusion of 
short duration and patient fasting and any reading should reference the normal range 
of the laboratory used.
6, 42
 Drugs such as thiazide diuretics, lithium, and vitamin D, 
that are likely to increase serum calcium concentration, should be discontinued 
before taking the blood sample, to minimise the likelihood of a false positive 
reading. In addition, a finding of hypercalcaemia in young patients often requires 
careful checking the case notes, as they are more likely in cases with hereditary 
mutation affecting calcium metabolism.
6
   
 
Although PHPT is the most common cause of hypercalcaemia, other conditions such 
as malignancy and sarcoidosis, are also possible causes. These confounding effects 
should be eliminated by scrutiny of hospital records and relevant PTH 
concentrations, plus a consideration of other biochemical values. Utilising the PTH 
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measurements generally can distinguish patients with hypercalcaemic PHPT from 
those suffering from other causes of hypercalcaemia, for example, patients with 
malignancy normally have low normal or suppressed PTH values.
7, 42, 220
 The 
immunoassays of the intact PTH molecule, in particular the second-generation 
IRMA assays, have proved to be the most specific measurements.
6, 57
 It is 
noteworthy that PTH concentration, as with serum calcium concentration, may not 
be elevated in every patient every time (evidence showing around two thirds of the 
patients with PTH levels within the reference range), thus PTH must always be 
appropriately interpreted in relation to the serum calcium concentration.
169
  
 
The diagnosis of PHPT can also be supported by other biochemical abnormalities, 
including a decreased or lower end of the normal phosphate level, normal or 
increased urinary calcium excretion, mildly elevated 1,25-dihydroxyvitamin D, 
and/or markers of increased bone turnover.
6
 Owing to the fact that borderline 
elevated or high normal values of PTH concentration, together with hypercalcaemia, 
may also be found in cases of FHH, a rare benign condition typically associated with 
very low urinary calcium (normally calcium/creatinine ratio is less than 0.01), 
urinary calcium excretion is useful in detecting any such cases.  
4.3.2 Summary of individual studies 
This section summarises findings from existing literature on diagnostic criteria, as it 
is important to learn how NIH Guideline criteria adapted in individual studies, 
before finalising an algorithm for this thesis. As mentioned in section 4.2, referrals 
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and health surveys are the two distinguished diagnostic methods that have been used 
since the mid 1960s. This part of the literature research focuses on two key 
questions, with the aim of assisting the derivation of a definite diagnostic criterion, 
these questions being:  
1. How has hypercalcaemia been defined? 
2. How have PHPT patients been identified? 
 
Studies undertaken in the United States have actively searched for PHPT patients 
since 1950 via referral records and reported several long-term epidemiological 
studies from 1965.
34, 69, 86, 89, 169, 221
 The Mayo Clinic, Henry Ford Hospital and 
Columbia University Hospital, were the sites of these studies, with the first two 
being the dominant resources. In Minnesota, a unique medical record-linkage 
system, namely the Rochester-Olmsted Epidemiology Project (ROEP), was created 
in 1966 and it encompassed population-based clinical documentations obtained from 
the Mayo Clinic (where a dossier-type medical record was maintained, dating back 
to the early 1900s), the Olmsted Medical Group and its affiliated community 
hospitals, for all the residents of Rochester and Olmsted County.
222
  Facilitated 
under the ROEP, the Mayo Clinic initiated the earliest complete epidemiological 
studies.
34, 86, 89, 221
 By virtue of their relatively large scale, that is, population-wide 
coverage and long-term follow up, they provided prominent evidence on the 
condition and laid the foundations for understanding the contemporary PHPT. Due, 
however, to the fact that patients were predominantly identified through 
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hospital/physician referrals in these studies, they often lack reported details on 
patients‟ biochemical criteria and were subject to limited numbers. Table 4.1 
summarises the diagnostic criteria used in these studies. 
 
Since 1969, countries under the Scandinavian healthcare systems successively rolled 
out nation-wide health screening programmes, which invited all adult employees 
(aged 20 years and over) for a free multi-phased health check. A spot blood sample 
test was made for those who agree to participate. On reviewing the results, people 
with suspected raised serum calcium have been subsequently invited for further 
testing. The results of all the biochemical indices, as well as serum calcium 
concentrations, were electronically recorded and therefore, PHPT diagnosis based on 
the biochemical features was made possible and available.
74, 115, 138, 223-227
 
Subsequently, several other European countries undertook similar types of 
epidemiological study on PHPT, using biochemical records obtained through various 
health surveys.
228-230
 Compared to the American studies, these European studies 
identified larger patient cohorts, with access to more biochemical results through 
health surveys. Table 4.2 summarises the findings of the European studies where 
either hypercalcaemia was clearly defined or PHPT diagnostic criteria were detailed, 
as described. 
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Table 4.1 Summary of PHPT diagnosis used in the American studies where patients were identified through referrals
3
 
Studies 
(Year) 
Place 
Study period PHPT diagnosis Calcium / PTH 
Reference (R) or 
baseline (B) 
Heath
34
 
(1980) 
Mayo Clinic 
1Jan 1965 – 
31 Jun 1976 
Histopathological proof of parathyroid adenoma or hyperplasia; or 
Hypercalcaemia and pathognominc radiographic signs; or 
Elevated serum immunoreactive parathyroid hormone concentrations; or 
Hypercalcaemia for more than a year without another cause found after careful evaluation 
(n=90) 
(B) Ca: 
2.53-2.75  
Rubin
69
 
(2008) 
Columbia 
University 
Hospital 
1984-? No details of diagnosis, but reported baseline Ca and PTH  
(n=116, with n=99 being asymptomatic patients) 
(B) Ca (mean): 2.63±0.03 (untreated); 2.7±0.03 (treated) 
(B) PTH (mean): 12.2±0.7 (untreated); 15.2±1.4 (treated) 
(R) Ca: 
2.1-2.55 
(R) PTH: 
1.1-6.8 
Scholz
86
 
(1981) 
Mayo Clinic 
 
1Jan1968-
1Jul1970 
No details of diagnosis 
(n=147, with provisional ‘biochemical’ hyperparathyroidism) 
(of them n=86 were surgically treated) 
 
 
 
 
NA 
                                                 
3
 Ca is short for Calcium. Unless stated, the unit of calcium is mmol/l, of PTH is pmol/l, and of creatinine is umol/l 
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Studies 
(Year) 
Place 
Study period PHPT diagnosis Calcium / PTH 
Reference (R) or 
baseline (B) 
Talpos
169
 
(2000) 
Henry Ford  
Hospital  
1Apr 1994 – 
30Mar 1997 
Age between 50 and 75 years, regardless of race or sex 
Persistent albumin-adjusted serum calcium level of 2.53-2.88 from at least 3 measurements 
over a period of at least 3 months 
Intact parathyroid hormone level > 2.1, determined by immunoradiometric assay 
No other cause for hypercalcaemia 
Women at least 5 years after menopause 
Willingness to participate and ability to give consent to a randomised clinical trial 
Living within 150-mile radius of central Detroit 
Not currently enrolled in any other clinical trial 
(R) Ca: Upper limit 
2.53 
Wermers
221
 
(1997) 
Mayo Clinic
4
  
1Jan 1965 – 
31 Jun 1976 
Histopathologic proof of parathyroid adenoma or hyperplasia; or 
Hypercalcaemia (ca>2.52 mmol/l) with inappropriately elevated serum immunoreactive PTH 
level (>2.1 pmol/l by two-site immunochemiluminometric assay or <20 uleg/ml by c-terminal 
radioimmunoassay); or 
Hypercalcaemia that had lasted longer than 1 year and for which no other cause (such as 
thiazide diuretics, cancer, creatinine level >176.8 umol/l, or lithum therapy) was identified, 
after careful evaluation. 
(R) Ca:  
2.20-2.52  
                                                 
4
 With the absence of PTH measurements, Wermers et al also identified two groups of hypercalcaemic patients with possible PHPT, these being: 
1. Patients with at least two elevated ca from at least three determinations, who were followed for less than 1 year 
2. Patients who had elevated serum ca in at least 2 different years, followed by three or more normal calcium values. 
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Table 4.2 Summary of diagnostic criteria used in the European studies where patients were identified through health surveys
5
 
Studies 
(Year) 
Country 
Study 
period 
Potential 
candidates 
Definition used for Calcium / PTH 
Reference (R) 
or Baseline (B) 
Hypercalcaemia 
(Number of patients) 
PHPT diagnosis 
(Number of patients) 
Christensson
223
 
(1976) 
Sweden  
Jul 1971 –  
Jul 1973 
Employees aged 
between 20 and 63 
(n=15903) 
Ca>2.78 on two occasions 
(n=95); or 
Ca>2.78 on one occasion 
together with hospital 
confirmed hypercalcaemia 
(n=12) 
Thiazide treatment with confirmed parathyroid 
adenoma (n=20);  
Tested for PTH (n=18); 
Possible PHPT, as no other causes of 
hypercalcaemia suspected (n=38) 
(B) Ca : 2.54-3.22  
Harrop
228
 
(1982) 
UK 
1Oct 1978 
– 30 Sept 
1979 
Persons aged 15 
years and over, 
with available 
electronic 
biochemical tests 
(n=24500) 
Ca>2.60 on two occasions 
(n=201) 
Hypercalcaemia with PTH > 0.4 ug/l 
(n=61) 
(R) Ca: 2.60  
Upper limit  
 
 
Jorde
224
 
(2000) 
Norway 
1994 – 
1995 
Survey attendees6 
(n=27159) 
Suspected cases if  
Ca > 2.60 at screening 
First Ca≥2.6, second Ca≥2.5, PTH≥6; or 
First Ca≥2.6, second Ca≥2.55, PTH≥5.5; or 
First Ca≥2.6, second Ca≥2.6, PTH≥5; 
Also added additional 990 cases aged 50-75  
 
(R) Ca: 2.2-2.6 
(R) PTH:  
1.1-6.8 (< 50yr) 
1.1-7.5 (≥ 50yr) 
                                                 
5
 Ca is short for Calcium. Unless stated, the unit of calcium is mmol/l, of PTH is pmol/l, and of creatinine is µmol/l 
6
 Only persons with Ca>2.6 who were aged under 75 and lived within reasonable distance to city centre were invited for a further check up 
110 
 
Studies 
(Year) 
Country 
Study 
period 
Potential 
candidates 
Definition used for Calcium / PTH 
Reference (R) 
or Baseline (B) 
Hypercalcaemia 
(Number of patients) 
PHPT diagnosis 
(Number of patients) 
Ljunghall
115
 
1991  
Sweden 
1969-1971 Residents of 
central district of 
Gavel, ≥25 yr, who 
agreed to 
participate  
(n=18543) 
Ca>2.6 at both screenings PHPT confirmed by surgery 
(n=32) 
 
Lundgren
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(1997) 
Sweden 
Jan 1991 – 
May1992 
Women aged 55-
75 who attended 
mammography 
screening 
(n=577) 
NA First Ca≥2.55, second Ca>2.6, PTH>2.6, cre<160 
umol/l; or 
First Ca≥2.55; second Ca<2.5, PTH>5.8; or 
First Ca≥2.55; second Ca~*2.5-2.6], PTH>3.7 
(B) Ca (mean): 
2.54-2.72 
(B) PTH (mean): 
4.7-9.6 
(44.5-91.3 ng/l) 
Mundy
229
 
(1980) 
UK 
Jul – Dec 
1979 
Patients with 
hypercalcaemia in 
Birmingham 
Ca>2.8 
(n=207 with Ca>2.8 on two 
occasions) 
Histology evidence (after PTX); or 
Increased circulating immunoreactive PTH 
concentrations (in the absence of renal failure); 
Clinical features consistent with the disease and no 
other obvious cause of hypercalcaemia. 
 
Sorva
230
 
(1992) 
Finland 
NA Random census 
samples of aged 
75, 80 ad 85 
(n=610) 
NA No details of diagnosis reported 
(n=14 with raised calcium, of them 10 with PTH>5.8) 
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4.4 Proposed patient identification method 
Based on the evidence from existing epidemiological studies on PHPT, in 
combination with the reference range of laboratory tests in Tayside, the initial 
diagnostic criteria and process using the biochemistry data were proposed as below. 
a) Serum calcium concentration above the upper limit of reference range (2.55 
mmol/l) on more than one occasion; and 
b) Serum PTH concentration above the upper limit of reference range (6.9 
pmol/l) or within upper half of the reference range (i.e. which is 
inappropriately normal); and 
 
If patients fit these criteria, they will be labelled as probable hyperparathyroidism, 
and if the following urinary criteria are available, a definite diagnosis will be 
established. 
c) Increased urine calcium excretion as measured from a spot urine sample (i.e. 
a urine calcium/creatinine ratio, calculated as below, > 0.03), or a 24 hour 
urinary calcium excretion > 7 mmol/day. 
 
Calculation of calcium excretion rate 
1000


ionconcentratcreatinineurine
creatinineserumionconcentratcalciumurinespot
rateexcretionCalcium
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1000


UCR
CREUCA
EXRrateexcretionCalcium  
Biochemistry records from all over Tayside, linked via the unique patient identifier, 
CHI (See Chapter 3), will be used. In the absence of confirmatory urine results, case 
notes and nuclear medicine records will be checked and the following assumptions 
will be made: 
 
If patients have had a positive histology record for a parathyroid adenoma after 
surgery or a positive nuclear scan indicating a parathyroid adenoma, the definite 
diagnosis is confirmed. In addition, if patients were known to have either PHPT 
diagnosis from in-patient admission data (SMR01) or PTX from OPCS, the positive 
diagnosis is also confirmed and any additional patients arising from the hospital 
records will be added to the cohort. Moreover, among the remaining probable cases, 
tertiary hyperparathyroid cases will be identified and excluded, if persistently 
elevated serum creatinine (creatinine > 200 µmol/l on at least two occasions for more 
than six months‟ interval) were observed prior to the first raised serum calcium or 
confirmed from case notes. Otherwise, the diagnosis of PHPT is assumed valid 
unless there is a definite diagnosis of FHH. As FHH is very rare, with an estimated 
prevalence of 1 in 78,000 in Scotland, in our population of 380000, we would expect 
only about 5 FHH cases and therefore, its confounding effects, if any, are unlikely to 
be major. 
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 Hospital records will be used for this purpose. 
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Once the base population has been established, prescription data of their historical 
usage, if any, of lithium or thiazide diuretics are retrieved and linked. If, on review 
of the prescription records, it is clear that these drugs are the sole cause of raised 
serum calcium, that is, by scrutiny of timings and doses, these patients will be 
excluded from the cohort; otherwise, they will be included in counts but with a 
cautionary indication. 
 
Thus, our patient cohort should include all definite and probable PHPT patients, 
based on serum calcium measurements. The date of the first raised calcium is treated 
as the date of PHPT diagnosis. 
 
4.5 Data requested 
According to the proposed diagnostic process, calcium measurements were used to 
sift the potential cohort base from the Tayside general population. Thus, the initial 
data-request on biochemical records included all Tayside residents, with no 
discrimination on grounds of age or gender, with at least one serum calcium 
concentration of greater than 2.55mmol/l, from April 1995 through to December 
2006, as potential eligible subjects. This date was two years prior to the proposed 
study date (1 January 1997), in order to eliminate any catch-up effects in calcium 
measurements. Cases identified during the screening period were treated as prevalent 
cases. For these selected subjects, all their biochemical measurements on serum 
calcium, serum PTH, serum creatinine, cholesterol, alkaline phosphatase (ALP), 
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urine calcium and vitamin D made during the same period, were extracted. Units and 
reference ranges used in Tayside for these biochemical measurements are listed in  
Table 4.3 Serum calcium and PTH concentrations of all selected patients were firstly 
assessed to generate a probable cohort of PHPT.  
As described in section 4.4, in addition to the biochemistry data, several hospital 
level data were also requested, in order to:  
1) Confirm the diagnosis;  
2) Add in additional PHPT cases;  
3) Exclude non-eligible subjects;  
4) Validate biochemical algorithm of diagnosis.  
These data were:  
1) Hospital admission data on PHPT;  
2) Hospital surgery records on PTX;  
3) Nuclear medicine of positive Sestamibi Tc-99 scans;  
4) Histology data of proved parathyroid adenoma;  
5) Hospital letters indicating PHPT diagnosis;  
6) Tayside prescription data on lithium or thiazide diuretics.  
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Furthermore, Tayside Master Patient Index was requested to provide demographical 
information for the selected patients, using the anonymised patient identifier, namely 
PROCHI. 
Table 4.3 Reference values for quantities in blood, serum or plasma, that were used 
for this thesis 
Quantity Container Reference 
interval 
Units Age Sex 
ALP SST 20 – 455 
25 – 455 
130 – 390 
120 – 365 
130 – 455  
130 – 390  
120 – 455 
130 – 455 
120 – 420 
120 – 455 
25 – 90 
45 – 195 
20 – 80 
30 – 105 
40 – 150 
45 – 130 
50 – 190 
65 – 150 
 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
U/L 
< 3 years 
< 3 years 
3 - 11 
3 - 11 
11- 13 
11 - 13 
13 - 15 
13 - 15 
15 - 19 
15 - 19 
19 - 26 
19 - 26 
26 - 55 
26 - 55 
56 - 75 
56 - 75 
> 75 years 
> 75 years 
F 
M 
F 
M 
F 
M 
F 
M 
F 
M 
F 
M 
F 
M 
F 
M 
F 
M 
Calcium
1
 
 
SST 1.90 - 2.85 
2.10 - 2.55 
 
mmol/L 
mmol/L 
up to 21 days 
> 21d  & adults 
 
Cholesterol
2
 SST  less than 5.00 
 
mmol/L ideal value  
Creatinine
3
 SST 27 - 62 
28 - 71 
30 - 74 
40 - 82 
40 - 84 
46 - 95 
50 - 105 
50 - 100 
64 - 120 
60 - 98 
66 - 128 
60 - 160  
80 – 190 
 
mol/L 
mol/L 
mol/L 
mol/L 
mol/L 
mol/L 
mol/L 
mol/L 
mol/L 
mol/L 
mol/L 
mol/L 
< 4 years 
4 - 10 
4 - 10 
10- 14 
10 - 14 
14 - 18 
14 - 18 
18 - 55 
18 - 55 
55 - 75 
55 - 75 
> 75 years 
> 75 years 
 
F 
M 
F 
M 
F 
M 
F 
M 
F 
M 
F 
M 
PTH SST – 6.9 
 
pmol/L   
Vitamin D
4
 SST 25 - 170 nmol/L   
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1 
Calcium adjusted for albumin;  
2 
Reference values inappropriate – see SIGN Guideline 40 ad BNF for Joint British Societies risk 
prediction chart for details;  
3 
Depends on muscle mass;  
4
 25 – hydroxycholecaciferol 
4.6 Methods 
There were many processes involved in deriving the cohort of patients required for 
this study. As a result of the entire patient cohort being primarily identified using the 
retrospective electronic database on biochemistry records, it is important and useful 
to know the laboratory tests in the biochemistries used in this thesis during the data 
collecting period. On consulting the quality manager of the Department of 
biochemical medicine in NHS Tayside (Dr. JB), the relevant names of the suppliers 
of assays and analysers are summarised first followed by the exact patient 
identification process used in this thesis. 
 
4.6.1 Biochemistry methods 
Serum ALP, calcium, cholesterol and creatinine were analysed on the same 
analysers, which changed over the period as follows: 
January – November 1995:  Techincon AXON 
November 1995 – May 1998:  Bayer DAX 
May 1998 – June 2003:  Roche/Hitachi 917 
June 2003 to date:   Roche Modular P800 
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These analysers made use of spectrophotometric methods for ALP, calcium, 
cholesterol and creatinine. 
 
ALP: methods use p-nitophenyl phosphate as substrate with 2-amino-2-methyl-1-
propanol (AMP) buffer at 37
o
C.  ALP catalyses the reaction of p-nitrophenyl 
phosphate and water to form phosphate and p-nitrophenol. The p-nitrophenol 
released is proportional to ALP  activity and is measured spectrophometrically. 
 
Calcium: methods are based on cresolphthalein complexone.  Calcium reacts with o-
cresolphthalein in an alkaline medium to form calcium-o-cresolphthalein complex 
which is measured spectrophotometrically. 
 
Cholesterol (total): methods are based on the determination of cholest-4-en-3-one 
after enzymatic cleavage of the cholesterol ester by cholesterol esterase, conversion 
of cholesterol by cholesterol oxidase, and subsequent measurement by the Trinder 
reaction of the hydrogen peroxide formed. 
 
Creatinine: methods are based on the Jaffe reaction where creatinine reacts with 
picrate in an alkaline solution to form a orange-yellow complex which is measured 
spectrophotometrically. The rate of formation of this coloured complex is 
proportional to the concentration of creatinine. 
118 
Serum PTH was measured using a variety of methods: 
Until a point between September and November 1996: Nichols Allegro IRMA 
September/November 1996 – August 2002:  DPC IMMULITE 
August 2002 – June 2003:    DPC IMMULITE („new kit‟) 
June 2003 – November 2005:    Roche Elecsys 2010 
November 2005 to date:    Roche Modular E170 
All of the PTH assays measure(d) intact PTH.  The Nichols Allegro method is an 
immunoradiometric assay (IRMA).  The DPC and Roche assays are automated 
immunochemiluminometric assays. 
 
Urine calcium was measured using several different analysers over the years: 
October 1996 – May 1998:  Du Pont DIMENSION 
May 1998 – June 2003:  Roche/Hitachi 917 
June 2003 to date:   Roche Modular P800 
The methods used on these analysers are based on cresolphthalein complexone as for 
serum calcium.  No information on the methods used to measure urine calcium 
before October 1996. 
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Serum vitamin D was sent to another laboratory for analysis (Biochemistry, 
Glasgow Royal Infirmary) and thus no assay details were provided. 
 
4.6.2 Patient identification methods 
Various considerations and different approaches were made during the initial 
screening in response to the features of data presented, so that the cohort represents a 
complete and accurate group of PHPT patients fulfilling the diagnostic criteria. 
Figure 4.1 is a flow chart showing the screening process used in patient 
identification. 
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Figure 4.1 Flow chart illustrating process of patient identification using record 
linkage technology 
 
Calcium measurements 
for all Tayside residents 
April 1995 – December 2006 
Calcium≥2.55 mmol/l at least one occasion 
Yes 
All PTH measurements 
Record linkage 
Inappropriately normal or elevated PTH 
Yes 
No Exclude 
Surgery records 
Histology records 
Scan data 
Hospital letters 
 
Record linkage 
Urine data 
Hospital admissions 
Positive PHPT records 
Yes No Urinary calcium excretion 
Case notes 
Record linkage 
Positive FHH diagnosis 
Yes Exclude 
Include 
No 
Prescription data 
Record linkage 
Confirmed sole cause of hypercalcaemia 
Yes Exclude No 
Hospital letter 
Creatinine records 
Record linkage 
Confirmed tertiary hyperparathyroidism 
Yes Exclude No Hospital data 
Case notes 
Record linkage 
Indicating other cause of hypercalcaemia than PHPT 
Yes Exclude No Include 
No Exclude 
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The key of the diagnosis is to specifically define what inappropriately normal or 
elevated PTH concentrations (as highlighted in Figure 4.1) are, in relation to serum 
calcium concentrations.  Based on the clinical performance of the assay and the 
reference range used at the Ninewells Hospital laboratory, the following cut-off 
values are used for identifying potential PHPT patients in Tayside:  
a) Serum calcium > 2.55 mmol/L on at least two occasions and PTH > 3 pmol/L;  
b) Serum calcium > 2.55 mmol/L on one occasion with PTH > 6.9 pmol/L.  
 
These two different diagnostic cut-offs of serum PTH and calcium concentrations 
concretise the proposed diagnostic criteria a) and b), as listed in Section 4.4. 
 
Initial data screening was undertaken to examine the availability of calcium and PTH 
records. The preliminary analysis showed that there were 34,215 Tayside residents 
with at least one raised calcium concentration and there have been a total of 608,206 
calcium measurements made for these patients since April 1995. Of these, PTH 
measurements were only made for 5,469 patients with a total of 29,827 records. If, 
therefore, the initial PHPT diagnosis was made using the conjunction criteria of 
calcium and PTH concentrations, approximately 85% (n=28,746) of the selected 
people (with at least one raised calcium) will be excluded from the first diagnostic 
step, due to a lack of PTH records. At this stage, an additional criterion was added in 
order to capture a possible group of hypercalcaemic PHPT patients, that is, if a 
patient had at least two raised calcium for more than a year apart, he/she will be 
labelled as a possible PHPT patient.  This criterion was made taking the criteria of 
possible diagnosis used by Wermers et al (1999) as a reference.
221
 This group of 
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possible PHPT patients will allow further investigation being made in comparison to 
the diagnosed PHPT patients (patients who fulfilled the proposed diagnostic criteria). 
 
The accuracy of the electronic database will be validated against patient case notes. 
For patients with definite case-note diagnoses, their biochemistry algorithm based 
diagnoses will be checked. The agreement between the two diagnostic modes is 
compared. 
 
  
4.7 Results 
In total, there were 3,529,832 biochemistry records extracted for record linkage 
during patient identification for the selected cohort (n=34,215). Appendix 3 lists the 
frequency of all these biochemistry tests, together with their laboratory codes used. 
Before any diagnostic criteria were applied to the data, a plot was drawn to show the 
number of calcium and PTH tests taken for the selected potential cohort (n=34,215) 
by year (Figure 4.2). Throughout the whole study period, the number of calcium 
tests increased greatly over time, whilst PTH tests increased steadily, with a low 
number of tests by comparison. It can clearly be seen from the calcium tests that 
there were some noticeable upsurges in 1995, 1998 and 2000 respectively and a dip 
in 2003. Appendix 4 represents the same data but includes a number of additional 
biochemical tests, as well as calcium and PTH and it can be seen that the 
distributions of ALP, creatinine, cholesterol, were similar to calcium, in terms of 
numbers and patterns. When the number of patients tested for calcium and PTH was 
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plotted, as shown in Figure 4.3, however, it displayed a similar but less dramatic 
pattern in terms of the rise and fall. 
 
Regarding the initial batch of tests, which were made using serum calcium and PTH 
records, a total of 3,346 (9.8%) patients were identified as having probable PHPT 
and 13,334 (39.0%) as having possible PHPT. Table 4.4 shows the number of patient 
who met each individual criterion, by patient types. Patients identified as „unsure‟ 
due to the incompleteness of the data are excluded from further analysis, as well as 
those labelled as „definite No‟s‟. 
Figure 4.2 Number of calcium and PTH tests by year 
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Figure 4.3 Number of patients tested for calcium and PTH tests by year 
 
Table 4.4 Frequency of initial patient types identified from calcium and PTH records 
Patient Type PTH values Number Percent (%) 
Probable PHPT One raised Ca, PTH>6.9; or 
At least two raised Ca, PTH>3 
 
306 
3040 
0.9 
8.9 
Possible PHPT One raised Ca, PTH>3; or 
At least two raised Ca, no PTH 
 
411 
12923 
1.2 
37.8 
Definite No One raised Ca, PTH≤3; or 
At least two raised Ca, PTH≤3 
 
167 
703 
0.5 
2.0 
Unsure 
 
One raised Ca, no PTH 16,665 48.7 
Total  34,215 100 
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4.7.1 Baseline characteristics 
For the probable PHPT cases, further diagnostic criteria were applied to derive the 
base population of diagnosed PHPT. As shown in Figure 4.4, there were a total of 
2761 patients identified, including 102 additional cases added from the hospital 
admission records (i.e. SMR01 and OPCS). Of the 2659 probable cases, definite 
diagnoses were confirmed in 706 patients, using the other data sources as listed in 
Figure 4.1. All together, these 2761 patients formed the base population for the 
thesis and will be used in detailed epidemiological and outcome studies in 
subsequent chapters.  
Figure 4.4 Derivation of diagnosed base population from probable PHPT cases 
 
 
 
 
Biochemical identified probable PHPT cases 
N=3346 
Confirmed 
cases 
N=706 
Identified base population with diagnosed PHPT 
N=2761 
Further screening by other criteria 
Excluded cases 
N=687 
Urinary  
+ve 
N=400 
Histology 
+ve 
N=252 
Additional 
SMR cases 
N=102 Scan  
+ve 
N=187 
Letter 
+ve 
N=86 
SMR 
+ve 
N=345 
Hypercalcaemic cases with no other 
causes than PHPT  
N=1953 
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Of the total diagnosed PHPT patients, over 70% were female with a mean age of 67 
(SD=16), whilst 29.6% were male with a mean age of 62 (SD=18) (P<0.001). The 
female predominance was consistent over time (Figure 4.5). There were 418 (15.1%) 
cases diagnosed prior to 1997, which were treated as prevalent cases; of these 292 
(10.5%) cases diagnosed during the screening period of 1995 and 1996, and 126 
(4.6%) were cases identified from additional data sources, such as admission data 
and surgery records, which went as far back as 1981. Table 4.5 shows their 
demographic characteristics at baseline. It is worth noted that 7.7% (n=213) of the 
diagnosed cases were marked as possible drug related PHPT. They were patients 
who had been prescribed with either lithium or thiazide diuretics sometime before 
the first elevated calcium but because they were on intermittent prescription with a 
low dose, it was unclear if the drugs caused their hypercalcaemia or if it was 
coincidental, they were included in the cohort. By the end of 2006, 823 (29.8%) 
cases had died with cardiovascular disease and cancer being the main underlying 
causes of death. 
Figure 4.5 Number of PHPT patients diagnosed by year 
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Table 4.5 Baseline characteristics of the base patient cohort with PHPT (n = 2,761) 
  Total Male Female 
Variables Mean (SD) or count 
(column %) 
Mean (SD) or count 
(row %) 
Mean (SD) or count 
(row %) 
     
Counts  2761 818 (29.6%) 1943 (70.4%) 
     
Age
Sig 
 66 (17) 62 (18) 67 (16) 
     
Age Group    
(yrs) 0-9 32 (1.2%) 18 (56.3%) 14 (43.8%) 
 10-19 20 (0.7%) 9 (45.0%) 11 (55.0%) 
 20-29 40 (1.4%) 20 (50.0%) 20 (50.0%) 
 30-39 112 (4.1%) 55 (49.1%) 57 (50.9%) 
 40-49 183 (6.6%) 61 (33.3%) 122 (66.7%) 
 50-59 384 (13.9%) 108 (28.1%) 276 (71.9%) 
 60-69 687 (24.9%) 206 (30.0%) 481 (70.0%) 
 70-79 793 (28.7%) 234 (29.5%) 559 (70.5%) 
 80+ 510 (18.5%) 107 (21.0%) 403 (79.0%) 
     
     
    
Possible drug related cases
2 
213 (7.7%) 45 (21.1%) 189 (78.9%) 
     
Surgery treated 347 (12.6%) 88 (25.4%) 259 (74.6%) 
Sig
: Statistically significant difference between male and female 
1
: Total definite probable cases confirmed by case notes, hospital data, nuclear medicine, histology 
records or urinary criteria 
 
 
 
For the possible cases, when additional criteria were applied there were 2950 
patients with raised calcium for more than a one-year period, without other known 
causes. Their baseline characteristics are shown in Table 4.6, with a comparison to 
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those with diagnosed PHPT. The number of patients identified per year is shown in 
Appendix 5. Although Wermers et al. included such a group as PHPT patients
221
 and 
this is a group may be of value for further investigation of borderline PHPT patients 
with clinical insignificance, they were only retained in Chapter 5 for estimating the 
possible upper limit of  ID and PP in Tayside. As the thesis objective is set to 
investigate the outcomes in patients with diagnosed PHPT, only those diagnosed 
PHPT patients are used with further selection criteria in the subsequent chapters. 
 
Table 4.6 Baseline characteristics of possible PHPT patients, with a comparison to 
diagnosed patients 
Variables Diagnosed PHPT Possible PHPT P 
Count 2761 2950 NA 
Age (SD) 65.7 (16.5) 67.1 (14.2) 0.001 
Female (%) 1943 (70.4) 1998 (67.7%) 0.03 
Baseline Ca (SEM) 2.67 (0.003) 2.62 (0.001) <0.001 
Deaths (%) 823 (29.8%) 1152 (39.1%) <0.001 
 
4.7.2 Validation 
Among the 808 definite diagnoses, 706 cases were confirmed in addition to 
biochemical screenings. This allowed us to test the agreement between the two 
diagnostic modes (biochemistry vs. other sources) on these patients. There were 693 
probable PHPT cases identified using the biochemical algorithm, which gave a 
98.2% accurate agreement. There were 13 patients marked as possible PHPT cases 
due to their incomplete biochemical records. Only 4 patients did not meet the 
biochemical criteria of positive PHPT diagnoses, therefore, if these possible cases 
are included, there would be a total of 99.4% agreement between the two modes. 
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4.8 Discussion 
The aim of this chapter was to derive the base population with diagnosed PHPT in 
Tayside who had met the biochemical features of the condition, that is, 
hypercalcaemia with inappropriately elevated PTH concentration. This base 
population was successfully derived with almost 2800 patients, which is the largest 
cohort identified from unselected observations in a geographically defined 
population, with long-term follow up. As the majority were “incidental” discoveries 
with mildly biochemical abnormalities, this will have identified all cases that have 
been tested and is likely to reflect a true contemporary PHPT cohort in the „real-
world‟. Electronic record-linkage to several datasets encompasses information on 
demography, biochemistry and all other health-care related records, is thus another 
strength of this study. The linked database will allow separating the cohort into 
subgroups for further analyses. The PHPT cohort can, however, suffer under 
ascertainment, as patients with borderline hypercalcaemia were often omitted from 
further PTH tests. In addition, as the diagnosis heavily relies on electronic data 
sources, patients with asymptomatic PHPT, who never had their calcium checked, 
will not be identified.  
 
The results show that PHPT could affect all ages, with two-thirds of the patients 
being women and the female preponderance increases with age. These findings were 
similar to the existing evidence.
7, 34, 221, 223-225, 228, 230
 Since, however, the analysis 
held no pre-assumption on the age distribution and included Tayside residents of all 
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ages, 52 (2%) probable patients with under 20 years of age at diagnosis were 
identified. Although the number is relatively small, young patients are exceedingly 
rare and therefore, often require careful checking of case notes.
6
 After scrutiny of 
their cases notes and consulting with clinicians, those cases that appeared to have 
identified were indeed more likely to be cases of calcium sensing mutations. 
Therefore, a decision has been made to exclude these 52 cases from further analysis. 
The same age cut off (20 years and older) will be used when performing further 
analyses on those possible PHPT group in Chapter 8. 
 
In Tayside, for the entire duration of this study, both the number of PTH tests 
performed and the patients tested with PTH were significantly lower when compared 
to other tests undertaken (Figure 4.2, Figure 4.3). As a result, by using a biochemical 
algorithm in combination with calcium and PTH concentrations, a large proportion 
of the potential candidates would be excluded at the initial screening. As PHPT has 
been considered as the most common cause of hypercalcaemia, a group of possible 
PHPT who were patients with persistently raised calcium but without PTH 
measurements, were retained.
216, 221
 The criteria of hypercalcaemia were similar to 
existing evidence but with a slightly lower cut off in consideration of the reference 
range used in Tayside laboratories.
216
 As described earlier, these possible cases will 
be used to give an upper limit estimate of the total possible screened PHPT cases in 
Tayside. However, since „elevated serum calcium with inappropriately normal or 
raised PTH concentrations‟ is the recommended diagnostic criteria for PHPT, this 
thesis is focused on diagnosed PHPT, i.e. patients with definite PHPT, only.
6, 57, 220
  
 
131 
A complete study population, with diagnosed and possible PHPT, has been 
successfully identified, but this process is not without its problems. As shown in 
Figure 4.2 and Appendix 4, the biochemical records held at the HIC have a 
noticeably sharp rise from 1998 and dip from 2002, which is also reflected in the 
numbers of PHPT patients identified by year (Figure 4.5 and Appendix 5). By 
questioning the HIC staff and Ninewells Hospital laboratory technicians, these 
variations were explained by a series of changes in the Masterlab system. During 
these changes, the Stracathro laboratory data from 1998 were fed into the Ninewells 
system and Perth data from 2003, were merged with the Ninewells‟ system. 
Although Ninewells have subsequently collected biochemistry data from other older 
systems, Wynne Carter‟s system (1976-1995), Pinnacle (Nov 1995 – Nov 1998), 
LabCentre (Nov 1998 – Present), there may be some Perth biochemistry (1998 to 
2002) data from the Perth Royal Infirmary (PRI) missing, as they were stored in the 
PRI IT department on the Telepath server to which the physical access was no longer 
possible (staff leaving, thus the encrypted password is no longer known, plus cost 
issues). To test if there were any considerable missing biochemistry records and the 
possible effects on the patient identification, two approaches were made: firstly, the 
annual number of total calcium measurements made in Tayside and the total patients 
with calcium measured (including those with normal readings) were plotted; 
secondly, the number of diagnosed PHPT patients per year was plotted, only 
including Dundee patients via postcode linkage.  
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Figure 4.6 Distribution of total calcium measurements and patients tested over time 
 
 
As shown in Figure 4.6, both the total calcium tests and the number of patients with 
calcium tests increased steadily, with only slight fluctuations over time. This 
indicates that the effects of missing biochemistry records, if any, are minor. By 
postcode linkage, over 75% (n=2,129) of the diagnosed patients were residents from 
the City of Dundee. It can be seen from Figure 4.7 that apart from a slightly reduced 
number diagnosed each year, both the gender ratio and the overall pattern of 
diagnosis, reflected the Tayside plot (Figure 4.5).  This result further, reassured the 
reliability of the biochemistry records held by the HIC. Interestingly, during the 
postcode linkage, it was found that 7% (n=239) of the original identified probable 
cases (n=3,346) were actually NOT Tayside residents. For some unknown 
underlying reasons, they had their blood sample taken within Tayside region and 
thus, they were incorrectly picked up when the biochemistry records were extracted 
from the Tayside Lab Centre. This was an unexpected but very important finding, 
which emphasised the importance of using postcode to double check a potential 
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cohort, when geographically identified population were used. These 239 non-
Tayside patients had been excluded from the final cohort (they were counted as part 
of the 687 excluded cases), before presenting the results. Postcode checking was also 
done for the possible group, so that all the 2950 cases are confirmed Tayside 
residents. 
 
Figure 4.7 Number of PHPT patients diagnosed in Dundee 
 
 
4.9 Chapter summary 
In summary, this chapter has described the derivation and characteristics of the base 
population. It also identified a group of possible PHPT patients, whose diagnoses 
were not definitely established, due to the missing PTH values. In addition, this 
chapter has summarised the diagnostic criteria used in the existing studies and 
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discussed problems of the data and difficulties encountered during the patient 
identification. The next chapter will continue, by measuring the prevalence and 
incidence of PHPT in Tayside. 
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CHAPTER 5  
EPIDEMIOLOGY OF DIAGNOSED PHPT IN 
TAYSIDE 
5.1  Overview 
This chapter will provide a systematic overview of the epidemiology of diagnosed 
PHPT in Tayside, with a focus on evaluating its prevalence and incidence between 
1997 and 2006. It will start with a brief summary of the literature, followed by a 
discussion on the weaknesses of existing estimates. Thereafter, the patients and 
methods used will be described before detailed baseline characteristics of the 
selected patients are presented. The prevalence and incidence will be presented on a 
year-on-year basis by gender and age group respectively and any trend over time will 
be estimated by using the age and gender adjusted rates. The annual all-cause 
mortality rate will also be presented in the latter part of the chapter.  Finally, the 
merits of findings, strengths and weaknesses of this part of the study will be 
discussed, as compared to the current literature and the chapter will be concluded by 
a short summary. 
 
5.2 Introduction 
With the increasing accessibility to routine biochemical screenings, more patients 
with mildly-elevated serum calcium are now being diagnosed with PHPT and the 
136 
proportion of such mild patients has increased from 18% in the early 1960‟s, to over 
80% currently.
5-8, 85, 163, 232-235
  
 
Current estimates of prevalence of PHPT vary from 0.5 to 34 per 1,000 population 
and the incidence lies between 0.4 and 18.8 per 10,000 person-years, depending on 
the screening methods, definitions and population surveyed.
7, 15, 34, 40, 221, 224, 229, 234, 236, 
237
 The risk of PHPT is affected by age and gender but the prevalence is highest in 
adults aged between 40-70 years and the risk is 2 to 3 times higher in women than in 
men (with further increased differences between genders, in midlife adults).
7, 8, 15, 34, 
40, 224, 235, 238
 In the US, the prevalence has been estimated at about 2 per 1000 
population in women and 0.5 in men, which approximates to 10 per 1,000 population 
of adults aged over 40 and an even higher prevalence, 34 per 1,000, in 
postmenopausal women.
221, 237
 In a Danish study, the prevalence was reported as 
between 4 and 10 per 1,000 population and up to 30 in postmenopausal women.
239
 
The increasing incidence observed in the early 1970‟s was explained by the „catch-
up‟ effect (prevalent cases identified as automated calcium measurement became 
widespread, followed by a fall once most of these had been identified as post catch 
up effect). Some evidence has also shown a decline in the incidence over the last 
decade.
34, 224, 235
 None of these studies, however, reported year on year incidence 
within the same centre. In addition, current epidemiological estimations at 
population level are primarily derived from specific selected study populations, 
mostly from referral centres or health surveys (as described in Chapter 4, Section 4.3) 
and assume a consistent distribution of PHPT among men and women at different 
ages.
235
 These estimates, therefore, are limited by their study designs and require 
further estimation at on a real “population-level”. 
137 
In summary, an updated „real‟ population-based study is needed to address the wide 
variation in prevalence and incidence estimation of PHPT. Using the diagnosed 
patients identified in Chapter 4, this Chapter will systematically evaluate the 
epidemiological trend of diagnosed PHPT in Tayside, Scotland, over a ten-year 
period (1997 – 2006). The main aim is to provide an accurate estimate of its 
prevalence and incidence, without pre-assumption as to age distribution. In addition, 
the prevalence and incidence of the possible patients identified in the last chapter 
were also estimated in order to give an upper limit of the total likely screened PHPT 
cases in Tayside and the findings were discussed in Section 5.5. 
 
5.3 Patients and methods 
5.3.1 Patients 
As described in Chapter 4, an algorithm was developed to identify all diagnosed 
PHPT patients using six principle databases, namely the Tayside Master Patient 
Index, biochemistry database, hospital data, Tayside prescription data, the histology 
database and nuclear medicine records, in Tayside, Scotland. In brief, if a Tayside 
resident had met one or more of the following criteria, a positive diagnosis was 
established and the person was included, as having diagnosed PHPT: 
 
1. Pathologically proven PHPT diagnosis; 
2. Hospital admissions with PHPT or surgical procedures, with 
parathyroidectomy (PTX);  
3. Biochemically met the diagnostic criteria of PHPT, of raised serum calcium 
with elevated or inappropriately normal plasma PTH concentration and 
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normal or raised urine calcium excretion, with no other known causes of 
hypercalcaemia. 
 
This chapter included all such identified patients who were over the age of 20 at 
diagnosis, in order to reflect a true cohort of PHPT cases (reasons for excluding 
young cases were discussed in Chapter 4, Section 4.8 and also briefly mentioned 
later in Section 5.5). 
 
5.3.2 Methods 
Descriptive statistics were used to summarise baseline characteristics and the 
biochemical profile of the patients. Baseline age was the age at which a positive 
diagnosis of PHPT was made, which was the date of the first raised calcium or the 
first date of hospital discharge on a PHPT admission for those who were solely 
identified by hospital data (n=101). Differences between men and women were 
compared using the Independent Samples t-test or Mann-Whitney U test, as 
appropriate. The trend of biochemical profile and demographic characteristics over 
time were compared using ANOVA and test for trend.  
 
The primary outcomes were the incidence and prevalence of diagnosed PHPT, 
including both unadjusted and adjusted rates. ID and PP were calculated for each 
year. The ID was computed as new cases arising from the beginning to the end of 
each calendar year, divided by the population at risk and expressed as number per 
10,000 person-years; 95% CIs were calculated, assuming a Poisson distribution.
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The PP was calculated as the number of existing cases up to the end of each year, 
divided by the population at risk and denoted as number per 1,000 population; 95% 
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CIs were estimated for proportions, assuming a Binomial distribution for each 
year.
241
 Detailed information on PP and ID was described in Chapter 3, Section 3.4. 
Mid-year population estimates for Tayside Health Board Area were obtained from 
the General Registry Office and were used in all calculations.
188
 Unadjusted rates 
provided an approximate estimate at population level, with no discrimination for age 
and gender structure. Age specific rates were also presented for men and women 
separately, by dividing the cohort into four different age groups (under 40, 50-59, 
60-69, 70+). These cut-offs were decided after preliminary examination of the age 
distribution of the patient cohort. Adjusted rates were standardised rates calculated 
by using age and sex stratified cases, divided by a standard population. Adjusted 
rates would make cross-time comparisons possible. The average Tayside population 
structure between 1997 and 2006 was used as the standard population, in order to 
provide a better grasp of trends over time. For each calendar year, mid-year (30 June) 
estimations were used to calculate age for all persons. The difference in unadjusted 
incidence and prevalence between men and women was examined using the χ2-tests. . 
The significance of any changes in incidence and prevalence year-on-year were 
assessed using ANOVA.  
 
The secondary outcome was mortality rate, being defined as the number of patients 
with diagnosed PHPT who had died in a given year, divided by the total population 
at risk (person-years) for that year and was expressed as number per 1,000 PHPT 
patients. The 95% CI was calculated assuming a Poisson distribution. 
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Curve estimation was used to determine if there were any trends in incidence, 
prevalence and mortality over the course of time. Statistical significance was reached 
when the p value was less than 0.05. All analyses were carried out using SPSS 
(version 17.0) or SAS (version 9.2) software.  
 
5.4 Results 
5.4.1 Characteristics of patients 
During the study period (1997 to 2006), the population of Tayside adults aged 20 
years and over increased from 299,029 to 302,720 and there were 28,470 residents 
with at least one elevated serum calcium concentration, who were selected as 
potential subjects. There were 3049 probable PHPT cases identified by the end of 
2006. Patients with tertiary hyperparathyroidism (N=441), who were identified using 
the additional data resources (described in detail in Chapter 3), were excluded and 
definite PHPT diagnosis was confirmed in 798 cases, including an additional group 
of 101 cases identified solely from hospital admission, giving a complete cohort of 
2,709 patients with diagnosed PHPT (Table 5.1). The validation process (See 
Chapter 4) indicated that the electronic patient identification was an accurate 
diagnosis mode, with a total agreement of 99.4%. As shown in Table 5.1, the 
baseline biochemistries were similar between men and women except for creatinine, 
which was significantly higher in men than that in women. 
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Table 5.1 Characteristics of diagnosed PHPT patients in Tayside, Scotland 
Variables 
 
Total Male Female P 
Counts (%) 2709 791 (29%) 1918 (71%) NA 
Age mean (SD)
Sig. 
67 (14.4) 64 (15.2) 68 (14.0) <0.001 
Period 
    
0.40 
Pre 1997 410 (15%) 110 (14%) 300 (16%) NA 
97-01 1029 (38%) 297 (38%) 732 (38%) NA 
02-06 1270 (47%) 384 (49%) 886 (46%) NA 
Biochemical indices mean (SEM) 
 
 
Ca 
    
 
Patients count (%) 2608 (96%) 766 (97%) 1842 (96%) NA 
Baseline 2.67 (0.003) 2.68 (0.003) 2.67 (0.007) <0.001 
Mean of first two raised 2.64 (0.003) 2.62 (0.007) 2.64 (0.004) <0.001 
Maximum 2.78 (0.004) 2.79 (0.01) 2.78 (0.05) 0.001 
PTH 
    
 
Patients count (%) 2585 (95%) 763 (96%) 1822 (95%) NA 
Baseline 12.5 (0.26) 12.6 (0.51) 12.5 (0.30) 0.13 
Maximum 17.9 (0.53) 20.3 (1.25) 16.9 (0.53) 0.83 
Creatinine 
   
 
Patients count (%) 2605 (96%) 766 (97%) 1839 (96%) NA 
Baseline 138.6 (2.14) 170.2 (5.09) 125.2 (2.07) <0.001 
Maximum 239.0 (4.66) 317.8 (11.1) 206.1 (4.5) <0.001 
ALP 
   
 
Patients count (%) 2608 (96%) 766 (97%) 1842 (96%) NA 
Baseline 114.6 (1.68) 112.4 (2.74) 115.5 (2.1) 0.26 
Maximum 212.7 (4.54) 228.9 (9.89) 206.0 (4.93) 0.33 
Total definite positives
1 
798 (29%) 196 (25%) 602 (31%) 0.001 
Histology +ve 246 (9%) 70 (9%) 176 (9%) 0.78 
Scan +ve 170 (6%) 40 (5%) 130 (7%) 0.09 
Letter +ve 86 (3%) 15 (2%) 71 (4%) 0.02 
SMR +ve
2 
444 (16%) 115 (15%) 329 (17%) 0.10 
Urinary +ve 378 (14%) 87 (11%) 291 (15%) 0.004 
Possible drug related cases 213 (8%) 45 (6%) 168 (9%) 0.007 
1
: Total definite cases confirmed by case notes, hospital admissions or urinary criteria 
2
: definite cases identified by hospital admission data (SMR01) and hospital operation and procedure 
records (OPCS) 
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Figure 5.1 shows the number of patients diagnosed each year for men and women 
separately and it can be seen that a small proportion (4.5%) of patients was 
diagnosed prior to 1995, of these, the majority were cases identified solely by the 
hospital admission data. During the screening period (1995 and 1996), there was a 
slight „catch up‟ effect in 1996, when a total of 195 (7.2%) patients were identified. 
Altogether, there were 410 (15.1%) prevalent cases at the start date of the study, all 
of whom were patients identified prior to 1997 (Table 5.1). 
 
Figure 5.1 Number of patients diagnosed each year 
 
 
From all the patients, 213 (7.9%) had been prescribed with thiazide diuretics or 
lithium but were included in the cohort with a caution mark because they were on a 
low dosage and the causal relationship between the drugs and the hypercalcaemia 
was unclear (Table 5.1). In total, there were 791 (29.2%) male patients identified as 
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having PHPT, with a mean age of 64 years (SD=15), and 1,918 (70.8%) female 
patients, with a mean age of 68 (SD=14) (p<0.001). As shown in Figure 5.2, most 
patients (over 90%) were over 40 years of age and the risk increased with age for 
both sexes; the female/male ratio rose from 2 (age 40-49 years old) to nearly 4 (age 
80+). Below 40 years of age, the number of cases was similar in both sexes. 
 
Figure 5.2 Distribution of baseline age by gender 
 
 
 
The mean age of both male and female incident patients increased in 2006, when 
compared to 1997; the preponderance of female patients was stable over the ten 
years (Table 5.2). The mean value of calcium concentrations fluctuated each year but 
the means of the maximum calcium concentrations significantly decreased (female: 
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2.86 mmol/L in 1997 to 2.73 mmol/L in 2006; male: 2.89 mmol/L to 2.72 mmol/L). 
Both mean PTH concentrations and mean of maximum PTH concentrations, among 
incident cases significantly decreased during the period of study. The mean PTH 
concentration was 13.24 pmol/L in female and 18.00 pmol/L in male in 1997; it 
reduced to 9.14 and 12.00 respectively, in 2006.   
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Table 5.2 The trend of demographic characteristics and biochemical profile in incident patients with PHPT at diagnosis 
 Year   1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 P 
  % Female 74.6% 75.4% 72.7% 66.0% 69.0% 64.1% 70.8% 69.9% 67.9% 72.7%  
             
 
 
 
 
Female 
 
 
Mean 
(SD) 
Age 67 (15) 69 (13) 68 (14) 67 (15) 68 (14) 67 (14) 70 (13) 70 (12) 70 (14) 71 (14) <0.001 
            
Ca_mean 
2.59 
(0.14) 
  
2.55 
(0.16) 
  
2.5 
 (0.14) 
  
2.52 
(0.13) 
  
2.55 
(0.14) 
  
2.55 
(0.13)  
 
2.5 
 (0.13) 
  
2.55 
(0.13) 
  
2.56 
(0.15) 
  
2.55 
(0.16) 
  
0.023  
Ca_max 
2.86 
(0.23) 
  
2.81 
 (0.18) 
  
2.81 
(0.22) 
  
2.75 
(0.19) 
  
2.78 
(0.19) 
  
2.77 
(0.17)  
 
2.77 
(0.15)  
 
2.76 
(0.18)  
 
2.76 
(0.20) 
  
2.73 
(0.21) 
  
<0.001 
PTH_mean 
13.24 
(11.15)  
 
15.28 
(17.01) 
  
13.73 
(18.23) 
  
12.70 
(11.32)  
 
14.13 
(12.04) 
  
10.83  
(8.34) 
  
12.46 
(10.04)  
 
10.95 
(10.57) 
  
10.15  
(9.00) 
  
9.14 
(7.01) 
  
<0.001 
PTH_max 
18.71 
(22.31) 
21.68 
(31.02)  
19.60 
(31.87)  
17.42 
(20.77)  
17.75 
(16.10)  
14.76 
(16.06)  
16.00 
(16.36)  
13.38 
(15.04)  
11.89 
(12.02)  
10.85  
(9.80)  
<0.001 
             
Male 
 
 
Mean 
(SD) 
Age 61 (15) 60 (14) 62  (15) 63 (14) 67 (13) 65 (15) 68 (15) 65 (16) 70 (14) 71 (13) <0.001 
            
Ca_mean 
2.53 
(0.17) 
  
2.51 
 (0.13) 
  
2.52  
(0.16) 
  
2.48  
(0.11) 
  
2.49  
(0.12) 
  
2.49  
(0.11)  
 
2.55 
 (0.17) 
  
2.53  
(0.13)  
 
2.51  
(0.14)  
 
2.51  
(0.15)  
 
<0.001 
Ca_max 
2.89 
(0.27) 
  
2.83 
(0.22) 
  
2.85 
(0.33) 
  
2.74 
 (0.20) 
  
2.80 
 (0.43)  
 
2.71  
(0.16)  
 
2.81 
 (0.24) 
  
2.78  
(0.20) 
  
2.70 
 (0.16) 
  
2.72 
 (0.23) 
  
<0.001 
PTH_mean 
18.00 
(22.36) 
  
14.07 
(13.60) 
  
14.54 
(20.77) 
  
11.27 
(13.21) 
 
15.74 
(16.60)  
 
10.04 
 (8.13) 
  
10.68 
 (7.73) 
  
7.94  
(4.55) 
  
10.76  
(9.26) 
  
12.00  
(9.21) 
  
<0.001 
PTH_max 
32.96 
(52.48)  
23.48 
(32.20)  
19.23 
(28.61)  
19.77 
(33.95)  
26.07 
(43.75)  
14.85 
(18.48)  
14.54 
(17.01)  
9.63  
(6.36)  
14.14 
(14.55)  
15.14 
(13.51)  
<0.001 
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Table 5.3 Annual incidence density (ID) for all diagnosed PHPT patients 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
No. of patients tested 14,943 15,524 17,975 19,644 24,700 25,583 32,799 40,052 42,599 44,054 
% of patients tested 5.0% 5.2% 6.0% 6.6% 8.3% 8.6% 11.0% 13.4% 14.2% 14.6% 
Male data           
Population 140,280 139,895 139,879 139,784 140,002 139,929 140,614 140,369 141,436 142573 
Incident cases 31 43 61 110 52 62 55 99 95 73 
Unadjusted Incidence 2.21 3.07 4.36 7.87 3.71 4.43 3.91 7.05 6.72 5.11 
95% CI 1.43-2.99 2.16-3.99 3.27-5.46 6.40-9.34 2.70-4.72 3.33-5.53 2.88-4.95 5.66-8.44 5.37-8.07 3.94-6.29 
Age adjusted ID
ns 
2.28 3.15 4.46 7.95 3.74 4.41 3.82 6.83 6.45 4.85 
95% CI 1.49-3.07 2.22-4.08 3.36-5.57 6.48-9.43 2.73-4.75 3.32-5.51 2.80-4.85 5.47-8.20 5.12-7.78 3.70-6.00 
     
Female data     
Population 158,749 158,299 158,081 157,814 157,649 157,456 157,141 157,819 158,746 159,967 
Incident cases 90 132 169 224 117 114 141 234 199 198 
Unadjusted ID 5.67 8.34 10.69 14.19 7.42 7.24 8.97 14.83 12.54 12.38 
95% CI 4.50-6.84 6.92-9.76 9.08-12.30 12.34-16.05 6.08-8.77 5.91-8.57 7.49-10.45 12.93-16.73 10.79-14.28 10.65-14.10 
Age adjusted ID
ns 
5.78 8.50 10.78 14.27 7.44 7.20 8.87 14.60 12.31 12.18 
95% CI 4.60-6.96 7.07-9.94 9.16-12.39 12.41-16.13 6.09-8.78 5.88-8.53 7.41-10.34 12.72-16.48 10.58-14.04 10.46-13.90 
     
Total population           
Unadjusted ID 4.05 5.87 7.72 11.22 5.68 5.92 6.58 11.17 9.79 8.95 
95% CI 3.33-4.77 5.00-5.74 6.72-8.72 10.02-12.43 4.82-6.53 5.04-6.79 5.66-7.50 9.97-12.37 8.67-10.91 7.89-10.02 
Age and sex adjusted ID
ns 
4.13 5.98 7.81 11.30 5.70 5.89 6.50 10.95 9.56 8.73 
95% CI  3.40-4.86 5.11-6.86 6.80-8.81 10.09-12.50 4.84-6.55 5.02-6.76 5.58-7.41 9.76-12.13 8.45-10.66 7.67-9.79 
**Significant difference (P < 0.001), * Significant difference (P < 0.05), ns, Not significant 
ID was calculated as number of new cases each year divided by the total person-time of observation, expressed as number per 10,000 person-years 
Age adjusted ID = (ΣIij/pij*Pi)/ ΣPi, I: incident cases; p: age year specific person years; P: age specific standard person years; i; age group; j:year. 
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5.4.2 Incidence and prevalence 
As shown in Table 5.3, both the number and the percentage of patients tested for 
serum calcium increased steadily, from 14,943 (5.0%) in 1997 to 44,054 (14.6%) in 
2006, in Tayside, Scotland. Despite this steady trend, the incidence of diagnosed 
PHPT showed an unexpected apparent cyclical trend (Figure 5.3). The adjusted 
incident cases varied from 123 to 338, during the study period. Thus annual 
incidence density varied from 4.13 to 11.30 per 10,000
 
person-years, in the general 
population (2.28 to 7.95 in men and 5.78 to 14.27 in women). Incidence increased 
from 4.13 in 1997 to 11.30 in 2000 (p < 0.05), then fell to 5.70 in the following year 
but reached another peak in 2004 (10.95 per 10,000 person-years) before falling 
again. There was a small decline in both the absolute incident cases and the 
incidence over the last two years observed (adjusted cases dropped from 327 in 2004 
to 261 in 2006, and ID dropped from 10.95 to 8.73). The overall change in the 
incidence did not reach any statistically significant level, however, the incidence of 
PHPT in women was significantly higher than in men (p < 0.001 in both instances). 
In addition, the annual incidence significantly increased by age group, for both men 
and women. (Figure 5.4, Figure 5.5) 
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Figure 5.3 Adjusted annual ID with 95% CI for men and women, separately 
 
Figure 5.4 Age specific incidence with 95% CI by year for male patients 
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Figure 5.5 Age specific incidence with 95% CI by year for female patients 
 
There was a general increase in the prevalence of diagnosed PHPT in Tayside over 
the duration of the study, the total adjusted prevalence increasing significantly over 
time (p<0.001). Adjusted prevalent cases increased from 398 in 1997 to 1,427 in 
2006 in women, and 145 to 581 in men (Figure 5.6). The prevalence increased from 
1.82 to 6.72 per 1,000 adult population (p < 0.001) during the study period, which 
showed more than a twofold increase in the total number of adjusted prevalent cases 
(n=543 in 1997 and 2,008 in 2006) (Table 5.4). The percentage of year-on-year 
increase in prevalence varied from 2%-44% for men and 6%-30% for women, and 
neither yearly increase reached statistical significance. As shown in Figure 5.7 and 
Figure 5.8, in each year, the number of patients aged 60 years and over was more 
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prevalent than those of less than 60 years and there was a significant 
difference in prevalence among the four age groups (p<0.001 in both instances). 
 
Figure 5.6 Adjusted annual PP with 95% CI for men and women, separately 
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Figure 5.7 Age specific prevalence with 95% CI by year for male patients 
 
Figure 5.8 Age specific prevalence with 95% CI for female patients 
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Table 5.4 Annual period prevalence (PP) for all diagnosed PHPT patients 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Male data           
Population 140,280 139,859 139,879 139,784 140,002 139,929 140,614 140,369 141,436 142,753 
Prevalent cases 141 179 234 340 376 414 445 520 585 606 
Unadjusted PP (‰) 1.01 1.28 1.67 2.43 2.69 2.96 3.17 3.70 4.14 4.25 
95% CI 0.84-1.17 1.09-1.47 1.46-1.89 2.17-2.69 2.41-2.96 2.67-3.24 2.88-3.47 3.39-4.02 3.80-4.47 3.91-4.58 
Adjusted PP (‰)** 1.03 1.30 1.70 2.45 2.70 2.95 3.14 3.63 4.04 4.13 
95% CI 0.86-1.20 1.11-1.49 1.48-1.91 2.19-2.71 2.42-2.97 2.67-3.23 2.85-3.43 3.31-3.94 3.71-4.37 3.80-4.47 
Female data       
Population 158,749 158,299 158,081 157,814 157,649 157,456 157,141 157,819 158,746 159,967 
Prevalent cases 390 506 657 853 930 993 1082 1253 1372 1461 
Unadjusted PP (‰) 2.46 3.20 4.16 5.41 5.90 6.31 6.89 7.94 8.64 9.13 
95% CI 2.21-2.70 2.92-3.47 3.84-4.47 5.04-5.77 5.52-6.28 5.92-6.70 6.48-7.29 7.50-8.38 8.19-9.10 8.67-9.60 
Adjusted PP (‰)** 2.52 3.25 4.20 5.44 5.91 6.29 6.82 7.83 8.52 9.02 
95% CI 2.27-2.76 2.97-3.53 3.88-4.52 5.07-5.80 5.53-6.29 5.90-6.68 6.41-7.22 7.40-8.27 8.07-8.98 8.56-9.49 
Total population           
Unadjusted PP (‰) 1.78 2.30 2.99 4.01 4.39 4.73 5.13 5.95 6.52 6.83 
95% CI 1.62-1.93 2.13-2.47 2.79-3.19 3.78-4.24 4.15-4.63 4.48-4.98 4.88-5.39 5.67-6.22 6.23-6.81 6.53-7.12 
Age and sex adjusted  
PP (‰)** 1.82 2.33 3.02 4.03 4.40 4.72 5.09 5.85 6.41 6.72 
95% CI 1.66-1.97 2.28-2.39 2.96-3.08 3.94-4.10 4.32-4.47 4.64-4.79 5.01-5.16 5.77-5.94 6.33-6.50 6.63-6.81 
**P < 0.001; * P < 0.05; ns, Not significant. PP was calculated as the proportion (‰) of the existing cases divided by population during the same period, 
expressed as number per 1,000 population 
Age adjusted PP=(Σprij/pij)*Pi)/ ΣPi, pr: age specific prevalent cases; p: age specific population; P: age specific standard population; i: age group; j: year. 
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Table 5.5 Annual all-cause mortality rate (per 1,000) by gender 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Male data           
Person-years 123.2 146.9 191.2 270.3 336.7 370.8 402.8 452.2 504.3 537.6 
Deaths 5 6 5 16 24 23 26 30 52 54 
Mortality rate 40.6 40.8 26.2 59.2 71.3 62.0 64.5 66.3 103.1 100.4 
95% CI 5.0-76.2 8.2-73.5 3.2-49.1 30.2-88.2 42.8-99.8 36.7-87.4 39.7-89.4 42.6-90.1 
75.1-
131.2 73.7-127.2 
       
Female data       
Person-years 336.2 423.9 535.0 711.3 836.4 896.8 961.3 1080.7 1197.5 1282.0 
Deaths 16 19 29 40 52 52 63 80 110 120 
Mortality rate 47.6 44.8 54.2 56.2 62.2 58.0 65.5 74.0 91.9 93.6 
95% CI 24.3-70.9 24.7-65.0 34.5-73.9 38.8-73.7 45.3-79.1 42.2-73.7 49.4-81.7 57.8-90.3 74.7-109.0 76.9-110.4 
           
Total population           
Mortality rate 45.7 43.8 46.8 57.1 64.8 59.2 65.2 71.8 95.2 95.6 
95% CI 26.2-65.3 26.6-61.0 31.1-62.6 42.1-72.0 50.2-79.4 45.8-72.6 51.7-78.8 58.4-85.2 80.5-109.9 81.4-109.8 
 154 
5.4.3 Mortality 
Table 5.5 shows evidence that the all-cause mortality rate for patients with diagnosed 
PHPT increased from 45.7 per 1,000 patients in 1997, to 95.6 per 1,000 patients in 
2006. Although rates slightly fluctuated within the ten year period, there was a 
significant upward linear trend (Adjusted R
2
=0.86, p<0.001). No difference in the 
annual mortality rate between men and women was found. 
 
5.5 Discussion 
This chapter systematically evaluated the epidemiological changes in diagnosed 
PHPT in Tayside, over a ten-year period. The data and methods used in this chapter 
have three particular strengths compared with other epidemiological studies:  
 
1. The routine collected and collated data was provided from a robust 
population database of biochemical tests. PHPT diagnoses were made when 
hypercalcaemia coexisted with inappropriate normal or elevated PTH 
concentration, from a large population
5, 6, 8, 155
 The accuracy of the diagnosis 
was successfully validated, with a total agreement between electronic and 
case notes identification, indicating that this is a reliable resource by which to 
identify patients.  
 
2. The patient selection was made more inclusive by using 2.55mmol/L as the 
initial calcium cut-off point, to include more mild (but true) PHPT patients, 
who are now the majority with boundary biochemical profile. This allowed a 
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larger patient cohort to be captured. The significant 
decrease in both the maximum calcium and PTH concentrations over the 
years may well reflect less „severe‟ cases being identified over time (Table 
5.2). 
 
3. Incident and prevalent cases were scrupulously classified. To avoid existing 
patients being misclassified as incident cases, by utilizing a repetitive 
measurement, biochemical records were retrospectively checked with the 
available calcium concentrations prior to 1997, for selected patients. If there 
had been any prior raised calcium, a patient was then considered as a 
prevalent case. 
 
The weaknesses of this analysis include the fact that diagnoses were dependent on 
electronic case records and that paper records were checked in a small minority of 
cases. Electronic records, however, seem robust, as indicated in the validation.  
 
Secondly, not all cases will have been identified, as the existing diagnoses are 
subject to biochemical measurements. Therefore, the 2,709 patients identified are 
patients with diagnosed PHPT, indicating a current prevalence of 6.7 per 1,000 
population. This estimate only represents the prevalence of diagnosed PHPT patients, 
which will be lower than the true prevalence. The general increasing trend of 
prevalence tends to suggest improving rates of diagnosis within a population where 
there are a significant number of, as yet, undiagnosed cases. In addition, as discussed 
in Chapter 4, both the number of PTH tests and the number of patients tested for 
PTH were significantly lower than calcium measurements, there were also a large 
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number of people who had raised calcium with no defined cause being 
identified but not included (labelled as „possible PHPT‟ in Chapter 4). If these 
possible cases were included, then that would increase the current estimates. Since 
patients with prolonged hypercalcaemia without PTH measurements have been 
included as PHPT patients in a previous study
221
, due to the fact that PHPT is the 
most common cause of hypercalcaemia, additional estimates of the ID and PP were, 
therefore, calculated by combining both definite and possible patients. As described 
in Chapter 4, Section 4.7, there were in total 2950 possible patients (aged 20 and 
over at the time of the first raised calcium) who were with raised calcium 
concentrations for more than a one-year period with no other known causes. Their 
baseline characteristics in comparison to those diagnosed PHPT cases were 
presented in Section 4.7, Chapter 4 and their annual ID and PP are presented in 
Appendix 5.1 and 5.2. By including these extra possible patients, the combined 
adjusted annual incidence varied from 10.93 per 10,000 person-years in 1997 to the 
highest of 27.45 in 2000, indicating the adjusted ID for all likely PHPT patients that 
screened (i.e. at least with calcium measurements) was more than doubled compared 
to that presented in Table 5.3 (Table 5.6). As shown in Table 5.7, when the possible 
patients were added, the combined adjusted PP also doubled from 3.68 per 1,000 
population in 1997 to 13.38 in 2005 compared to that presented in Table 5.4. Note 
that the definition of possible patients required calcium records for at least one year 
from the first raised calcium, thus, the number of possible cases identified in 2006 
was incomplete because the biochemical data request was made only till the end of 
2006. Hence, only combined estimates of IDs and PPs for the period of 1997 to 2005 
are valid. This study demonstrates an ongoing increase in incidence and prevalence 
of PHPT, which suggests there may well be a large number of „undiagnosed‟ cases 
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and this presumption is supported by considering these „possible‟ cases and 
that the undiagnosed cases are commonly asymptomatic. The only way to measure 
true prevalence would be to undertake a population-based routine screening 
programme, which would be potentially expensive. The primary focus of this thesis 
has, however, been on „diagnosed‟ cases of PHPT. 
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Table 5.6 Annual ID for the total likely PHPT patients that screened (definite and possible) 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Male data           
Incident cases 97 103 170 263 134 139 149 211 172 93 
Unadjusted Incidence 6.91 7.36 12.15 18.81 9.57 9.93 10.60 15.03 12.16 6.51 
95% CI 5.54-8.29 5.94-8.79 10.33-13.98 16.54-21.09 7.95-11.19 8.28-11.59 8.89-12.30 13.00-17.06 10.34-13.98 5.19-7.84 
Age adjusted ID 7.18 7.56 12.39 19.03 9.63 9.90 10.41 14.56 11.73 6.20 
95% CI 5.78-8.58 6.12-9.00 10.55-14.23 16.75-21.31 8.01-11.25 8.26-11.55 8.72-12.09 12.57-16.56 9.94-13.52 4.90-7.51 
     
Female data     
Incident cases 222 283 416 547 310 287 310 446 323 231 
Unadjusted ID 13.98 17.88 26.32 34.66 19.66 18.23 19.73 28.26 20.35 14.44 
95% CI 12.14-15.82 15.79-19.96 23.79-28.84 31.76-37.57 17.47-21.85 16.12-20.34 17.53-21.92 25.64-30.88 18.13-22.57 12.58-16.30 
Age adjusted ID 14.26 18.17 26.67 34.93 19.70 18.13 19.51 27.82 20.01 14.21 
95% CI 12.40-16.12 16.07-20.27 24.13-29.22 32.02-37.84 17.52-21.89 16.03-20.23 17.34-21.69 25.22-30.41 17.80-22.21 12.35-16.06 
     
Total population           
Unadjusted ID 10.67 12.95 19.67 27.22 14.92 14.32 15.42 22.03 16.49 10.70 
95% CI 9.50-11.84 11.65-14.24 18.07-21.26 25.34-29.09 13.53-16.30 12.96-15.69 14.01-16.83 20.35-23.72 15.04-17.94 9.54-11.87 
Age and sex adjusted ID 10.93 13.18 19.96 27.45 14.97 14.26 15.23 21.58 16.11 10.44 
95% CI  9.75-12.12 11.88-14.48 18.35-21.56 25.57-29.33 13.58-16.35 12.90-15.61 13.83-16.63 19.92-23.25 14.47-17.55 9.28-11.60 
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Table 5.7 Annual PP for the total likely PHPT patients that screened (definite and possible) 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Male data           
Prevalent cases 309 393 544 784 871 943 1027 1173 1260 1224 
Unadjusted PP (‰) 2.20 2.81 3.89 5.61 6.22 6.74 7.30 8.36 8.91 8.57 
95% CI 1.96-2.45 2.53-3.09 3.56-4.22 5.22-6.00 5.81-6.63 6.31-7.17 6.86-7.75 7.88-8.83 8.42-9.40 8.10-9.05 
Adjusted PP (‰) 2.29 2.88 3.96 5.66 6.25 6.71 7.22 8.17 8.69 8.35 
95% CI 2.04-2.54 2.60-3.16 3.63-4.28 5.27-6.06 5.84-6.66 6.29-7.14 6.78-7.67 7.70-8.64 8.20-9.17 7.88-8.83 
       
Female data       
Prevalent cases 763 1014 1383 1861 2085 2241 2410 2695 2827 2840 
Unadjusted PP (‰) 4.81 6.41 8.75 11.79 13.23 14.23 15.34 17.08 17.81 17.75 
95% CI 4.47-5.15 6.01-6.80 8.29-9.21 11.26-12.32 12.6-13.79 13.65-14.82 14.73-15.94 16.44-17.72 17.16-18.46 17.11-18.40 
Adjusted PP (‰) 4.92 6.51 8.86 11.88 13.25 14.18 15.17 16.83 17.55 17.52 
95% CI 4.58-5.26 6.12-6.91 8.40-9.33 11.35-12.41 12.69-13.81 13.59-14.76 14.57-15.78 16.20-17.47 16.90-18.20 16.88-18.17 
           
Total population           
Unadjusted PP (‰) 3.58 4.72 6.47 8.89 9.93 10.71 11.54 12.97 13.62 13.42 
95% CI 3.37-3.80 4.47-4.96 6.18-6.76 8.55-9.23 9.57-10.29 10.34-11.08 11.16-11.93 12.57-13.38 13.20-14.03 13.01-13.83 
Age & sex adjusted PP (‰) 3.68 4.80 6.55 8.96 9.96 10.67 11.43 12.76 13.38 13.21 
95% CI 3.47-3.90 4.73-4.88 6.47-6.64 8.85-9.06 9.85-10.06 10.56-10.78 11.32-11.55 12.64-12.88 13.26-13.50 13.09-13.33 
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Thirdly, for the 213 patients receiving thiazide diuretics or lithium, the number of 
these cases diagnosed due to the influence of the drugs, rather than being 
coincidental, was unclear. It is likely that the majority were coincidental, as they 
were on intermittent prescription and the dosage of thiazide diuretics tended to be 
low and calcium may have normalized soon after. Furthermore, this factor represents 
just 7.9% of all cases and is thus unlikely to bias the results in a major way. 
 
The study results were similar to previous findings, in terms of the age and sex 
distribution of PHPT after midlife.
15, 40, 224, 235, 238
 The majority of patients (over 90%) 
in Tayside were adults aged over 40, with a female preponderance. Previous studies 
derived prevalence and incidence, assuming consistent age and sex distributions 
across different cohorts (i.e. horizontally applicable).
225, 235
 Unlike these studies, 
however, the information as described in this chapter made no such assumption: all 
patients aged 20 years and over were included and the found incidence of diagnosis 
was identical in men and women, prior to the age of 40. This indicates that it may be 
unreliable to use selective patient cohorts (e.g. patients at high risk of having PHPT 
only), as a basis on which to estimate the same information at population level.
235
 
There were 52 PHPT cases identified who were aged less than 20 years at diagnosis. 
They were excluded from the study after scrutinising their case notes and consulting 
with paediatricians in the Tayside region, as they were mostly cases of calcium 
sensing mutations. The findings on prevalence are consistent with existing 
estimations but with a much narrower range (1.82 to 6.72 per 1,000 population). 
Prevalent cases of diagnosed PHPT increased by 100-300 cases per year, resulting in 
a nearly three-fold increase in patients with PHPT, between 1996 and 2006.  
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The annual incidence of diagnosed PHPT displayed an unexpected cyclical aspect, 
during the ten year study period. The apparent cyclical trend in incidence density had 
a cycle length of 3-4-years approximately (Figure 5.3) which was consistent in the 
combined incidence when possible cases were added (Figure 5.9).  
 
Figure 5.9 Adjusted annual ID combining both definite and possible cases 
 
This did not reflect a trend in the number of calcium tests performed each year (or 
the number of patients tested. There are a number of possible reasons for the 
observed apparent cyclical aspect of incidence. Firstly, it may simply reflect 
increased ascertainment as a result of the increased number of biochemical tests 
being performed. The number of biochemical tests, however, steadily increased, 
whilst the incidence of diagnosed PHPT varied significantly from year to year, even 
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decreasing in some years. Thus, it seems unlikely that the increasing number of 
biochemical tests is the only cause of the cyclical incidence. Secondly, the 
phenomena may be due to missing data or variable collection methods. The data 
was, however, collected in the same manner throughout the study and the reference 
ranges for all tests are consistent. Thirdly, the variable incidence may reflect periods 
of increasing and decreasing medical interest in Tayside. Asymptomatic conditions 
such as PHPT may be prone to this kind of bias. There are, however, no known 
research projects, incentivised scheme or new medical intervention, which would 
have encouraged increased interest in calcium checking during the period of the 
study. Fourthly, it is possible that there is a genuine cyclical variability to the 
incidence reflecting nutritional, environmental, viral or iatrogenic factors.
221, 224
 In 
addition, there may have been other unknown factors reflecting on the test requesting 
behaviour, which may explain the cyclical aspect. It is only possible to test fully 
when data on serial incidences of PHPT become available from other centres, or 
after prolonged follow-up in Tayside.  Cyclical incidences of PHPT are, however, 
not unique, and have been observed in the Wermers‟ study, although over on a much 
longer time spectrum.
221
 
 
The significant decrease in the maximum values of both calcium and PTH 
concentrations shown in the results (Table 5.2), confirmed the current study findings 
that more and more patients are diagnosed as mild cases.
221, 232
 The significant 
increase in the all-cause mortality, however, may reflect the increase in the patients‟ 
mean age and this will be explored in Chapter 6 and 7. 
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5.6 Chapter summary 
In summary, this chapter has provided an up to date epidemiological estimate of 
PHPT using the general population in Tayside, Scotland, with no pre-assumption of 
age and gender distribution. It demonstrates that in Tayside, Scotland, there is an 
increasing prevalence of PHPT. The overall age and sex distribution in incident 
cases corresponds to previous studies but gives a more precise population estimate. 
A cyclical incidence trend may reflect trends in etiological factors affecting PHPT 
and suggests further work would be of value to explore this pattern. 
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CHAPTER 6  
RISK OF PHPT – POPULATION SMR 
6.1 Overview 
In Chapter 5, the descriptive epidemiology of diagnosed PHPT in Tayside, Scotland, 
was described in detail; this chapter addresses the question as to whether PHPT is 
associated with increased risk of mortality and co-morbidity.  This is assessed using 
the standardised mortality ratio (SMR) as a simple epidemiological measure, to 
evaluate the risk of mortality and disease specific co-morbidity in patients with 
PHPT, as compared to the general population of Tayside. The study cohort consists 
of the incident patients diagnosed between 1997 and 2006. According to patients‟ 
biochemical features and whether or not they had received surgical treatment, 
patients will be divided into three sub-groups. Baseline characteristics will be 
described and methods and outcome measures used will also be described. All 
results will be presented; any key findings and methodological issues, leading to 
further analyses, will be discussed. This chapter will provide an overall summary of 
mortality and morbidity risks associated with PHPT over the long-term, stratified by 
its disease severity. 
 
6.2 Introduction 
Some patients with PHPT are associated with a high mortality risk, mainly due to the 
increased risk of CVD, as well as an increased prevalence of hypertension, diabetes 
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mellitus, and dyslipidemia.
23, 24, 26, 51, 52, 102, 110-114
 They also have an increased risk of 
progressive renal impairment and are linked with a high incidence of malignant 
disease.
52, 110, 111, 138
 Studies that clearly confirmed positive associations between 
increased mortality and PHPT mostly emanate from Sweden, Denmark and Germany, 
where patients were selected from hospital admissions and screening programmes. 
51, 
102, 110, 112, 114
  In American studies, increased mortality has been confirmed in 
patients with „serious‟ PHPT, who had undergone PTX. 23, 24, 26, 113 Although 
increased risks have been repeatedly reported in symptomatic patients, the risks 
among patients with mild PHPT who do not fit the NIH criteria for PTX, remains 
controversial.
23, 24, 26, 113
 This currently accounts for over 80% of all PHPT cases. 
Some studies have shown an increased risk among mild to moderate PHPT patients 
who had not undergone surgery.
51, 52
 By way of contrast, others have claimed that the 
overall survival among patients with mild PHPT was not adversely affected.
50
 
49
  
This discrepancy may derive from the inherent differences between Scandinavian 
systems and North American medical care systems or there may indeed be a genuine 
difference in disease progression between patients from European countries and  
those from the United States, or, the differences arise due to different designs and 
study population. 
 
In summary, over the past four decades, given that the clinical approach to PHPT has 
changed towards the mild and asymptomatic form, the connection between mild 
PHPT and increased mortality, including CVD, is no longer evident. As a result, the 
third NIH workshop on asymptomatic PHPT, held in May, 2008, revised the 
guidelines for diagnosis and management (surgical and medical) of asymptomatic 
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PHPT and identified key areas for further investigation, including an emphasis on 
the need for large population studies of mortality and the extent of cardiovascular 
involvement in those with mild PHPT. 
43, 150, 165, 217-219
 This chapter aims to answer 
this call for population studies. 
 
6.3 Chapter aims 
This chapter aims to describe all-cause mortality, cardiovascular and cancer 
mortality and disease-specific co-morbidities in patients with PHPT in Tayside, 
Scotland, diagnosed between 1997 and 2006, using population-based data.  
 
6.4 Methods 
6.4.1 Patients 
As described in detail in previous chapters, a total of 2709 patients, aged 20 years 
and over, with a definite diagnosis of PHPT, were identified using six principle 
anonymous patient-level datasets from 1997 to 2006, in Tayside, Scotland. This 
chapter includes only incident patients who were diagnosed with PHPT between 
January 1, 1997 and December 31, 2006 in calculations, as complete datasets were 
available for them.  
 
Each selected case was linked with demographic information, all available 
biochemical records and hospital admission records (from five years prior to the 
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PHPT diagnosis to the end of study, which is December 31, 2006) via the 
anonymous CHI, in accordance with the Data Protection Act, for further 
classification of the patient cohort and derivation of outcome data. 
183
, 
242
 According 
to the biochemical feature and whether or not PTX was performed, the study cohort 
was subsequently divided into: 1) mild PHPT, 2) surgically treated PHPT and 3) 
other non-operated PHPT, three sub-groups. In detail, patients were identified as a) 
having mild PHPT, if the first two raised calcium concentrations after a positive 
diagnosis were less than 2.9mmol/L, the maximum calcium concentration never 
exceeded 3mmol/L and they had never been surgically treated for 
hyperparathyroidism and had no known renal complications (as shown from renal 
data); or b) surgically treated PHPT, if they had undergone PTX; or c) other non-
operated PHPT, which designated all others, who had more aggressive disease than 
the mild group but had never been treated with PTX. This broadly follows the NIH 
criteria for PTX 
5, 155
.  
 
6.4.2 Data 
6.4.2.1 Mortality 
Mortality information was obtained from the GRO. In the patient cohort, the date of 
death and the underlying causes were recorded for all deceased people using the ICD 
codes, ninth (ICD-9) or tenth (ICD-10).
191
 Annual all-cause mortality in the Tayside 
general population was aggregated by 10-year age groups and by gender. 
Cardiovascular and cancer deaths were also extracted at the population level, using 
the same format. Regarding each condition, if a patient‟s first four causes of death 
were within the selected codes, a death for that condition was counted. The same 
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method was applied to the general population in Tayside, so as to maintain 
coherence. Corresponding ICD codes used are listed in Chapter 3, Section 3.3. These 
data have been routinely collected and collated since the 1970s and have been made 
available for research purposes ever since.
182
 
6.4.2.2 Morbidity 
Morbidity was defined as an in-patient hospital admission on a specified condition. 
Three datasets were used to obtain morbidity information. SMR01, which record 
details of all hospital admissions using ICD codes, served as the main source for 
hospital admission data.
194
 Two additional datasets, namely Cancer Registry, 
SMR06 and SCI-DC data, were used to provide accurate population data on cancer 
and diabetes morbidities.
185, 187
 The HIC holds the Tayside portion of these data.
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All these data were anonymised and were only linked using the unique anonymised 
identifier assigned for this proposed study, namely PROCHI.  
 
6.4.3 Outcome measures 
As described earlier, the mortality outcomes included all-cause mortality, as well as 
CVD and cancer related deaths. A total of eleven morbidity outcomes were 
measured, including CVD, cerebrovascular disease, renal failure, renal stones, 
psychiatric condition, hypertension, all fractures, cancer, diabetes, glaucoma and 
Parkinson‟s disease. Apart from glaucoma and Parkinson‟s disease, the outcomes 
included were based on existing literature which had these conditions shown to be 
associated with PHPT (See Chapter 2). Glaucoma and Parkinson‟s disease were 
included in order to validate the calculations with the pre-assumption that the risk of 
these two outcomes should NOT differ between PHPT patients and the Tayside 
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general population. All outcome data were primarily derived from the SMR01 data 
using ICD codes. The ICD codes used to identify each individual morbidity endpoint 
were listed in Chapter 3, Table 3.2. To maintain the completeness of the data, 
primary and secondary causes of admissions for both the PHPT patients and the 
Tayside general population were included. If the causes of admission fell within one 
of the undernoted conditions, with no previous recorded/known admission of the 
same type, an incident count for this endpoint was established and the date of 
discharge was recorded as the incident date. The SMR06 and the SCI-DC data were 
used to identify cancer and diabetes, respectively, as well as the SMR01 data. In 
addition, Parkinson‟s disease also included patients who were prescribed 
dopaminergic drugs in the community measured using the Tayside prescription data. 
 
6.4.4 Statistical methods 
All events were aggregated by incident year and gender at 10-year age groups.  The 
standardised mortality ratios (SMRs) and disease-specific standardised morbidity 
ratios (SMbRs), were defined as the observed number of events divided by the 
expected number of events. The SIR were defined as the observed incident events 
(excluding pre-existing conditions) divided by the expected incident events.  
Detailed information on these measures was described in Chapter 3, Section 3.4. The 
expected values were derived by multiplying population/person-years at risk in 
patient cohort, by the corresponding sex, calendar year and age group stratified rates, 
from the Tayside general population. The general population rates were calculated 
by dividing the number of persons suffering events in Tayside by the total population 
of Tayside in each stratum (sex and age group specific) on a yearly basis, from 1997 
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to 2006. All events were counted from the beginning to the end of each calendar 
year. The 95% confidence intervals (95% CIs) were estimated assuming a Poisson 
distribution, using an Exact method. Tayside population rates were also applied to 
derive all expected numbers in each sub-group, namely „mild‟, „operated‟ and „other 
non-operated‟ PHPT. Differences among sub-groups at baseline were compared 
using the Chi-square test or Kruskal Wallis H test as appropriate, with p-value of less 
than 0.05 being considered as significant. The Chi-square test was also used to 
compare risk differences between sub-groups and between genders, as measured by 
the crude rates (the number of events/the number of patients). All analyses were 
carried out using SPSS (version 15) and SAS (version 9.1).  
 
6.5 Results 
By the end of 2006, a total of 2,709 adults (aged 20 years and over) with diagnosed 
PHPT (70.8% female) were identified, as previously reported (Chapter 4). For the 
purposes of this chapter, the analysis was confined to the decade of 1997 to 2006, as 
complete data were available for them. Hence, there were 2,299 incident cases 
(70.4% female) diagnosed, with a total of 8,298 person-years of follow up. Overall 
1,683 (73.2%) had „mild‟ disease, 202 (8.8%) were „operated‟ PHPT patients and 
414 (18.0%) were „other non-operated‟ patients. There was no difference in the 
proportion of female patients among the groups (p=0.075) but mild PHPT patients 
had significantly lower baseline calcium (p<0.001). Surgically treated patients were 
significantly younger and with a shorter duration of the disease than the other groups. 
Table 6.1 shows the patient characteristics by sub-group. 
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Table 6.1 The baseline characteristics of PHPT patients by disease sub-group 
  Sub-group  
Variables Total PHPT Mild Operated 
 
Other  
non-operated
 
P value 
Count (%) 2 299 (100%) 1 683 (73.2%) 202 (8.8%) 414 (18.0%)  
Person- years 8 298 5 735 877 1 686  
Mean age (SD) 68 (14) 69 (14) 58 (14) 68 (14) <0.001 
Female (%) 1 618 (70.4%) 1 163 (69.1%) 153 (75.7%) 302 (72.9%) 0.075 
Baseline calcium
++
  2.67 (0.003) 2.63 (0.002) 2.87 (0.023) 2.75 (0.010) <0.001 
Disease duration (SD)
+ 
40 (32) 41 (32) 19 (22) 44 (33) <0.001 
All cause deaths (%) 659 (28.7%) 502 (29.8%) 22 (10.9%) 135 (32.6%) <0.001 
+ The duration of the disease diagnosis (in months), measured by subtracting the event date (end of study 31.12.2006, date of death, or PTX date where applicable) from 
the date of entry (PHPT diagnosis date). 
++
 The baseline calcium is presented as the mean (standard error or mean) of the first raised calcium. 
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6.5.1 Mortality 
Over the ten years of the study period, there were 46,221 total deaths observed in 
Tayside. In the PHPT cohort, 659 (28.7%) patients died, of which 502 (96.2%) were 
patients with mild PHPT. Table 6.2 shows the SMR results for all-cause mortality, 
cardiovascular and cancer deaths by patient sub-groups. Patients with PHPT had a 
significantly increased risk of all cause deaths, as well as cardiovascular and cancer 
deaths, as compared to the general population in Tayside. This increased risk was 
also observed in each sub-group for all the mortality outcomes, when an individual 
group was compared to the general population. When comparing the crude death 
rates (the number of deaths/the number of patients) among the sub-groups, the risk of 
deaths in the surgically treated group was significantly lower than with the untreated 
(Figure 6.1). No difference in death rates, however, was observed between men and 
women (Figure 6.2). 
Figure 6.1 Comparison of unadjusted mortality rates among sub-groups, with 
statistical significance level derived from the Chi-square test 
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Table 6.2 Standardised mortality ratios (SMRs) of all-cause mortality, as well as cardiovascular and cancer related deaths  
Cause of death 
Total 
events 
Total cohort 
n=2 299 
Mild 
n=1 683 
Operated 
n=202 
Other non-operated 
n=414 
Obs+ Exp++ SMR 95% CI Obs Exp SMR 95% CI Obs Exp SMR 95% CI Obs Exp SMR 95% CI 
All cause 46 221 659 255.2 2.58 2.39-2.79 502 191.8 2.62 2.39-2.86 22 12.3 1.78 1.12-2.70 135 51.1 2.64 2.22-3.13 
Cardiovascular 22 214 281 112.8 2.49 2.21-2.80 227 84.8 2.68 2.34-3.05 11 5.1 2.15 1.07-3.84 43 22.9 1.88 1.36-2.53 
Cancer 12 390 191 63.3 3.02 2.60-3.48 137 46.4 2.95 2.48-3.49 9 4.1 2.21 1.01-4.20 45 12.9 3.50 2.55-4.68 
+
 Obs, observed number; 
++
 Exp, expected numbers 
 
 
Table 6.3 SMRs among incident PHPT patients diagnosed between 1997-2001 and 2002-2006, respectively 
Period of 
diagnosis 
Incident 
patients 
Mean 
Calcium+ 
Total Male Female 
Obs++ Exp+++ SMR 95% CI Obs Exp SMR 95% CI Obs Exp SMR 95% CI 
1997-2001 1 029 2.79 398 168.6 2.36 2.13-2.6 119 46.2 2.57 2.13-3.08 279 122.4 2.28 2.02-2.56 
2002-2006 1 270 2.75 261 86.6 3.01 2.66-3.4 80 29.7 2.69 2.14-3.35 181 56.9 3.18 2.73-3.68 
+ 
The mean of the maximum calcium concentration; 
++ 
Obs, observed number; 
+++ 
Exp, expected number. 
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Figure 6.2 Comparison of unadjusted mortality rates between men and women by 
disease sub-group, with statistical significance level derived from the Chi-square test 
 
 
During the study period, there were 1,029 (44.8%) patients diagnosed in the first five 
years (1997-2001) and 1,270 (55.2%) in the second period (2002-2006). An 
increased risk of all cause mortality was observed separately, in both time periods. 
Patients diagnosed in the second period had a higher increased risk of death (p<0.05) 
but a slightly lower calcium concentration (p<0.001). There was no significant 
difference, however, in survival, between males and females (Table 6.3). 
 
6.5.2 Morbidity 
Table 6.4 presents disease specific SMbRs for the eleven co-morbidity outcomes 
observed. When the entire PHPT cohort (n=2,299) was compared to the general 
population, apart from glaucoma and Parkinson‟s disease, there was an increased 
sub-group 
mild                 operated   other non-operated 
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risk of co-morbidities for all other endpoints investigated, with renal disease being 
the highest identified. Patients also had a higher risk of having psychiatric condition, 
hypertension and diabetes, when compared to other conditions. There were 23,814 
CVD events in Tayside between 1997 and 2006 and 550 in the PHPT cohort, giving 
an SMbR for CVD of 1.64. Interestingly, when each sub-group was individually 
compared with the general population, in the operated and the other non-operated 
groups, the risk of cerebrovascular disease, psychiatric condition and fractures, 
became non-significant. Whereas, apart from glaucoma and Parkinson‟s disease, the 
risk of co-morbidities was significantly increased in the mild group, for all other 
endpoints observed. The comparison of co-morbidity rates between sub-groups 
showed a significantly higher risk of CVD, cerebrovascular disease and hypertension, 
in the mild sub-group than was the case for the other two sub-groups but the risk of 
renal stones was significantly higher in the operated patients (Figure 6.3). No 
significant difference was found between sub-groups in other observed endpoints. 
Figure 6.4 shows a comparison of morbidity rates between men and women. 
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Table 6.4 Disease specific SMbRs adjusted for age and gender, showing the observed and the expected number of events by disease sub-group 
Endpoint 
Total 
events 
Total 
n=2,299 
Mild 
n=1,683 
Operated  
n= 202 
Other non-operated  
n=414 
Obs+ Exp++ SMR 95% CI Obs Exp SMR 95% CI Obs Exp SMR 95% CI Obs Exp SMR 95% CI 
Cardiovascular  23 814 550 335.9  1.64 1.50-1.78 440 259.0  1.70 1.54-1.87 27 18.6  1.45 0.96-2.12 83 58.3  1.42 1.13-1.76 
Cerebrovascular  9 716 234 152.7  1.53 1.34-1.74 191 118.4  1.61 1.39-1.86 9 7.5  1.20 0.55-2.27 34 26.7  1.27 0.88-1.78 
Renal Failure 4 417 526 68.1  7.72 7.08-8.41 444 52.9  8.40 7.64-9.22 21 3.5  5.98 3.70-9.14 61 11.7  5.20 3.97-6.67 
Renal Stones 2 278 72 15.9  4.52 3.54-5.69 33 11.9  2.77 1.91-3.90 21 1.3  15.62 9.67-23.88 18 2.7  6.69 3.96-10.57 
Psychiatric condition 1 916 50 21.3  2.35 1.75-3.10 44 16.0  2.75 2.00-3.70 2 1.5  1.36 0.16-4.91 4 3.8  1.05 0.29-2.69 
Hypertension 8 617 350 120.5  2.90 2.61-3.23 285 91.8  3.10 2.75-3.49 27 7.8  3.48 2.30-5.07 38 20.9  1.81 1.28-2.49 
All fractures 15 530 265 196.0  1.35 1.19-1.52 200 149.5  1.34 1.16-1.54 18 10.8  1.66 0.98-2.62 47 35.7  1.32 0.97-1.75 
Cancer 25 136 411 331.5 1.24 1.12-1.37 303 252.9 1.20 1.07-1.34 31 20.9 1.48 0.97-2.05 77 57.6 1.34 1.06-1.67 
Diabetes 5 633 202 76.2  2.65 2.30-3.04 153 57.9  2.64 2.24-3.09 12 5.0  2.41 1.24-4.20 38 13.2  2.87 2.03-3.94 
Glaucoma 957 18 15.1 1.19 0.70-1.88 14 11.6 1.20 0.66-2.02 1 0.8 1.20 0.03-6.68 3 2.7 1.12 0.23-3.26 
Parkinson’s  2 444 44 37.1 1.19 0.86-1.59 39 28.8 1.35 0.96-1.85 2 1.9 1.04 0.13-3.77 3 6.4 0.47 0.10-1.38 
+ 
Obs, Observed number; 
++
 Exp, expected number 
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Figure 6.3 Comparison of unadjusted morbidity rates between sub-groups, with 
statistical significance level derived from the Chi-square test 
 
 
Figure 6.4 Comparison of unadjusted morbidity outcomes between men and women, 
with statistical significant level derived from the Chi-square test 
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Table 6.5 shows the disease specific SIRs adjusted for pre-existing conditions for 
each sub-group, this only included incident events that happened after PHPT was 
diagnosed. In the non-operated PHPT cohort (both mild and other non-operated), 
patients had a higher risk of having all the observed co-morbidities. Compared to the 
risk suggested in the standardised morbidities results (Table 6.4), the mild group had 
a higher risk of developing CVD, cerebrovascular disease, psychiatric condition and 
fractures post PHPT diagnosis, however, only the risk of post PHPT renal failure 
appeared to be higher in the non-operated aggressive group. For the operated 
patients, as well as the risk of cerebrovascular disease, psychiatric condition and 
fractures after the PTX remained insignificant, the risk of renal disease always being 
lower after surgery. Nonetheless, the risk of hypertension and diabetes remained 
significantly increased and the risk of developing CVD became significantly higher 
than that of the general population, after the surgery. Figure 6.5 shows the 
comparison of incident co-morbidity rates between sub-groups and it can be seen 
that the risk of developing cerebrovascular disease and renal failure after a positive 
PHPT diagnosis was significantly higher in the untreated groups than with the 
operated group. The difference as regards men and women is shown in Figure 6.6. 
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Figure 6.5 Comparison of unadjusted incident co-morbidity outcomes between sub-
groups, with statistical significant level derived from the Chi-square test 
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Table 6.5 SIRs showing the observed and expected number of events, adjusted for pre-existing conditions+
 
 Mild n=1,683 Operated n=202 Other non-operated N=414 
Endpoint Obs++ Exp+++ SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Cardiovascular  218 86.1 2.53 2.21-2.89 14 7.4 1.89 1.03-3.17 51 23.4 2.18 1.62-2.86 
Cerebrovascular  121 39.1 3.10 2.57-3.70 4 2.9 1.38 0.38-3.54 27 10.5 2.56 1.69-3.73 
Renal Failure 272 19.2 14.14 12.51-15.92 3 1.4 2.14 0.44-6.27 47 5.0 9.35 6.87-12.43 
Renal Stones 20 4.1 4.85 2.96-7.49 1 0.6 1.74 0.04-9.67 9 1.1 7.84 3.58-14.88 
Psychiatric condition 31 5.6 5.56 3.78-7.89 1 0.6 1.57 0.04-8.75 2 1.6 1.26 0.02-3.50 
Hypertension 159 42.1 3.77 3.21-4.41 13 3.9 3.34 1.78-5.71 22 11.0 1.99 1.25-3.02 
All fractures 101 51.5 1.96 1.60-2.38 6 4.3 1.41 0.52-3.06 27 14.4 1.87 1.23-2.72 
Cancer 120 77.9 1.54 1.28-1.84 13 8.4 1.54 0.82-2.63 42 22.3 1.88 1.36-2.54 
Diabetes (all diabetes) 44 20.4 2.16 1.57-2.90 7 2.2 3.20 1.28-6.59 16 5.7 2.81 1.61-4.56 
+
 Pre-existing conditions were adjusted by using the PHPT diagnose date for non-operated PHPT patients and the date of parathyroidectomy for operated patients 
respectively; 
++
 Obs, observed number; 
+++
 Exp, expected number 
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Figure 6.6 Comparison of unadjusted incident co-morbidity rates between men and 
women, with statistical significant level derived from the Chi-square test 
 
6.6 Discussion 
This study has, for the first time, described relative mortality and morbidity among 
patients with diagnosed PHPT in a large, less selective population, separating sub-
groups by disease severity and treatment.  
 
6.6.1 Mortality 
The results demonstrated increased mortality in a large population-based cohort of 
patients with confirmed primary hyperparathyroidism (PHPT).  This finding 
supported previous work from the Scandinavian healthcare system, where increased 
cardiovascular death was observed in patients with raised calcium concentrations, as 
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identified by health screening programmes.
51, 98, 102, 112
 In a Danish study, Ogard et al 
reported an increased risk of all-cause mortality in patients with PHPT, as compared 
to the Danish general population (SMR: M 1.6, 95% CI (1.3-2.0); F 1.7, 95% CI 
(1.5-1.9)).
112
 Their study, however, provided no information on patients‟ baseline 
characteristics in terms of calcium concentration. As a result of their patients having 
been recruited since 1977, based on hospital referrals, the baseline calcium is likely 
to be much higher than the cohort identified in this study. Another similar study 
undertaken by Hedback et al also reported an increased risk of mortality in a cohort 
of hospital diagnosed PHPT patients (SMR: M 1.30, 95% CI (1.07-1.57), F 1.31, 
95% CI (1.46-1.78)), with higher risk of cardiovascular related deaths (SMR: 1.71 
and 1.85 form men and women respectively).
102
 Their study, however, also failed to 
provide information on patients‟ baseline calcium concentration but these patients 
were likely to have suffered from the more severe type of PHPT, for the same 
reasons (i.e. patients had been recruited since 1984, based on hospital referrals). In 
my analysis, although the majority of the patients were mild untreated PHPT patients 
who did not meet the NIH criteria for surgery, the results, as indicated in Table 6.6, 
showed a much higher risk of mortality for both male and female patients, when 
compared with the aforementioned European studies.
102, 112
  In addition, the results, 
for the first time, demonstrated an increased mortality in patients with „mild‟ PHPT 
and the rate was similar to that of patients fitting the NIH criteria for surgery but who 
were not operated on.  
 
183 
Table 6.6 SMRs showing all-cause mortality, cardiovascular and cancer related 
deaths, separately for men and women 
Cause of death 
Men 
n=681 
Women 
N=1618 
Obs Exp SMR 95% CI Obs Exp SMR 95% CI 
All cause 199 75.9 2.62 2.27-3.01 460 179.3 2.57 2.34-2.81 
Cardiovascular 92 40.8 2.25 1.82-2.76 189 72.0 2.63 2.27-3.03 
Cancer 56 22.0 2.55 1.93-3.31 135 41.4 3.26 2.74-3.86 
 
There was a non-significant trend towards a lower overall risk of death in PHPT 
patients who had undergone PTXs than those non-operated. Studies from the US and 
recent data from Scandinavia, all supported this finding.
27, 243, 244
 It is intriguing that 
the mortality for patients with „mild‟ PHPT, as reflected by serum calcium less than 
2.9mmol/l, was similar to patients with non-operated aggressive disease.  This could 
have been because the difference in calcium level between the mild and aggressive 
groups (median corrected calcium = 2.45 & 2.57 mmol/l respectively) was not large 
enough to observe any difference in mortality. As shown in Chapter 5, the mean of 
the maximum calcium concentrations among PHPT patients had significantly 
decreased over the decade observed. 
245
 To elucidate the likely association between 
the calcium level, disease duration and mortality further, the study cohort was split 
into two by their diagnosis period but, it was found that when both were compared to 
the general population, there was a higher mortality rate in the latter group 
(diagnosed during the second 5 years) who had milder calcium profile and shorter 
follow-up duration. The number of events in the second period, however, was falling 
which was probably due to better preventative treatment. Hence, the results could be 
interpreted as indicating that the serum calcium was not associated with mortality 
and that it was simply a marker of the PHPT condition.   
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6.6.2 Morbidity 
In a similar manner to the mortality measurement, eleven co-morbidities were 
measured using the disease specific standardised morbidity ratios, which allowed an 
approximate estimate of the co-morbidities among PHPT patients, in comparison to 
the general population. The results showed that patients were exposed to an 
increased risk of CVD. For each sub-group, the risk of developing incident co-
morbidities, as opposed to the general population, adjusting for pre-existing 
conditions (expressed as SIRs), was also compared to the general population. Among 
the non-operated patients, a similar risk of developing other co-morbidities after 
PHPT being diagnosed was found, among both mild and other non-operated patients. 
The adjusted risk of having renal failure, psychiatric symptoms and hypertension, 
was even higher in the mild group than with the other non-operated patients. 
Although patients with aggressive disease were shown to have an increased risk of 
renal stones, the difference was insignificant between the mild and the other non-
operated patients, when adjusted for pre-existing conditions.  These differences 
might imply that patients with aggressive disease were more likely to have their 
condition diagnosed earlier as a result of the co-morbidity of renal stones and may, 
thus have had a shorter duration of undiagnosed disease. There was, however, a 
significant improvement in renal function in patients who had undergone surgery. 
Surgery might also improve fracture outcomes (towards significant) but operated 
patients were still exposed to a higher risk of hypertension, CVD and diabetes, even 
after the surgery, when compared to the general population. This supported earlier 
findings that some conditions, such as hypertension and CVD, were not reversible 
with surgery. 
25, 246
 Thus, this work suggested that some outcomes, such as the 
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development of renal stones and renal failures, are related to serum calcium 
concentrations and improved after PTX, and it is these outcomes that have informed 
practical guidelines such as the NIH guidelines. Nevertheless, some outcomes, such 
as CVD and diabetes, which are associated with PHPT but may not be closely 
related to serum calcium concentrations, may not benefit from PTX.  The better 
outcomes in other endpoints in this study suggest surgery may be still worth 
considering for such patients.  The key question to consider is whether surgery is 
indicated for patients with „mild‟ disease, but since patients with both mild and other 
non-operated PHPT, who suffered from a more aggressive condition, had a similar 
increased risk of mortality and co-morbidity, it is possible that surgery may be useful 
for all patients with diagnosed PHPT, including the „mild‟ cases. Perhaps, this could 
be answered in a full RCT. 
 
6.6.3 Strengths and limitations 
Due to the nature of observational studies, causal inferences could not be made from 
the results. As mentioned in previous chapters, the patients were subject to calcium 
checks and therefore, the true prevalence of our PHPT cohort would be 
underestimated. This is similar to studies of diabetes where diagnosed patients are 
included, but there are many undiagnosed remaining in the population. This analysis 
was, however, based on a large, relatively unselected population and therefore, 
patients who had no surgery, in particular mild cases that had never been referred to 
hospital, were captured, which is a major strength of this study. Secondly, the 
inclusion of glaucoma and Parkinson‟s disease in the outcomes for comparison 
improved the confidence in the patterns, i.e. increased risk association, suggested 
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from the data. These conditions were assumed to have no association with either the 
condition of PHPT, or the level of calcium. Indeed, no increased risk in these two 
conditions was demonstrated, which reduced the risk of having confounded findings. 
However, there are limitations with using SMR; as in each sub-group, patients were 
standardised compared to the Tayside general population, the SMR results could not 
be compared directly horizontally, i.e. across different sub-groups. Although the 
crude rates were compared across the sub-groups, there may be characteristics or 
confounders which could explain some of the differences but were not adjusted for 
in calculating the SMbRs. This study, however, did approximately adjust for pre-
existing conditions by using the SIRs, and found higher morbidity risk associated 
with PHPT patients than that by using the SMbRs. An accurate estimate of the risk 
can be addressed by using person-level data to adjust for more possible confounding 
factors (See Chapter 7). Thirdly, due to the small sample size of the surgically 
treated patients (n=202), the SMbRs and SIRs had wide confidence intervals and 
thus, there might be benefits of surgery that were not detected as statistically 
significant. Nonetheless, the results did show some significant improvement and 
reduced risk in this group compared to the other PHPT patients and surgery is 
considered to be safe.
244, 247
 Further analyses are needed to adjust for confounders in 
a time to event analyses using person-specific and these are considered in the next 
chapter. 
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6.7 Chapter summary 
In summary, this chapter has provided an approximate estimate of the risks of 
mortality and disease-specific co-morbidity associated with PHPT. It has also 
described such associated risk by dividing the cohort into the three sub-groups of 
mild, operated and other non-operated. The study results have indicated that patients 
who do not meet the NIH criteria for surgery have a similar risk of mortality and 
morbidity, as compared to those who do meet the criteria. Moreover, this chapter has 
demonstrated that surgery improved patients‟ renal function and reduced renal stone 
formation. As suggested from the results, the next chapter will continue, by 
evaluating the risk of mortality and morbidity in a further selected mild group using 
person specific data with a matched cohort, adjusting for all possible confounding 
factors. 
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CHAPTER 7  
SURVIVAL ANALYSIS OF OUTCOMES IN 
UNTREATED MILD PHPT 
7.1 Overview 
In the last chapter, using the SMR approach, for the first time, there was 
demonstrated an increased risk of mortality and co-morbidity in a large cohort of 
patients with untreated mild PHPT. This chapter is concerned with the impact of 
confounding factors unaccounted for at the patient level, which could explain some 
of the risk and so it aims to assess the outcomes using survival analysis. 
Incorporating hospital records at the individual level, a refined group of mild PHPT 
with a one-to-five matched cohort as comparators, will be used in this study. The 
selection criteria for both cases and comparators will be firstly described, together 
with a brief description of the additional data requested. It will then explain the 
process of statistical analysis, by expanding in detail, approaches used in survival 
analysis. The results derived from different survival models will be compared and 
the most appropriate model will be interpreted in comparison to the results derived 
from the previous chapter. This chapter will allow an accurate understanding of the 
potential risks involved in patients with mild PHPT and will conclude with how this 
may influence the current management of these patients.  
 
189 
7.2 Introduction 
Increased risk of mortality and co-morbidity in patients with symptomatic PHPT is 
reasonably well established from both existing literature and the results suggested in 
Chapter 6.
23, 24, 26, 50-52, 102, 110-112, 114
 In Chapter 6, such an association in patients with 
mild untreated PHPT was also demonstrated, in accordance with their increased 
SMRs. Incongruent evidence of the outcomes in these mild patients, however, still 
exist, this association having been explained by the variance in disease severity 
across study regions, the variation in study designs and the small patient numbers 
involved.
26, 50, 52, 102, 150
 Moreover, most existing evidence showed crude estimates of 
increased risks but were unable to make an accurate adjustment for confounding 
factors.
25, 102, 110, 112, 115, 248
 As a result of the lack of robust evidence on outcomes in 
contemporary mild patients and the inconsistent results of surgical benefits in small 
randomised trials, surgery, is still only recommended for a minority of patients with 
PHPT, despite the fact that a more liberal approach to surgery selection has been 
advocated since 1990.
5, 36-38, 42, 43, 56, 59
 
 
This chapter aims to examine the outcomes in a sub-group of mild untreated PHPT 
patients. It is designed to conduct a detailed analysis, using individual level data, to 
account for confounding variables in a matched cohort, in order to evaluate the risk 
of mortality and morbidity among them. 
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7.3 Methods 
7.3.1 Cases 
In Chapter 6, a total of 1,683 patients were classified as having mild PHPT, 
according to their calcium profile. As a highly detailed clinical record for each of the 
400,000 Tayside residents is available, dating from the 1980‟s, a further restricted 
selection was possible to reflect a more accurate group of untreated mild PHPT 
patients; the latter also had serum calcium concentrations less than 2.9 mmol/l and an 
absence of renal complications and osteoporosis at the diagnosis.  
 
Detailed inclusion criteria were:  
1) First two raised calcium concentrations lower than 2.90 mmol/l;  
2) No calcium exceeded 3 mmol/l during the study period;  
3) No surgical treatment;  
4) Not treated with Cinacalcet;  
5) Absence of pre-existing renal complications and  
6) Absence of osteoporotic fractures, both as indicated from the hospital 
admission data. 
 
These selected patients were treated as cases in this study and should closely reflect 
the majority of mild PHPT patients, who currently receive no treatment.  
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7.3.2 Comparators 
Once all the cases were identified, a further request was made to HIC for a matched 
comparator cohort. Providing the unique anonymised identifier, PROCHI and the 
date of PHPT diagnosis, each of the selected cases was then matched with five 
individuals or comparators, by exact age, gender and calendar year of PHPT 
diagnosis, from the general Tayside population, with either no calcium records or 
normal serum calcium concentration during the study period. The calendar year of 
the matching was the index date for each comparator. 
 
7.3.3 Additional data 
Additional detailed information, including biochemistry results, hospital admission 
records, prescription records and death certificates (for the deceased), for each of the 
comparators was extracted from the HIC database and then linked using the 
PROCHI.  
 
7.3.4 Outcome measurements 
This study, yet again, re-emphasised the strength of electronic record-linkage 
technology via the unique patient identifier, that is, PROCHI. The primary outcomes 
of this chapter were all cause mortality, fatal and non-fatal cardiovascular (CVD) 
events, which were suggested to be associated with PHPT.
23, 24, 26, 50-52, 102, 110-112, 114
 
A fatal CVD event was a CVD related death and a non-fatal CVD event was an in-
patient hospital admission with CVD as the underlying reason for admission. 
Secondary outcomes were cancer related deaths and nine other adverse hospital-
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admitted morbidities, including cerebrovascular disease, hypertension, renal failure, 
renal stones, diabetes mellitus, all fractures, osteoporotic fractures, cancer, and 
psychiatric conditions, which indicated an association with PHPT in Chapter 6. 
 
Mortality outcomes were derived from the GRO database, combined with the CHI 
death databases held by the practices and all morbidity outcomes were derived from 
the hospital admission databases, including SMR01, SCI-DC (diabetes population 
register), SMR06 (cancer registry), as described in detail in previous chapters. 
Morbidity outcomes were defined as the first event of an in-hospital admission after 
PHPT diagnosis, for cases or from the index date, for comparators. The ICD codes 
were used to identify each of the endpoints, as described in Chapter 3. Osteoporotic 
fractures were defined as all fractures at the sites of spine, wrist, humerus and femur 
(ICD9 805-809, 813, 820-821; ICD10 S12, S22, S32, S52, S72), which are 
classically viewed as sites related to osteoporotic fractures. Details of codes for other 
conditions were listed in Chapter 3, Section 3.3. Information on the history of all of 
the above co-morbidities was also sought within five years of diagnosis (for cases) or 
matching index date (for comparators). Tayside community prescription data were 
also used to consider any previous and existing use of bisphosphonates.
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7.3.5 Statistical analyses 
The characteristics of the study cohort, both cases and matched comparators, were 
reported, detailing the distribution of age, gender, previous usage of bisphosphonate, 
and history of any aforementioned conditions. Any difference between cases and 
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comparators was compared using the Chi-square test or the student t-test, as 
appropriate. The follow up time was calculated as the number of days from the date 
of diagnosis (for cases) or the index date (for comparators), until an observed event, 
or death or leaving Tayside whichever was earlier, occurred and thus, varied from 
patient to patient and was different for each of the outcomes. 
  
Survival analysis was used to follow up both cases and comparators until an event 
occurred, they were censored or at the end of the study. Data were modelled using 
the Cox Proportional Hazards Model to derive a hazard ratio (HR) of each observed 
outcome comparing cases and comparators. A stratification variable was created by 
combining age group and gender and included 10 categories, which was then treated 
as a stratification variable in all analyses (Table 7.1). This was done with 
consideration of the matching, to allow analyses to be performed matched by age and 
gender. The age cut-off points were decided by examining both the distribution of 
baseline age and the frequencies of observed outcomes, by age group, to give enough 
events in each age group. 
Table 7.1 Strata variable information 
Strata variable value Definition Strata variable value Definition 
1 Male, <50 yr 6 Female, < 50 yr 
2 Male, 50 - 59 yr 7 Female, 50 - 59 yr 
3 Male, 60 - 69 yr 8 Female, 60 - 69 yr 
4 Male, 70 - 79 yr 9 Female, 70 - 79 yr 
5 Male, 80 yr + 10 Female, 80 yr + 
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For each observed outcome, both unadjusted and adjusted HRs were presented with 
95% CIs and a statistical significance level (p value). The univariate model was used 
to derive an unadjusted HR, which only considered one factor denoting cases or 
comparators. The adjusted HR was then derived, by adjusting for other confounding 
factors. Possible confounders considered were socioeconomic deprivation, as 
measured by SIMD, previous prescription of bisphosphonates (yes, no), pre-existing 
conditions as shown from the hospital admission records and the propensity score of 
having a calcium check. The SIMD health board decile was used, with 1 indicating 
the most deprived and 10 being the most affluent. The assumption of proportional 
hazards over time was tested by plotting the log negative log of cumulative survival 
function against log survival time for all categorical variables, which included all the 
aforementioned variables, except the propensity score. Parallel lines in this plot 
indicate the PH assumption is reasonable. Before multiple modelling, each covariate 
was tested univariately and only variables with significance level less than 0.2 were 
considered in the multiple regression model following Hosmer-Lemeshow 
recommendations.
212
 For all covariates meeting this criterion, the Backward stepwise 
elimination method was used to remove non-significant regression variables, by 
testing the probability of the likelihood-ratio statistic based on the maximum partial 
likelihood estimates. The AIC was used to compare different model fit (See Chapter 
3, Section 3.4 for detail), with the smaller the value of AIC, the better the fit of the 
model. 
 
Since all the cases were primarily identified based on biochemistry data and having a 
calcium check which was not part of the routine screening in Tayside, there would 
be underlying reasons for people being calcium tested, which could bias the results. 
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Without weighting by this probability, the estimated risk would be over-emphasised, 
as not all the comparators had had a calcium check. For each outcome, therefore, a 
unique probability, or propensity, of having a calcium check was derived from 
multiple logistic regression, using with or without a calcium check as the binary 
dependent variable, including both covariates and other outcome measures, i.e. not 
the dependent variable under consideration, as independent varibles.
215
 This 
propensity score was then included in the adjusted models as a covariate. The use of 
a propensity score gave a greater weight to those who had never had a calcium check 
throughout the entire study period. 
215
 The effect of including such a propensity score 
on the model fit was assessed by comparing the AICs between models with and 
without propensity score adjustment. 
 
In addition, a Kaplan-Meier survival estimate was carried out to assess the risk 
distribution between cases and comparators over time, for each of the observed 
outcomes. Some data were missing for socioeconomic status. As it is a postcode 
linked summary measure of relative deprivation (see Chapter 3 for detail) and the 
missing data represented less than two percent (1.5%) of the whole data set, it was 
assumed that these were MCAR and a complete case analysis was performed. All 
statistical analyses were performed using SPSS (Version 17) and SAS (Version 9.2).  
 
7.4 Results 
From the original 1,683 patients, when additional selection criteria were applied, a 
total of 1,424 were eligible for the analysis in this chapter, with 5,005 years of follow 
up (median follow-up was 1,042 days (2.9 years)). The mean baseline calcium was 
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2.63 mmol/l (SEM 0.002).  Overall, 70.3% of the cases were female with a mean age 
of 69.3 ± 13.3 years, whilst the mean age for males was 65.9 ± 14.1 years. From the 
Tayside general population, 7,120 random comparators were selected matching for 
age group, gender and calendar-year of diagnosis, these being subjects free from 
PHPT. The total follow up time for the comparators was 27,322 person-years, with a 
median follow-up of 1,138 days (3.1 years). Over half of the matched cohort (54.0%) 
had at least one calcium measurement during the study period, which was within the 
normal reference range. The baseline characteristics of both these cases and matched 
comparators were shown in Table 7.2. Overall, compared to the matched individuals, 
there were a higher percentage of previous co-morbidities in the cases. 
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Table 7.2 Baseline characteristics of PHPT cases and their matched comparators 
Variables Cases Comparators P 
Count 1,424 7,120 NA 
Age 68.3 (13.6) 68.3 (13.6) NA 
Female (%) 1,001 (70.3%) 5,005 (70.3%) NA 
Previous bisphosphonate 105 (7.4%) 220 (3.1%) <0.001 
% with calcium records 1,424 (100%) 3,848 (54.0%) <0.001 
History of previous conditions   
Cardiovascular 213 (15.0%) 445 (6.3%) <0.001 
Cerebrovascular 59 (4.1%) 153 (2.1%) <0.001 
Hypertension 86 (6.0%) 117 (1.6%) <0.001 
Renal failure 0 29 (0.4%) 0.02 
Renal stone 0 28 (0.4%) 0.02 
Fractures 25 (1.8%) 250 (3.5%) 0.001 
Osteoporotic fractures 0 185 (2.6%) <0.001 
Psychiatric disease 15 (1.0%) 24 (0.3%) <0.001 
Diabetes 81 (5.7%) 107 (1.5%) <0.001 
Cancer 141 (9.9%) 346 (4.9%) <0.001 
 
By the end of 2006, there were 404 (28.4%) people who had died among the cases 
and 992 (13.9%), from the comparators (p<0.001). Over a third of the deaths were 
confirmed fatal CVD (40.1% of all deaths in cases and 33.7% in comparators) and 
approximately a quarter were cancer related deaths (29.2% of all deaths in cases and 
24.3% in comparators).  Table 7.3 shows the unadjusted HRs for both primary and 
secondary outcomes. For all endpoints, there was an increased risk in cases versus 
comparators, with the risk of developing renal failure being the highest (HR 19.30 
95% CI (15.08 - 24.70)). The unadjusted risk of mortality and fatal CVD was 
doubled in PHPT cases in comparison to their age, gender matched comparators, and 
that of non-fatal CVD was more than quadrupled. Figure 7.1 are the Kaplan-Meier 
plots showing the risk of developing all primary outcomes over time, which 
illustrates similar results for long-term follow up. Figure 7.2 are such plots showing 
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the risk of all secondary outcomes over time, between cases and comparators, in 
which a significant difference was found in cases in all but diabetes outcome. In 
addition, a great difference can be seen in renal failure and hypertension outcomes 
but a similar risk in hospital admitted renal stones and psychiatric condition 
reflecting their small number of events. 
 
Table 7.3 Unadjusted HRs comparing risks of primary and secondary outcomes, 
between cases (n=1,424) and matched comparators (n=7,120) 
Outcome Event (%) HR 95% CI P 
 Cases Comparators    
Primary outcomes     
All mortality 404 (28.4%) 992 (13.9%) 2.24 1.99-2.51 <0.001 
Fatal CVD 162 (11.4%) 334 (4.7%) 2.67 2.21-3.23 <0.001 
Non-fatal CVD 357 (25.1%) 544 (7.6%) 4.19 3.66-4.79 <0.001 
Secondary outcomes     
Cancer deaths 118 (8.3%) 241 (3.4%) 2.69 2.16-3.56 <0.001 
Cerebrovascular 129 (9.1%) 212 (3.0%) 3.51 2.82-4.37 <0.001 
Hypertension 161 (11.3%) 188 (2.6%) 5.01 4.06-6.19 <0.001 
Renal failure 269 (18.9%) 84 (1.2%) 19.30 15.08-24.70 <0.001 
Renal stones 19 (1.3%) 23 (0.3) 4.56 2.48-8.38 <0.001 
Psychiatric 32 (2.2%) 27 (0.4) 6.46 3.87-10.79 <0.001 
All fractures 109 (7.7%) 284 (4.0%) 2.16 1.73-2.69 <0.001 
Osteoporotic 
fractures 
81 (5.7%) 221 (3.1%) 2.06 1.60-2.66 <0.001 
Cancer 144 (10.1%) 370 (5.2%) 2.18 1.80-2.65 <0.001 
Diabetes 55 (3.9%) 207 (2.9%) 1.34 0.99-1.80 0.052 
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Figure 7.1 Kaplan-Meier plot showing risk of primary outcome, by cases and 
comparators
7
 
a) All cause mortality 
 
 
                                                 
7
  Note that in all figures showing Kaplan-Meier plots, solid lines represent cumulative risk for the 
PHPT cases and dashed lines represent that for the matched cohort (comparators). The difference 
was compared using the Log-rank test; P values represent the significance level from the test.  The 
numbers underneath are the number of events at each specific time point for both cases and 
comparators respectively. 
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b) Fatal CVD 
 
 
C) Non-fatal CVD 
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Figure 7.2 Kaplan-Meier plot showing risk of all secondary outcomes, by cases and 
comparators 
a) Cancer related deaths 
 
b) Cerebrovascular disease 
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c) Hypertension 
 
 
d) Renal failure 
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e) Renal stones 
 
 
f) Psychiatric condition 
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g) All fractures 
 
 
h) Osteoporotic fractures 
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i) Cancer outcome 
 
 
j) Diabetes 
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For all potentially considered covariates, the proportional hazards assumption was 
tested individually and was found to be supported in all assessed outcomes, which 
allowed valid further testing of the risk differences between cases and comparators 
with adjustment for confounders. Table 7.4 shows the comparison of model fit 
among unadjusted models, adjusted models without propensity score adjustment and 
adjusted models with propensity score adjustment, using AIC, for each of the models 
observed. It can be seen that the models improved greatly, that is, a reduction in the 
AIC value, when adjusting for confounding variables, with the propensity score also 
being adjusted for. Thus, the results from the latter model were interpreted in detail 
as final models. 
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Table 7.4 Comparison of model fit using the AIC (lower AIC = better fit) 
Outcome 
Unadjusted 
model 
Adjusted model 
No propensity 
score adjustment 
Changes in AIC 
From unadjusted 
With propensity 
score adjusted 
Changes in AIC 
From adjusted  
AIC1 AIC2 AIC1-AIC2 AIC3 AIC2-AIC3 
Primary outcomes     
All mortality  17,399.6 17,089.9 309.7 16,501.8 588.1 
Fatal CVD 6,043.5 5,812.5 861.0 5,649.0 163.5 
Non-fatal CVD 11,141.8 10,753.1 388.7 10,399.2 353.9 
Secondary outcomes     
Cancer deaths 4,489.1 4,316.5 172.6 4,128.8 187.7 
Cerebrovascular 4,295.9 4,203.4 92.5 4,055.4 148.0 
Hypertension 4,195.3 4,168.9 26.4 3,966.1 202.8 
Renal failure 3,827.2 3,753.7 73.5 3,609.8 143.9 
Renal stones 500.8 479.1 21.7 477.6 1.5 
Psychiatric 710.7 703.4 7.3 649.9 53.5 
All fractures 4,988.6 4,929.0 59.6 4,712.6 216.4 
Osteoporotic fractures 3,863.8 3,809.6 54.2 3,601.4 208.2 
Cancer 6,542.8 6,504.4 38.4 6,381.4 123.0 
Diabetes 3,392.1 3,363.9 28.2 3,250.6 113.3 
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Table 7.5 provides a summary of the adjusted HRs for cases versus comparators for 
all observed outcomes, with and without propensity score adjustment, respectively. 
Although the HRs were reduced for most of the end points when adjusted for 
confounding variables, as well as for the likelihood of being tested for serum calcium 
concentration, they remained statistically significantly raised. The increased 
mortality, as well as the risk of non-fatal CVD, in cases, were consistent over time 
and can be clearly seen in Figure 7.3, which displays the cumulative survival for 
both cases and comparators, after adjusting for all confounding factors. Compared to 
the matched comparators, the adjusted risk of developing renal failure remained the 
highest, with an HR of 13.83 (95% CI (10.41-18.37)). The risk of having renal 
stones and psychiatric conditions was four times higher in cases, than that in 
comparators and the risk of developing cerebrovascular disease and non-fatal CVD 
was doubled in cases, than that in controls. 
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Table 7.5 Adjusted hazard ratios (HRs) for comparing risks of all outcomes 
comparing cases and matched comparators, with results of further adjustment for the 
probability of having a calcium check listed separately. 
 No adjustment for propensity Propensity score adjusted 
Outcome HR 95% CI p HR 95% CI p 
Primary outcomes      
All mortality  2.12 1.87-2.39 <0.001 1.64 1.43-1.87 <0.001 
Fatal CVD 2.23 1.83-2.72 <0.001 1.64 1.32-2.04 <0.001 
Non-fatal CVD 3.57 3.11-4.10 <0.001 2.48 2.13-2.89 <0.001 
Secondary outcomes      
Cancer deaths 2.29 1.83-2.86 <0.001 1.32 1.03-1.68 0.03 
Cerebrovascular 3.17 2.53-3.97 <0.001 2.51 1.95-3.22 <0.001 
Hypertension 4.48 3.60-5.57 <0.001 2.60 2.04-3.31 <0.001 
Renal failure 19.00 14.55-24.82 <0.001 13.83 10.41-18.37 <0.001 
Renal stones 5.07 2.66-9.68 <0.001 5.15 2.69-9.83 <0.001 
Psychiatric 6.30 3.76-10.57 <0.001 4.25 2.33-7.77 <0.001 
All fractures 2.17 1.73-2.72 <0.001 1.75 1.36-2.26 <0.001 
Osteoporotic 
fractures 
2.11 1.63-2.73 <0.001 1.63 1.22-2.19 <0.001 
Cancer 2.08 1.71-2.53 <0.001 1.75 1.41-2.18 <0.001 
Diabetes 1.43 1.06-1.94 0.02 1.37 1.01-1.86 0.04 
Adjusted for SIMD, previous prescription of bisphosphonates (yes vs. no), pre-
existing conditions (yes vs. no) 
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Figure 7.3 Kaplan-Meier survival cumulative survival curves for all primary 
outcomes, by cases and comparators 
a) All cause mortality 
 
b) Fatal CVD 
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c) Non-fatal CVD 
 
For all primary outcomes, other factors that also contributed to the increased risk in 
cases, which were kept in the final model, are listed in Table 7.6 – 7.8, respectively. 
In addition to being a PHPT case, age at diagnosis, history of previous hospital 
admission with CVD, cerebrovascular, renal failure, psychiatric condition, fractures 
and cancer, also contributed to the increased risk of mortality (adjusted HRs 1.08, 
1.34, 1.54, 2.69, 2.38, 1.55, 1.32 respectively with p<0.05 in all instances). Higher 
socio-economic status, as measured by the SIMD, however, was associated with a 
reduced risk of mortality (HR=0.97, 95% (0.95-0.99)). Previous history of CVD was 
a significant risk factor for subsequent fatal and non-fatal CVD outcomes (HRs 2.68 
and 3.45 respectively, with p<0.001 in both instances) but baseline age was only a 
significant risk factor in predicting fatal-CVD. In addition, the probability of having 
calcium measured increased the risk of all primary outcomes (HRs 7.14, 9.40 and 
15.55 for mortality, fatal and non-fatal CVD respectively, with all p<0.001). In other 
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words, people who have calcium checked are ill. No difference in gender was found 
in all primary outcomes.  
Table 7.6 Variables that remained in the final models for all cause mortality 
Variables  HRs 95% CI p value 
Case 1.64 1.43-1.87 <0.001 
Age (+1 year) 1.08 1.06-1.09 <0.001 
SIMD (+1 decile) 0.97 0.95-0.99 0.004 
Propensity score (+ 1)
1 
7.14 4.96-10.27 <0.001 
Previous bisphosphonates (yes vs. no) 1.21 0.97-1.51 0.09 
Previous conditions (yes vs. no)    
CVD  1.34 1.15-1.56 <0.001 
Cerebrovascular 1.54 1.23-1.93 <0.001 
Renal failure 2.69 1.66-4.35 <0.001 
Psychiatric 2.38 1.52-3.73 <0.001 
Fractures 1.55 1.07-2.23 0.02 
Cancer 1.32 1.10-1.57 0.002 
1
 The range of the propensity score was between 0 and 1. 
Table 7.7 Variables that remained in the final models for fatal CVD 
Variables  HRs 95% CI p value 
Case 1.64 1.32-2.04 <0.001 
Age (+1 year) 1.09 1.06-1.12 <0.001 
SIMD (+1 decile) 0.97 0.94-1.001 0.06 
Propensity score (+ 1)
1 
9.40 5.01-17.62 <0.001 
Previous bisphosphonates (yes vs. no) 1.42 1.01-2.00 0.04 
Previous conditions (yes vs. no)    
CVD  2.68 2.16-3.32 <0.001 
Renal failure 3.42 1.87-6.25 <0.001 
Osteoporotic fractures 1.95 1.24-3.06 0.004 
Diabetes 1.51 1.07-2.13 0.02 
1
 The range of the propensity score was between 0 and 1. 
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Table 7.8 Variables that remained in the final models for non-fatal CVD 
Variables  HRs 95% CI p value 
Case 2.48 2.13-2.89 <0.001 
Age (+1 year) 1.02 1.00-1.04 0.055 
Propensity score (+1 )
1 
15.55 9.82-24.63 <0.001 
Previous conditions (yes vs. no)    
CVD 3.45 2.94-4.04 <0.001 
Renal failure 1.92 1.07-3.45 0.03 
Cancer 0.80 0.62-1.04 0.09 
Diabetes 1.50 1.16-1.93 0.002 
1
 The range of the propensity score was between 0 and 1. 
 
7.5 Discussion 
This chapter investigated the outcomes in a large cohort of patients with untreated 
mild PHPT, using survival analysis with comparison of a one-to-five, age, gender 
and calendar year matched cohort. Using the pre-defined biochemical criteria, in 
conjunction with additional hospital level data and prescription records, a group of 
1,424 (85%) mild PHPT patients were further selected as cases from the mild sub-
group (n=1,683), which was classified in Chapter 6. This was done to eliminate any 
patients who might be eligible candidates for surgery as indicated from previous 
hospital admission records, in order to ensure that the analyses were as robust as 
possible and generalisable in nature. Compared to those 259 unselected mild patients, 
the cases selected for this chapter were slightly younger with a higher proportion of 
female patients (P=0.024, 0.013 respectively) (Table 7.9). As all the cases selected 
were free from renal complications and osteoporotic fractures at the time of 
diagnosis and were never treated with Cinacalcet during the course of study, thus 
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they were closely representative of the majority untreated PHPT patients who did not 
fit the NIH criteria for surgery. 
 
Table 7.9 Comparison of the baseline characteristics between selected and 
unselected mild PHPT patients 
Variables  Cases in this chapter Unselected patients P value 
Count 1,424 259 NA 
Mean age (SD) 68.7 (13.6) 70.8 (13.8) 0.024 
Female (%) 1,001 (70.3%) 162 (62.5%) 0.013 
Baseline calcium (SEM) 2.63 (0.002) 2.62 (0.004) <0.001 
PTH (SEM) 10.2 (0.24) 15.1 (0.79) <0.001 
 
Despite the fact that these patients were cases with mild biochemical abnormalities 
and an absence of those clinical conditions traditionally associated with PHPT, the 
results consistently showed an increased risk of mortality and morbidity among them. 
Although the adjusted risk was not as high as in the previous chapter, this was 
because more confounding factors were adjusted for using a closer matching cohort 
selected from the general population and was in line with the pre-assumption that 
some of the risk could be explained by these confounding factors. The study used 
individual data for both cases and comparators and, thus, was likely to reflect an 
accurate risk estimate over time. It is notable that, despite adjusting for many 
potential confounding variables and the propensity to have calcium checked, the 
increased mortality and morbidity risk associated with mild PHPT persisted and 
were statistically significant. 
 
The patients included in this study had a milder hypercalcemia than both the total 
PHPT cohort identified in this PhD and patients identified in previous studies, and 
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were free from the NIH referral criteria, except that data on patients‟ self-reported 
symptoms were not available. The results indicated, however, that they had a similar 
increased risk of mortality and co-morbidity as was shown in those with 
symptomatic PHPT in other studies. 
51, 52 , 102, 110, 112
 In the adjusted models, the HRs 
were estimated for all endpoints by excluding and including a propensity term 
adjusting for the likelihood of calcium measurements being undertaken, and found 
slightly reduced risks in cases and a better fit in the latter models. This was done 
because all patients with diagnosed PHPT but not all matched comparators had 
serum calcium measured and therefore, more likely to be ill. Moreover, as expected 
and suggested from Table 7.6 - Table 7.8, previous co-morbidities also contributed 
to the risk. In addition, the socioeconomic status as indicated by the multiple 
deprivation scores, namely SIMD, had a marginal effect on the mortality, with 
people from the most affluent area as a protecting factor (HRs 0.97 95% CI (0.95-
0.99), p=0.004 for all cause mortality). Interestingly, although all the PHPT cases 
were patients free from renal stones at diagnosis, the risk of developing renal stones 
was higher when adjusted for other confounding factors and the propensity of having 
calcium checked, suggesting that patients with untreated mild PHPT have a 
genuinely increased risk of renal stone formation. 
 
Compared to the matched comparators, the cases had a higher prevalence of previous 
morbidities. Such presence of high pre-existing co-morbidity would have increased 
the chance of serum calcium being checked and PHPT being diagnosed.  In addition, 
although the cases had mildly elevated serum calcium and an absence of classic NIH 
referral criteria, for example, renal complications, it is possible that some of these 
patients could have had vague symptoms that were connected to the PHPT condition, 
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as this was thought to be quite common.
40, 56
 At the other extreme, however, some of 
the patients identified in this study were even unaware of their PHPT condition. As 
described previously they were identified from electronic databases based on 
biochemical criteria and so may not have received a diagnosis.  Although the degree 
of hypercalcaemia predicts the risk of renal calculi forming, it seems that both mild 
and severe elevations in serum calcium concentration could result in increased 
mortality.  Thus, the results result suggested that, the degree of biochemical 
derangement may not predict the risk of mortality and morbidity, thus perhaps the 
severity of hypercalcaemia should be questioned as the main determinant for PTX. 
 
Some covariates (possible confounders) could not be accommodated, due to a lack of 
data. For example, the data on smoking were not available but smoking rates would 
not be expected to differ between mild PHPT patients and the general population.  
Body mass index (BMI) was another potential confounder in patients with PHPT but 
these measurements were not universally available.
250, 251
 Such information, however, 
was available for all diabetic patients in Tayside and was all recorded on the SCI-DC 
database. In order to investigate if BMI had any possible effects on patient outcome, 
a further data request was made to HIC, extracting the BMI data, as well as 
demographic information (e.g. date of birth, gender and date of death for those who 
were deceased) for all diabetic patients in Tayside. During the study period, 316 
(22.2%) out of the total 1,424 cases had diabetes and BMI information whilst a 
further 24,122 patients with diabetes but without PHPT also had valid BMI data. 
Among these diabetic patients, the median BMI for those with PHPT was 29.4 kg/m
2
 
and it was 29.6 kg/m
2
 for those without PHPT (p=0.80). The all cause mortality in 
all diabetic patients was measured using multiple logistic regression, adjusting for 
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age, gender, BMI and the presence of PHPT. The risk of mortality was found to be 
significantly higher in the PHPT cohort than in those without PHPT, with an odds 
ratio of 2.73 (95% CI (2.23-2.34), p<0.001), indicating that within this diabetic 
subgroup, patients with mild PHPT were not heavier but did have an increased 
mortality, when compared to those without PHPT. Thus, these extra data suggested 
that body weight was unlikely to be a major risk factor, which could bias the 
outcome of estimates associated with the mild PHPT that was undertaken in this 
chapter.   
 
There were a number of strengths to this chapter‟s analysis. Firstly, both cases and 
matched individuals were from a large less-selective population, in an area where 
there are 400,000 residents, with a similar population structure to Scotland as a 
whole and representative of the UK population, although with slightly lower ethnic 
minorities. The complete long-term data for both cases and comparators at the 
individual level was another key strength. Due to the observational nature of the 
study, patient selection was based on electronic records and subject to biochemical 
measurements and thus, it could be subject to selection bias, as cases without 
calcium measurements were undiagnosed. The data had, however, been adjusted for 
the propensity score of having a calcium measurement predicted from a multiple 
regression model, regardless of the status of PHPT diagnosis. Thus, the likely effects 
introduced by the dependence of biochemical records were reduced. Moreover, 
compared to the previous chapter, this chapter‟s analyses had taken account of the 
history of previous prescription, history of previous morbidities and socio-economic 
status, as well as age and gender. 
   
218 
 
7.6 Chapter summary 
In summary, this chapter has demonstrated that, patients with mild PHPT not fitting 
the NIH criteria for referral had an increased risk of mortality, as well as fatal and 
non-fatal CVD. These patients were also subject to an increased risk of developing 
other co-morbidities, with renal disease being the highest of these. These results 
were consistent with the findings in the previous chapter and suggested that the 
severity of hypercalcaemia should not be a dominant surgical criterion. A large 
randomised controlled trial of PTX in patients with mild PHPT, who are otherwise 
seemingly healthy, is therefore, needed to assess likely efficacy in this patient group. 
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CHAPTER 8  
 DOES PHPT PROGRESS IF LEFT UNTREATED? 
A NATURAL HISTORY STUDY 
8.1 Overview 
The previous two chapters consistently gave evidence of an increased risk of 
mortality and morbidity in patients with mild untreated PHPT, using two different 
measures. This chapter addresses the natural history of the mild untreated PHPT in 
terms of disease progression, with comparison to those who were surgically treated. 
Using a complete biochemistry records, a subset of eligible mild PHPT patients will 
be selected for this study, the patient selection criteria and methods will be firstly 
described. The results relating to the changes of patients‟ biochemical indices will 
then be presented separately, for both untreated and treated patients.  Key findings 
will be discussed and these followed by a brief summary of the chapter. 
 
8.2 Introduction 
The severity of hypercalcaemia has been used to reflect the severity of the PHPT 
condition for decades, since the majority of cases now lack any traditional 
symptoms. As a result, the level of calcium concentration has consistently been 
agreed as the dominant criterion for surgical selection, at all three NIH workshops on 
the management of asymptomatic PHPT.
43, 150, 217-219
 Some studies, together with the 
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results from the prior two chapters have, however, shown an increased risk of 
mortality and co-morbidity in patients with mild PHPT. Thus, to answer the question 
as to whether or not these patients could safely be left without surgery, issues on 
disease progression, the involvement of other complications and possible predictors 
of complications among mild PHPT patients, would need to be addressed and were 
recommended as further research areas at the last NIH workshop.
43
 This chapter is, 
therefore, aimed at providing an update of the natural history, with a focus on 
calcium progression in the untreated mild PHPT patients with raised but milder 
hypercalcemia (calcium<2.90 mmol/l at the baseline). Complete observational data 
at population level, including biochemical records and hospital admissions, will be 
linked to observe the long-term results in these patients and to compare the outcomes 
with those who had undergone surgery.  
 
The specific objectives of the chapter are to examine: 
1. Disease progression, being defined as an increase in calcium concentrations 
in patients with mild untreated PHPT; 
2. Changes in PTH concentrations and other biochemical indices related to the 
PHPT condition, in patients with mild untreated PHPT; 
3. Surgical cure rate and the outcome in patients with „surgically treated‟ PHPT; 
4. Possible predictors of calcium progression in mild untreated PHPT patients. 
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8.3 Patients and methods 
8.3.1 Patients 
The study population for this chapter was selected from the original 2,299 incident 
PHPT cases diagnosed between 1997 and 2006. By linking these patients with their 
complete biochemistry data on serum calcium, history and present hospital records, 
the „mild untreated‟ group was defined as:  
1) Untreated PHPT patients; 
2) Serum calcium concentrations were less than 2.9 mmol/l within the first six 
months after a positive diagnosis; 
3) With absence of previous fragility fracture43 and renal complications; 
4) Not been treated with Cinacalcet. 
Previous fragility fracture was defined as previous admissions with osteoporotic 
fractures, which included fractures at the sites of spine, wrist, humerus and femur, as 
suggested from the hospital admission data. Previous renal complications were any 
previous hospital admissions on renal failure and/or renal stones. Non-normal renal 
functions were also indicated, if the baseline serum creatinine level was above 
150µmol/l.  
 
As the study was focused on patients‟ serum calcium, further exclusion criteria were 
applied to the „mild untreated‟ group. These were: 
1) Serum calcium was followed up for less than 6 months; 
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2) Less than two calcium measurements within the first six months. 
For the purpose of comparison, a group of „surgically treated‟ PHPT patients were 
also selected for this study, these being:  
1) Patients who had undergone PTX between 1997 and 2006; 
2) With valid records on serum calcium. 
These two subsequent cohorts of „mild untreated‟ and „surgically treated‟ PHPT 
patients formed the basis of this study. 
 
8.3.2 Definition of disease progression 
For the selected patients, an additional data request was made to HIC, extracting an 
update of their biochemical records, including serum calcium, serum creatinine, PTH 
and ALP, from 1 January 2007 until 30 September 2009 (which were the most recent 
records held by HIC at the time of data extraction). All calcium records after a 
positive PHPT diagnosis were then compared to the baseline. If calcium increased by 
0.2 mmol/l, compared to the baseline or calcium reached 2.9 mmol/l during the 
follow-up period, a marker was made indicating a biochemical progression of the 
disease. For those who were biochemically identified as PHPT patients, the date of 
first raised calcium (>=2.55 mmol/l) was treated as the incident date and the 
corresponding calcium was treated as the baseline value; for those who were 
identified via hospital records, the result of calcium concentration tested on the date 
of admission, was treated as the baseline value. 
 
223 
8.3.3 Statistical methods 
Descriptive statistics were used to summarise baseline characteristics of the patients. 
Differences in biochemical indices and follow up times were tested using Non-
parametric methods because their distributions were non-Normal. Other differences 
were examined using the Chi-square test and the independent-samples t-test, as 
appropriate.  
 
For the „surgically treated‟ group, postoperative calcium and PTH concentrations at 
2, 6, and 12 months after surgery, were compared with the baseline. Any changes 
over time in the pooled biochemical indices, including calcium, PTH, ALP and 
serum creatinine were observed, using curve estimation. The Wilcoxon Signed Rank 
test was used to compare the overall median biochemical indices, before and after 
surgery. The surgical cure rate was estimated by using the number of patients with 
normalised calcium after surgery, divided by the total number of „surgically treated‟ 
patients. To examine the surgical outcomes, the rate of developing other co-
morbidities, denoted as number of events per five person-years, before and after 
surgery were also compared, using the Poisson Exact test. As described in earlier 
chapters, co-morbidity information was obtained from hospital admission records 
indicating an in-patient admission. „Before surgery events‟ included any admission 
occurring from a positive PHPT diagnosis being made at the time of surgery; and 
„post surgery events‟ were any post-operative admission which occurred before the 
end of the study.  
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For the „mild untreated‟ group, pooled median calcium, PTH, ALP and serum 
creatinine were estimated using curve estimation for any trends over time. In 
addition, within-subject changes in calcium and PTH concentrations during the 
follow-up period were estimated using the Linear mixed model, allowing repeated 
but unequal numbers of measurements within subjects. 
252
 The AIC was used to 
select the best model in describing the trend. 
253
 Furthermore, the Cox proportional 
hazards model was used to examine possible predictors of calcium progression. An 
event was defined as an observed progression. The follow-up time was the duration 
from the date of diagnosis, up to the date of an event, death or last calcium check-up. 
The predictor variables considered were baseline age, gender, baseline biochemical 
values and other pre-existing clinical complications. Each factor was tested 
individually, initially, to identify the most important predictors, as indicated with a p 
value <0.2. Selected variables were then entered into the multiple model using the 
backward LR selection method. All statistical analyses were carried out using the 
SPSS (version 17) and SAS (Version 9.1) software, and statistical significance was 
demonstrated with p<0.05. 
 
8.4 Results 
8.4.1 Baseline characteristics 
Using the aforementioned selection criteria, from the 2,299 incident PHPT patients, 
there were 996 patients identified as being eligible „mild untreated‟ PHPT cases and 
200 as being „surgically treated‟ cases, for the purpose of this study. Figure 8.1 is a 
flow chart showing the results from the patient selection process. The baseline 
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characteristics of these patients are tabulated in Table 8.1. Serum calcium was 
followed up from the date of PHPT diagnosis and was continued until the end of 
September 2009, giving a respective median follow-up of 4.8 years for the „mild 
untreated‟ and 5.8 years for the „surgically treated‟ group, respectively. „Surgically 
treated‟ patients were younger and with higher baseline calcium and PTH 
concentrations than the „mild untreated‟ patients (p<0.001 in all instances). They 
also had higher urine calcium excretion rate but a lower serum creatinine level, than 
the untreated patients (p=0.001 & p<0.001 respectively). 
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Figure 8.1 Flow diagram of patient selection process 
 
 
 
 
2,299 patients identified 
(1997-2006) 
“Surgically treated” 
N=200 
Untreated 
N=2,095 
Potential mild untreated 
N=1,343 
Excluded 
N=347 
Ineligible  
N=752 
Follow up < 6 months 
N=199 
 
Ca measurements < 2 
N=148 
 
“Mild untreated” 
N=996 
Without Ca records 
N=4 
High baseline calcium 
N=187 
Previous fracture fragility
 
N=68 
Previous renal 
complications N=168 
Non-normal renal function 
N=329 
227 
Table 8.1 Baseline characteristics of patients with mild untreated PHPT and PHPT 
treated with surgery 
Variables 
Mild 
untreated 
Surgically 
treated p-value 
Number of patients 996 200 - 
Age
 
66.6 (13.7) 58.2 (13.9) <0.001 
Female
 
736 (73.9%) 151 (75.5%) NS 
Calcium follow up 
(months) 57 (6.2-152.1) 70 (7.5-154.7) <0.001 
Baseline biochemical indices, median (range)  
Serum calcium 
(mmol/l) 2.61 (2.55-2.89) 2.80 (2.56-5.49) <0.001 
PTH 
(pmol/l) 6.3 (0.8-46.8) 12.50 (2.20-274.0) <0.001 
ALP 
(u/l) 95 (28-1187) 91 (43-516) NS 
Serum Creatinine 
(µmol/l) 96 (56-150) 92 (2-1266) <0.001 
Total Cholesterol 
(mmol/l) 5.1 (1.6-14.1) 5.23 (2.40-9.40) NS 
Urine calcium  
excretion 0.04 (0.003-0.30) 0.07 (0.01-0.34) 0.001 
 
By the end of September 2009, there were 347 (34.8%) who had died in the „mild 
untreated‟ group and 28 (14.0%), in the „surgically treated‟ group (Chi-square=33.61, 
p<0.001).  
8.4.2 Surgical cure rate 
By the end of September 2009, a total of 7,614 calcium measurements had been 
made for the „surgically treated‟ patients (n=200), with a mean of 38 (SEM=5) 
measurements per patient. Over half of the measurements (n=4,170, 54.8%) were 
made on or after the date of surgery. PTH measurements were available for 189 
(94.5%) patients, with a mean of 4 (SEM=0.4) measurements per patient. Of the total 
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817 PTH measurements, 325 (39.8%) were made post-operatively. In addition, there 
were 7,598 available ALP records for these „surgically treated‟ patient, with 3,684 
(48.5%) made on or after the date of surgery and 9,229 available creatinine records, 
with 4,050 (43.9%) made post operatively. 
 
Compared to the baseline, calcium concentration was normalised after surgery, with 
median postoperative calcium concentration at 2 months being 2.44 mmol/l, 
significantly lower than the baseline measurement (p<0.001) and remained stable 
within the normal range at the 6 and 12 months‟ check-up (2.42 mmol/l and 2.36 
mmol/l respectively). Figure 8.2 shows the pooled median calcium concentrations in 
these patients over time. It can be seen that the calcium concentration appeared to be 
an increasing trend before surgery followed by a sharp decrease immediately after 
surgery and then fluctuating within the normal ranges. Overall, the median calcium 
concentration before surgery was significantly lower than that after surgery (median 
calcium 2.79 and 2.39 respectively, p<0.001).  PTH was reduced from a median 
value of 12.5pmol/l at baseline, to a postoperative value of 6.4 pmol/l at 2 months. 
Figure 8.3 shows the PTH changes over time and it can be seen that there was a 
slight decrease in the median PTH after surgery compared to that before surgery 
(median PTH 12.4 pmol/l and 6.1 pmol/l respectively, p<0.001).  
 
The changes in ALP and serum creatinine are shown in Figure 8.4 and Figure 8.5. 
As can be seen from the figures, the ALP fluctuated over time, with no clear trend 
but there was an apparent decline in serum creatinine after surgery.   
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Figure 8.2 Pooled median calcium concentrations in 'surgically treated' PHPT 
patients 
 
 
Figure 8.3 Pooled median PTH concentrations in 'surgically treated' PHPT patients 
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Figure 8.4 Pooled median ALP concentrations in 'surgically treated' PHPT patients 
 
Figure 8.5 Pooled median serum creatinine concentrations in 'surgically treated' 
PHPT patients 
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Over half of the „surgically treated‟ patients (n= 108, 54.0%) were surgically treated 
within a year of diagnosis (median =11 months). There were 74 (37 %) patients who 
had shown evidence of calcium progression prior to surgery, with a median time to 
progression of 12.6 months. There was no difference in the baseline calcium between 
these patients (n=74) and the remaining „surgically treated‟ patients (n=126) 
(p=0.06). Four patients showed evidence of calcium progression six months after the 
surgery, indicating a surgical failure rate of 2%. As shown in Table 8.2, there was no 
homogeneity among these four patients in terms of baseline characteristics and 
disease details. 
Table 8.2 Individual information of patients whose calcium progressed six months 
after surgery 
Patient A B C D 
Gender F F M F 
Age at diagnosis 69 52 30 71 
Year of diagnosis 2002 1999 2000 1998 
Baseline S-Ca (mmol/l) 2.67 3.04 3.33 2.56 
Year of PTX 2003 1999 2000 1999 
Time of S-Ca progression  
(years after PTX)  
5.3 10.5 3.3 4.2 
 
When the co-morbidity outcome was compared, as shown in Table 8.3, surgery 
significantly reduced the risk of developing renal complications and cancer but not 
CVD, osteoporotic fractures or psychiatric conditions.  
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Table 8.3 Rates (event per 5 person years) of developing other co-morbidities before 
and after parathyroidectomy, in the 200 surgically treated PHPT patients. 
Other complications 
Before 
 surgery 
 After 
 surgery 
P value
 
Cardiovascular disease 0.124 0.083 NS 
Renal stones 0.155 0.019 0.01 
Renal failure 0.248 0.045 <0.001 
Osteoporotic fractures 0.078 0.038 NS 
Cancer 0.093 0.115 NS 
Psychiatric disease 0.016 0.006 NS 
 
8.4.3 Disease progression among mild, untreated PHPT patients 
Of the 996 „mild untreated‟ patients, biochemical indices were followed up over a 
maximum of a 12- year period, with a total of 24,972 post-diagnosis measurements 
of calcium being made. Figure 8.6 illustrates changes in pooled calcium 
concentrations by follow-up time and it can be seen that the calcium regressed to the 
normal range within the first year and remained stable, with a significant decreasing 
trend (p<0.001) over the ten-year period of observation. Figure 8.7 shows the 
changes in PTH concentrations over time, which displayed a persistently raised PTH 
above the upper limit of normal range (6.9 pmol/l), with an increasing trend 
(p<0.001). Over the course of the follow-up period, ALP fluctuated slightly, with a 
small degree of decreasing linear trend (p=0.043) (Figure 8.8). As shown in Figure 
8.9, serum creatinine, however, increased gradually, with a cubic trend over time 
(p=0.008). 
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Figure 8.6 Changes in pooled median calcium concentrations in patients with „mild 
untreated‟ PHPT  
 
Figure 8.7 Changes in pooled median PTH concentrations in patients with 'mild 
untreated' PHPT 
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Figure 8.8 Changes in pooled median ALP concentrations in patients with 'mild 
untreated' PHPT 
 
Figure 8.9 Changes in pooled median creatinine concentrations in patients with 'mild 
untreated' PHPT 
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According to the AIC, the Linear mixed model adjusted for age as a time dependent 
variable and gender, provided the best fit for both calcium and PTH concentrations, 
which showed a decreasing trend in calcium by time and an increasing trend in PTH 
(p<0.001 in both instances).   
 
Over one tenth of the „mild untreated‟ patients (n=144, 14.5%) developed evidence 
of progression, with a mean time to progression of 2.6 years. Half of these patients 
(n=79, 54.9%) showed evidence of progression within the first three years after a 
positive PHPT diagnosis, Figure 8.10 shows the number of patients, progressed by 
time.  
Figure 8.10 Number of „mild untreated‟ patients who showed evidence of calcium 
progression 
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As shown in Table 8.4, patients who progressed had a longer follow-up and higher 
baseline PTH concentration than those who did not progress but no difference in 
their baseline calcium concentrations or their age and gender. According to the 
changes in individual‟s calcium concentrations, two types of progression were 
observed, these being „unsustained progression‟ and „persistent progression‟. 
Thirteen patients (1.3% of the total “mild untreated” patients) had „persistent 
progression‟, i.e. their calcium remained at a progressed level for more than a six-
month interval, with the last calcium check-up being progressed compared to the 
baseline. In the majority of patients (n=122, 85% of the total progressed patients) 
who progressed, calcium concentration later decreased, being defined as 
„unsustained progression‟. Nine patients of the original 144 patients who progressed 
could not be grouped by progression type, due to insufficient follow-up time and of 
these, seven with a single calcium measurement being progressed and two with 
calcium progression for two occasions but both measurements were taken within six 
months. 
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Table 8.4 Comparison of baseline characteristics between progressed and un-
progressed mild untreated PHPT patients 
Variables No progression Progression p 
Number
 
852 (85.5%) 144 (14.5%) - 
Age 66.4 (13.6) 69.5 (14.5) NS 
Female 636 (74.6%) 100 (69.4%) NS 
Follow up time (months) 56 (6.2-151.9) 65 (7.4-152.1) 0.003 
Progression time (months) - 32 (6.8-114.0) - 
Baseline biochemical indices, median (range)   
Serum calcium (mmol/l) 2.61 (2.55-2.88) 2.62 (2.55-2.89) NS 
PTH (pmol/l) 6.1 (0.8-46.8) 8.0 (2.1-25.6) 0.005 
Alkaline phosphatise (u/l) 95 (28-1187) 97 (35-258) NS 
Serum creatinine (µmol/l) 96 (56-150) 97 (57-150) NS 
Cholesterol  
(mmol/l) 5.1 (1.6-14.1) 5.5 (2.2-8.7) 
NS 
 
Twenty-six (2.6%) patients from the „mild untreated‟ group were surgically treated 
during the follow-up period from January 2007 to September 2009. Of these, nine 
had shown progression in calcium prior to surgery and the others had developed 
other surgical indications. In all patients who progressed, there was a higher PTH 
concentration as compared to the remaining „mild untreated‟ patients (p=0.046), but 
no difference in calcium at the baseline was observed (Table 8.4). 
  
8.4.4 Predictors of disease progression 
In the unadjusted model, age at diagnosis and baseline PTH concentration, 
independently, were risk factors of calcium progression (Table 8.5). As shown in 
Table 8.4, these two variables were the only factors kept in the final adjusted model, 
both having demonstrated a positive association with the outcome. The risk of 
progression increased by 31% for each 5 pmol/l increase in the baseline PTH 
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concentration (p=0.020) and the risk increased by 23% for each 5 years increase in 
age at diagnosis (p=0.038). Figure 8.11 illustrates the increased rate of calcium 
progression in the „mild untreated‟ patients by the range (in quintile) of their baseline 
PTH concentration. In each PTH quintile, there was no difference in the baseline 
calcium concentration. The overall rate of progression, as denoted by the number of 
patients who had shown progression of calcium divided by the total number of 
patients in each quintile, however, showed a significant increasing trend (p<0.001). 
Table 8.5 Results from the unadjusted and adjusted Cox proportional hazards models 
looking at possible predictors of calcium progression 
Variables 
Unadjusted Adjusted
* 
HR 95% CI P HR 95% CI P 
Age  
(+5 year) 1.11 (1.04-1.19) 0.002 1.23 (1.01-1.50) 0.038 
Female  
(v.s. Male) 0.83 (0.58-1.18) NS - - - 
 
Baseline biochemical indices    
PTH  
(+ 5 pmol/l) 1.29 (1.09-1.54) 0.003 1.31 (1.04-1.63) 0.020 
Creatinine  
(+5 µmol/l) 0.98 (0.94-1.02) NS - - - 
ALP 
(+5 u/l) 0.99 (0.98-1.01) NS - - - 
Cholesterol  
(+1 mmo/l) 0.96 (0.82-1.13) NS - - - 
 
Pre-existing conditions (yes v.s. no)   
CVD 1.01 (0.64-1.57) NS - - - 
Cerebrovascular 
disease 0.88 (0.41-1.89) NS - - - 
Hypertension 0.65 (0.29-1.48) NS - - - 
Cancer 0.94 (0.52-1.69) NS - - - 
Diabetes 1.19 (0.72-1.97) NS - - - 
*Adjusted for previous hospital admissions, baseline biochemical indices, age and gender. 
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Figure 8.11 Progression rate of serum calcium (line with dots) among „mild 
untreated‟ PHPT patients, arranged by the baseline PTH quintiles, with fitted trend 
line (straight line). R
2
 indicates the closeness of the regression line to the actual rates. 
 
8.5  Discussion 
This chapter has provided up-to-date information on the natural history of mild 
PHPT patients with a long follow-up period, in terms of the biochemical progression 
of the disease, based on a larger patient cohort when compared to previous studies.
36-
38, 69, 89, 254
 The „mild untreated‟ group were largely identified biochemically, as being 
those who had mild hypercalcemia with normal renal function and absence of 
previous fracture fragility at the time of diagnosis, therefore, they reflected the 
contemporary asymptomatic PHPT patients, who had no overt symptoms. The 
definition of calcium progression, which broadly followed the guidelines and the 
conventional limits for calcium, was made in consultation with endocrinologists in 
Tayside and represented an important clinical change in calcium, indicating 
worsening of the disease from PHPT.
5, 6, 10, 43, 48
  In support of previous studies on the 
natural history of asymptomatic PHPT, the majority of our mild patients (85.5%) had 
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stable or decreased calcium over the ten-years of follow up from initial diagnosis.
69, 
89
 
 
By definition, there were three patterns of calcium development, these being 1) no 
progression, 2) unsustained progression and 3) persistent progression. In 
approximately 85% of all patients who progressed, the calcium concentration later 
decreased by the end of study, without surgical intervention. However, 3% of the 
total „mild untreated‟ patients did develop surgical indications and had undergone 
PTX by the end of September 2009. The results suggested that the rates of calcium 
progression did not differ by the baseline calcium concentration but were positively 
correlated with the baseline PTH concentration. PTH, as well as baseline age, were 
also demonstrated as being genuine risk factors of disease progression in the multiple 
regression, when both baseline biochemical indices and pre-existing co-morbidities 
were taken into consideration. 
 
What was unique and intriguing from the present study was that the results suggested 
that not only was there no progression in the majority but that the calcium fell to 
within the normal range and stayed stable over time. There were a few possible 
explanations for such results.  
 
Firstly, because patients selected for this chapter were primarily identified using a 
biochemical algorithm, that is, raised calcium in conjunction with inappropriately 
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elevated PTH levels, thus a large number of patients with borderline raised serum 
calcium concentrations were identified.  This is different from other studies where 
patients were identified through referrals, that is, they were patients with clinician 
interpreted PHPT. As mild PHPT can only be diagnosed incidentally through blood 
tests, the patient-identification approach used in this chapter was more likely to 
identify all possible patients, including those „mild‟ cases, which could have been 
overlooked by the previous studies. The results were, therefore, likely to reflect a 
true natural history of mild PHPT, as patients possibly missed when relying on 
referrals were included in this study. As discussed in the previous chapter, however, 
there was still an underestimation of the cohort, due to the absence of nation-wide 
routine blood screening.  
 
Secondly, there might be a „survivor‟ effect, which means that patients with high 
serum calcium either died or were offered surgery. To address this issue, the baseline 
calcium concentrations were compared with both those who had deceased during the 
study and those „survivors‟ but interestingly, no difference was established (median 
calcium was 2.60 mmol/l for both deceased and surviving patients, p=0.29). This 
indicated that the level of hypercalcaemia might not predict the severity of PHPT or 
any adverse outcome, such as mortality, which was also implied in the results shown 
in Chapters 6 and 7. 
 
Thirdly, due to this analysis using a retrospective observational design, a substantial 
proportion of patients was lost-to-follow-up or had incomplete biochemical 
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measurements, which might have influenced the patterns on those biochemical 
indices observed.  Nevertheless, since an exhaustive database of all laboratory 
records in the population was available, the reason for those non-follow-ups was 
more likely to have been linked to cases with normalised test results.  To test this 
assumption, both calcium and PTH changes over time were observed by dividing the 
„mild untreated‟ cohort into two sub-groups by the length of follow-up time. As 
shown in Figure 8.12, the calcium showed a similar pattern between patients who 
were followed up for at least ten years and those who were followed up for less than 
ten years. The same similar patterns were also evident in the PTH concentrations, 
when separating the cohort into with and without eight years of follow up (Figure 
8.13). These findings supported the original assumption that for the patients who 
survived for ten (or eight) years, the loss-of-follow-ups were more likely to have 
been due to calcium and PTH normalisation, thus further measurements were not 
needed. The interpretation of the present study results on disease progression in 
terms of calcium increases, therefore, was robust, overcoming the limitations of the 
study design. 
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Figure 8.12 Comparison of changes in calcium concentration for patients with and 
without 10 years of follow-up 
 
Figure 8.13 Comparison of changes in PTH concentration for patients with and 
without 8 years of follow up 
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Fourthly, some of the normalisation of serum calcium could be explained by the co-
existence of vitamin D insufficiency, which would tend to minimise the rise in serum 
calcium or result in a slight fall in the calcium. If there were an undue effect of low 
vitamin D level, it would be assumed that more of the calcium measurements and 
patients‟ diagnosis had been made in winter or spring, when vitamin D insufficiency 
is more prevalent due to the lack of sunshine. To assess if there were any such 
influence, the number of calcium measurements made in each calendar month was 
checked and found to be approximately equal throughout the year, with similar 
median calcium concentrations.  In addition, the number of diagnoses made in each 
calendar month was also checked to test if there were any predominance in winter 
time but it was found the outcome was also similar for each month (Table 8.6). 
These results suggested that the influence of vitamin D insufficiency on the results 
was minimal.  
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Table 8.6 Number of calcium measurements made among study population and the 
number of patients diagnosed in each calendar month. 
Calendar 
month 
Ca measurements Patients diagnosed 
Median 
Calcium Count Percent Count Percent 
Jan 2138 8.6 89 8.9 2.49 
Feb 2013 8.1 63 6.3 2.49 
Mar 2082 8.3 77 7.7 2.48 
Apr 1895 7.6 74 7.4 2.48 
May 1935 7.7 80 8.0 2.47 
Jun 1760 7.0 81 8.1 2.47 
Jul 2065 8.3 90 9.0 2.48 
Aug 1848 7.4 77 7.7 2.49 
Sep 2318 9.3 90 9.0 2.49 
Oct 2393 9.6 106 10.6 2.50 
Nov 2351 9.4 70 7.0 2.49 
Dec 2174 8.7 99 9.9 2.48 
Total 24972 100.0 996 100.0  
 
 
In addition, as the diagnosis was based on biochemical features, rather than clinical 
referral patterns, the baseline calcium was the first raised serum calcium. As a result 
of there always being some clinical reason for checking the serum calcium, none of 
the calcium checks across the Tayside population could really be considered as 
„random‟. At the diagnosis, therefore, a significant proportion of patients would be 
generally unwell and/or dehydrated, either as an inpatient or as an outpatient, which 
might increase the calcium concentration temporarily during the illness. As the 
patients‟ condition improved, it was likely that their serum calcium decreased. 
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Although the median calcium was within the reference range in the majority of „mild 
untreated‟ patients, the PTH concentration was persistently raised among them over 
long-term follow-up. There is existing evidence showing that the majority of the 
untreated PHPT patients tend not to progress over a long time and it has been the 
NIH consensus, that patients with mild PHPT can have occasionally normal calcium 
concentrations.
43, 89
 It seems that the concept of „normocalcemic‟ PHPT may be 
much more common that has been previously realised. These patients might have 
seemingly „normal‟ calcium but were more likely cases of „normocalcemic‟ PHPT, 
rather than cases free from the PHPT condition, due to the borderline 
hypercalcaemia they had at diagnosis. With this rising awareness of the existence of 
„normocalcemic‟ PHPT, further investigations as regards PTH and possibly other 
factors, as potentially a better marker for predicting disease progression and long-
term complications are required. 
 
In the 200 „surgically treated‟ PHPT patients, a high surgical success rate (98%) was 
detected, which was compatible with existing evidence reporting successful rate of 
95%.
38, 114, 165, 180
 In support of existing evidence, the study results showed that both 
calcium and PTH concentrations were normalised postoperatively.
69, 97, 114, 159, 255-257
 
In a recent randomised study, Bollerslev et al. found that successful PTX normalised 
calcium and PTH concentrations but had no observable benefit on cardiovascular 
morbidity.
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 This chapter, using the hospital admission data, evaluated the impact of 
successful PTX on cardiovascular involvement, renal complications and 
neuropsychological complaints and found no significant improvement in 
cardiovascular risk.  Although the situation of drop-outs was addressed by using the 
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person-time, the limited number might still not enable detection of such a difference. 
Moreover, it was unable to detect any surgical benefits on psychiatric symptoms; this 
was possibly due to the fact that any neuropsychological complications in mild 
PHPT patients were too vague to result in hospital admission. Existing evidence 
showing neurocognitive improvements was often detected retrospectively, when 
asking patients to compare particular symptoms before and after surgery.
36-38, 85, 178, 
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 The results indicated, however, that the risks of developing renal complications 
were significantly reduced after successful surgery (Table 8.3). 
 
There are a number of strengths to this chapter, as compared to previous studies. 
Firstly, a much larger cohort of „mild untreated‟ PHPT patients were included in this 
study, compared to previous studies.
69, 89
 Silverberg et al initiated a long-term 
observational study on the natural history of PHPT in 1984, based on physicians‟ 
referrals. Although their study has a prospective design with a 15-year follow up, the 
number of patients was small (n=116) and at year 15, only 15 untreated patients were 
followed. In Tayside, because all the electronic data had been prospectively collected 
since the 1980s, this study has a historical prospective feature. Although there was a 
significant number of loss-to-follow-up, the population-level coverage of data 
enabled the study to have more than 100 patients being followed over ten years. 
Secondly, compared to the studies undertaken under the Scandinavian system, the 
nature of the diagnosis being made based on biochemistry data, allowed this study to 
include more patients with mild PHPT who had borderline hypercalcaemia at 
diagnosis, incorporating both calcium and PTH records for diagnosis.
223-225, 230
 
Thirdly, with access to exhaustive laboratory data, this chapter, for the first time, 
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reported long-term changes in other biochemical indices, such as PTH, ALP and 
creatinine, as well as serum calcium. 
 
8.6 Chapter Summary 
In summary, this chapter has described the natural history of PHPT in a large cohort 
of „mild untreated‟ patients. It has demonstrated that most mild PHPT patients did 
not have progression of the disease if left untreated but over one tenth of them did 
show some evidence of progression. High baseline PTH concentrations, as well as 
age at diagnosis, were important predictors of progression. It also demonstrated that 
PTX normalised the patients‟ biochemical values associated with PHPT, with a high 
success rate (98%). The risks of renal complications were also decreased, after 
successful PTX. The increased risk in mortality and co-morbidity in patients with 
mild untreated PHPT as suggested in previous chapters (Chapters 6 and 7) and the 
normalised and stable calcium in these untreated patients over the long-term as 
shown in this chapter, raise the question that calcium may not be an accurate 
surrogate of disease progression. Further investigation of other factors, such as PTH, 
as markers of predicting disease progression and long-term complications is needed 
and will be the focus of the next chapter. 
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CHAPTER 9  
 WHAT PREDICTS ADVERSE OUTCOMES IN 
UNTREATED PHPT? 
9.1 Overview 
This chapter focuses on the survival analysis of the data using proportional hazards 
models to examine what baseline biochemistry provides the best predictor of the risk 
of outcomes associated with untreated PHPT when adjusting for other possible 
confounding factors. Patients selected for this study will be described first and that 
followed by a brief description of the outcomes that will be examined in this chapter, 
together with the biochemistry indices that will be tested. The method will then be 
expanded by describing the various approaches considered in dealing with missing 
data, since some of the biochemistry values are missing at baseline. The process of 
initial data analyses and data formatting will then be described step by step before 
the results of survival analysis being presented. Any significant findings will be 
discussed and the main findings of this chapter will then be summarised. 
 
9.2 Introduction 
The level of baseline calcium concentration has been used as a main criterion for 
surgical selection since the early 1980‟s, when the majority of PHPT patients were 
recognised incidentally, from blood tests.
5, 6, 42, 43, 219, 220
 The reason for this is that 
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severe PHPT, which results in surgical treatment, is assumed to be associated with 
markedly elevated serum calcium concentration and consequently, mildly raised 
calcium is considered as mild PHPT. Since some long-term studies of the natural 
history of PHPT have shown that the majority of untreated patients do not progress 
over time, thus, patients with mild hypercalcaemia are considered as being safely 
monitored, without surgery.
6, 29, 55, 56, 59, 62, 86, 94, 150, 151, 156, 228, 258-262
 In agreement with 
this existing evidence, Chapter 8 has demonstrated that over 85% of the mild PHPT 
patients did not develop signs of disease progression in terms of a rise in calcium 
concentration, however, these patients did have a similarly increased risk of 
developing adverse complications, including mortality, when compared to those with 
a high level of calcium at baseline, as shown in Chapter 6. Some large-scale 
European studies on mild untreated PHPT have also indicated such increased risk in 
patients with mild PHPT, as compared to the general population.
51, 52, 110, 112, 115
 This 
rising evidence of the increased risk associated with patients with mild PHPT 
suggests that calcium may not be an accurate indicator of the severity of the 
condition or at least, it is not a reliable predictive factor of its long-term 
consequences. Identification of predictive factors, as recommended at the first NIH 
conference, will help to distinguish subgroups of patients who will be at risk of 
mortality and co-morbidity, from those who will tolerate the condition without 
complications and therefore, will have a significant impact on the justification for 
optimal management of the condition.
42
 This chapter will, thus, try to identify such 
predictive factors in a group of patients with untreated PHPT, using person-level 
data. Both biochemistry indices and other possible confounders will be examined. 
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The aim of this chapter is to identify what baseline biochemistry measures can be 
used as markers of outcome predictors, when other confounding factors are adjusted 
for. 
 
9.3 Patients and methods 
9.3.1 Study population 
All incident patients with PHPT diagnosed between 1997 and 2006, who had not 
undergone PTX, were included in this study. 
 
9.3.2 Methods 
As in Chapter 7, the primary outcomes considered were all-cause mortality, plus 
fatal and non-fatal cardiovascular endpoints. The secondary outcomes were nine 
disease-specific hospital admitted co-morbidities, including cerebrovascular 
disease, renal failure, renal stones, all fractures, osteoporotic fractures, 
psychiatric conditions, hypertension, diabetes and cancer, as identified using the 
ICD codes. Corresponding codes for each condition were described in Chapter 3, 
Section 3.3. Survival analysis as outlined in Chapter 3, was used to examine the data. 
The biochemical indices tested as potential predictive factors were baseline serum 
calcium, plasma PTH, serum creatinine and ALP. In all cases, the covariates 
considered were gender, age at diagnosis, socio-economic status as measured by the 
SIMD index, previous usage of bisphosphonates and previous co-morbidities, as 
shown from the hospital admission records. 
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For each observed outcome, the proportional hazard assumption was tested by using 
the log negative log of cumulative survival (LLS) plot, against the log of time, 
individually for all categorical covariates. Parallel lines indicate the proportional 
hazard assumption is reasonable. These categorical variables were gender, SIMD 
scores, previous usage of bisphosphonates and previous co-morbidities.  For 
continuous variables, including age and all the baseline biochemical indices, the 
assumption was tested by including a time-interaction term in the Cox model and the 
assumption was not violated if the score test for this additional term was NOT 
significant. Taking baseline age for example, an interaction term 
AGET=AGE*TIME, was created and included in the Cox model with age variable 
and the proportional hazard assumption was not violated if the score test for variable 
AGET was not significant. In the case of non-proportionality, two approaches were 
considered to address the issue. Firstly, data were split into periods by time, if the 
proportional hazard assumption could be met in small time periods; alternatively, a 
time interaction term was created for the variable that violated proportional 
assumption and kept in the model, allowing the rates of hazards to vary by different 
time periods. 
 
Once the proportional assumption was tested for all variables in all outcomes, for 
each of the baseline biochemical indices, separate univariate Cox proportional 
hazards model was first fitted to assess the crude risk association between them and 
the outcomes. As a result of the biochemical indices being correlated with each other 
(some could be said to be intermediate and so not true confounders, there was a 
potential hazard of biasing the results due to colinearity when they were entered in 
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the same models (Appendix 8). Thus two different approaches were adopted: firstly, 
all these biochemical variables were forced to be included in the adjusted survival 
models; secondly, separate adjusted models were fitted for each of the biochemical 
indices, with other covariates adjusted for. For other possible covariates, the same 
process as described in Chapter 8, Section 8.3 was used to select variables with a 
significant level less than 0.2, to be considered for inclusion in the multiple model. 
For each outcome observed, the AIC was used to decide the best predicting model. 
As stated in Chapter 3, the smaller the AIC, the better the model fit. In the situation 
of similar AIC, that is a difference of less than 3, the smaller model (i.e. the model 
with less variables) was chosen.
263-265
  In addition, the concordance statistic (C-
statistic) was used to assess the model discriminative performance, as well as to 
assist the final model selection. As with the area under the receiver operating 
characteristics (AUROC) in logistic regression models, the C-statistic assesses the 
discriminative ability in survival models.
266-268
 The discriminative ability indicates 
how well a model can distinguish patients with different risks of developing an 
event. The C-statistic varies between 0.5 and 1.0 for sensible models. A predictive 
model with a C-statistics of 0.5 has no predictive value, while a model with a C-
statistic of 1.0 perfectly discriminates high risk from low risk among patients. 
Generally, values above 0.6 are considered as a reasonable discriminative ability and 
values between 0.7 to 0.8 are considered as good to excellent predictive performance 
in practice.
269, 270
 The PROC IML programme in SAS software, was used to 
calculate the corresponding C-statistic for each model. 
 
Descriptive statistics were used to summarise the baseline characteristics of the 
patients. Differences in biochemical indices and follow up times were tested using 
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non-parametric methods because their distributions were non-Normal. Other 
differences were examined using independent-samples T-test or chi-square test, as 
appropriate. 
 
9.3.3 Missing data 
Missing data occurs in almost all observational studies on routine data and this study 
is no exception. In this study, the missing data primarily existed in baseline 
biochemistry readings. This was because the diagnosis of PHPT relied on electronic 
biochemistry data and the date of diagnosis was set as the date of the first raised 
calcium, therefore, if, for example, ALP was not tested on the same day as the 
calcium being measured, its baseline value would be missing. Since not all blood 
tests would request a full blood count, the missing baseline biochemical variables 
were inevitable. Even when the „baseline‟ was defined as within a month before/after 
a positive PHPT diagnosis, as shown in Table 9.1, there were still missing values for 
the study population. It is important to appropriately address this lack, before any 
complex statistical analyses are applied to the data, to avoid potentially biased 
results.  
Table 9.1 Frequency of missing data and the number of imputations, with the 
estimated relative efficiency 
Variables Frequency of missing 
data (%) 
Number of 
imputation 
Estimated relative 
efficiency 
Calcium 4 (0.2%) 5 0.9996 
ALP 6 (0.3%) 5 0.9994 
Creatinine  22 (1.0%) 5 0.9980 
SIMD10 50 (2.4%) 5 0.9952 
PTH 941 (45.0%) 20 0.9780 
The relative efficiency (RE) is calculated as RE = (1+λ/n)
-1
, where λ=percentage of missing data and n 
is the number of imputations 
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As mentioned in Chapter 3, the simplest way to deal with missing data is to „ignore‟ 
those with missing information, that is, to use „complete case only‟ in analyses. This, 
however, requires the assumption of „MCAR‟. This is often not plausible but when 
the proportion of missing data is relatively small and missingness can be assumed to 
be at random, then „complete case analysis‟ can be used, as in Chapter 8, when 
dealing with the missing socio-economic scores.  Since the reason for the missing 
baseline biochemical readings was, however, most likely due to selective testing by 
the GP rather than actual missing or lost data, these missing data could not be 
assumed MCAR. The „complete case analysis‟, therefore, was inappropriate in 
dealing with such missing biochemical data, as it would bias the result (subject to 
selection bias). Another simple way of dealing with such missing data is to calculate 
the mean of the variables with missing data and replace the missing values by the 
calculated mean values. As there always is some underlying reason for a patient 
being tested for some but not other biochemical indices, this approach, again, cannot 
deal with the uncertainty of what could be predicted if the data were not missing and 
would result in the variances of the parameter estimates being biased towards zero 
(understating variability).
207
 Weighting the complete data, as mentioned in Chapter 
3, Section 3.4, gives the cases with similar properties as those with missing values, 
greater weight than the remaining cases with complete values. This weighting 
method could be used but the most appropriate approach is MI. 
 
MI replaces missing values with a set of plausible values that represent the 
uncertainty of the correct value.
207, 271
 Since this requires a looser assumption of 
MAR but not MCAR, which means the missingness is random after controlling for 
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missingness due to observed quantities (that is, the probability of an observation 
being missing does not depend on the missing values) but can be predicted by the 
observed values. This results in valid statistical inferences that properly reflect the 
uncertainty due to missing values. There are four steps involved in MI:
271
  
1. Impute missing values using an appropriate model that incorporates random 
variation. 
2. Do this M times (usually 3-10 times), producing M „complete‟ data sets. 
3. Perform the desired analysis on each data set using standard complete-data 
methods. 
4. Average the values of the parameter estimated from the M data sets to 
produce a single combined point estimate. 
 
Although the MAR assumption cannot be formally evaluated, it has been noted that 
the use of a rich multivariate data set can make the MAR assumption more plausible 
by minimising the biases incurred where the assumption is violated.
272-274
 As a result 
of MI introducing appropriate random error into the imputation process, it is possible 
to obtain approximately unbiased estimates of all parameters and this provides a 
useful strategy for dealing with the missing values. The MI method was used in this 
study to address the missing baseline values as listed in Table 9.1, because both 
history and existing hospital data, as well as patients‟ demographic information were 
complete and available, which might indicate or at least, be associated with why 
certain biochemistry was not measured at baseline. The number of imputations was 
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decided according to the percentage of missing data for each variable, in order to 
keep the relative efficiency of MI over 0.97 for each variable (Table 9.1). The 
relative efficiency is an arbitrary measure of the efficiency of an estimate obtained 
from M imputations relative to one obtained from an infinite number of imputations, 
with obviously, the closer the value to 1, the better. 
 
9.3.4 MI process 
The MI process was carried out using SAS software in three steps (Figure 9.1). 
Firstly, plausible values for missing observations were created, which reflected 
uncertainty about the missing values. The imputation was carried out by PROC MI, 
resulting in the creation of a number of „completed‟ datasets. Secondly, standard 
SAS procedures were used with the complete datasets using the „complete case 
method‟, with a „BY‟ statement to allow the process to be repeated for each of the 
imputed datasets. Finally, the results were combined using PROC MIANALYZE, 
which allowed the uncertainty regarding the imputation to be taken into account.
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Figure 9.1 Process of MI in SAS software 
 
PROC MI 
Analytical 
PROC 
BY imputation 
PROC 
MIANALYZE 
Create multiply imputed data sets 
Use standard procedure to analyse complete data, repeat 
the analysis for each imputed data set using ‘BY’ statement 
Combine complete data results for inference 
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As mentioned in Chapter 3, Section 3.4, there are many methods used to estimate 
missing values, depending on the patterns of missingness; the PROC MI procedure 
in SAS incorporates three methods for imputing missing values, these being the 
regression method, the propensity score method and the MCMC method. For 
monotone missing data patterns, either a parametric regression method that assumes 
multivariate normality or a nonparametric method that uses propensity scores, is 
appropriate. For an arbitrary missing data pattern, a MCMC method, that assumes 
multivariate normality, can be used. The latter method was used in this study, which 
was the default method in PROC MI. 
 
Since there was more than one variable with missing values, the process began by 
including only one of the variables that had missing values at a time, with all other 
complete variables in each MI analysis. As shown in Table 9.1, for baseline calcium, 
there were four missing values. This was because these four patients were identified 
solely from the hospital data, with the date of admission being the date of diagnosis. 
As calcium was the variable with the least missing data, it was firstly imputed using 
the PROC MI procedure to create 5 complete datasets. As well as calcium, other 
covariates included in the PROC MI procedure were history of hospital admission, 
previous usage of bisphosphonates, gender, baseline age, year of PHPT diagnosis, 
dummy variables indicating whether other biochemistry measurements were 
available at baseline and mortality outcome. In each of the complete datasets, a 
linear regression model was fitted to estimate parameters, with calcium being the 
dependent variable adjusted for all other covariates included in the PROC MI 
process. PROC MIANALYZE was used to combine the parameters, which were the 
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regression coefficients estimated from the five multiple linear models. An imputed 
calcium variable was then calculated for each patient in the original dataset using the 
combined parameter. For those patients with missing calcium in the original dataset, 
that is, the four missing values, their calcium was allocated with the corresponding 
values that were newly imputed, thus, a brand new variable of baseline calcium with 
complete values was created. This accounted for one complete MI process, which 
followed the flow chart illustrated in Figure 9.1. This process was reiterated for the 
remaining four variables, in the order as they appeared in Table 9.1. At each MI 
iteration, the variable with the least missing value was imputed and the actual value 
of the complete biochemical variable created from previous MI process replaced the 
corresponding dummy variable in the model. Therefore, once the variable with the 
most missing data, which was PTH, was imputed, all available biochemical 
variables, as well as other covariates, would contribute to its prediction. Although, 
the missing socio-economic variable, denoted as SIMD10, could be assumed as 
MCAR (as described in Chapter 8), to keep the completeness of the dataset, it was 
also included in the MI process. 
 
As each complete MI was a complex and intensive process, Appendix 9 takes the MI 
analysis for calcium for example, provides all the SAS statements used in the 
programme to give an additional illustration. 
  
9.3.5 Checking functional form 
For continuous variables, for example, age and baseline calcium, the functional form 
was assessed before these variables were entered into the survival model. The 
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functional form of a variable is the form of association of that variable with the 
outcome. This is an important aspect of model adequacy because the fit of a survival 
model could be improved by using the correct functional form instead of the default 
assumption of linearity. For example, the model might give a better fit by using a 
non-linear function of baseline age and the natural logarithm of baseline calcium 
than using their original values. Checking the Martingale residuals obtained from 
fitting a null survival model, that is, the Cox model that contains no covariates, is a 
straightforward method of assessing this and is the method used in this study. The 
Martingale residual is the difference between the observed and expected number of 
events, over the time interval ti for the i
th
 individual.
211
  
 
The SPSS software was employed to check the functional form for all continuous 
variables. The Martingale residuals were plotted against the values of each covariate 
of interest respectively, using a scatter plot. As shown by Therneau et al, this plot 
should display the functional form required for the covariate.
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 A smoothed spline 
was used to assist the judgment and the functional form that displayed a straight line 
or closest to a straight line, indicated the most appropriate transformation of the 
variable. The Martingale residual is not a direct output computed by the software but 
can be manually computed using the Cox-Snell residual, which is the value of the 
cumulative hazard function. Take AGE for example, Appendix 10 gives the SPSS 
syntax used for assessing its functional form.  
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9.4 Results 
9.4.1 Baseline results 
During the period of 1997 to 2006, a total of 2,299 incident PHPT patients were 
identified in Tayside, Scotland, as described in Chapter 4. Of these, less than 10% 
(n=202) were surgically treated. The remaining 2097 untreated PHPT patients were 
eligible for the study, with a total follow up of 7338 person years. The median follow 
up was 1046 days (2.9 years). Overall, 69.9% of the subjects were female, with a 
mean age 69.5+/-13.3 years, whilst 30.1% of the subjects were male, with a mean 
age of 65.7+/-14.4 years. The baseline biochemical measurements are shown in 
Table 9.2. Of all untreated patients, the mean serum calcium at baseline was 2.65 
mmol/l, whilst the mean of maximum calcium was 2.75 (SE=0.004).  
 
Table 9.2 Baseline characteristics of study cohort by gender 
Variables Total Male Female p 
Count 2097 632 (30.1%) 1465 (69.9%) NA 
Age 68.4 (13.7) 65.7 (14.4) 69.5 (13.3) <0.001 
Baseline biochemistry (mean (SEM))   
Calcium 2.65 (0.003) 2.64 (0.004) 2.66 (0.003) <0.001 
PTH 10.3 (0.34) 10.0 (0.64) 10.4 (0.39) 0.15 
Creatinine 131 (1.67) 154 (3.66) 121 (1.73) <0.001 
ALP 114 (1.92) 107 (2.60) 117 (2.51) 0.01 
Cholesterol 5.1 (0.04) 4.7 (0.07) 5.2 (0.05) <0.001 
 
In total, there were 648 (30.9%) patients who died during the follow up, 249 
cardiovascular deaths and 182 cancer related deaths. Prior to the PHPT diagnosis, 
16% had a history of cardiovascular disease, 9.7% and 1% had a history of in-patient 
admission for renal failure or renal stones, respectively; 5.6% had a history of 
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fractures, two-third being osteoporotic fractures. Table 9.3 shows the incidence of 
co-morbidities before and after PHPT diagnosis. Overall, patients had a higher risk 
of developing all the observed co-morbidities following diagnosis than prior to 
diagnosis, apart from diabetes. 
 
Table 9.3 Comparisons of incidence (per 5 person years) of comorbidities, before 
and after PHPT diagnosis 
 Pre PHPT diagnosis Post PHPT diagnosis  
Variables Freq. (%) Rate Freq. (%) Rate p 
Cardiovascular 336 (16.0%) 0.16 511 (24.4%) 0.35 <0.001 
Cerebrovascular 89 (4.2%) 0.04 180 (8.6%) 0.12 <0.001 
Hypertension 153 (7.3%) 0.07 218 (10.4%) 0.14 <0.001 
Renal failure 204 (9.7%) 0.10 434 (20.7%) 0.30 <0.001 
Renal stone 22 (1.0%) 0.01 35 (1.7%) 0.02 0.003 
Fractures 117 (5.6%) 0.06 157 (7.5%) 0.11 <0.001 
Ost. Fractures 82 (3.9%) 0.04 118 (5.6%) 0.08 <0.001 
Psychiatric condition 19 (0.9%) 0.01 36 (1.7%) 0.02 <0.001 
Cancer 200 (9.5%) 0.10 212 (10.1%) 0.14 <0.001 
Diabetes 127 (6.1%) 0.06 86 (4.1%) 0.06 0.835 
The difference was compared using Poisson Exact test. 
 
 
9.4.2 Functional form 
Using the Martingale residuals, the functional forms for all continuous variables 
were tested. Taking the all cause mortality outcome as an example, Figure 9.4 shows 
the comparison of the functional form plots before and after transformation fitted 
with a corresponding smoothed line. It can be seen that after the correct functional 
form was selected, the fitted line improved significantly. In this case, therefore, for 
baseline PTH, creatinine and ALP, the natural log of these variables was used for 
further model testing, rather than their original values and the squared calcium was 
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used instead of the original calcium values (labelled as LNTH, LNCRE, LNALP and 
CASQ respectively in tables). The original age variable was retained, as it was more 
appropriate than any transformation, as illustrated in Figure 9.2-e. These 
transformations were found to be ideal when the functional forms of these 
continuous variables were checked against other outcomes. 
 
Figure 9.2 Comparison of functional form before and after transformation 
a) PTH vs. Ln(PTH) 
   
b) Creatinine vs. Ln(creatinine) 
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c) Ca vs. Ca
2
 
     
d) ALP vs. Ln(ALP) 
    
e) AGE vs. Ln(AGE) 
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9.4.3 Proportional hazards assumption 
The results of testing the proportional hazards assumption were presented using the 
all cause mortality outcome as an example. For all other outcomes of interest, the 
same procedure was undertaken, before the final Cox model was tested.  
 
On checking the LLS against log time, the proportionality assumption was 
approximately supported for all categorical covariates in all interested outcomes. 
Figure 9.3 illustrates the LLS plots, with all cause mortality being the interested 
outcome. Approximately parallel plots can be seen in the figure for previous 
bisphosphonates, previous CVD, cerebrovascular and psychiatric conditions. Gender 
and SIMD10 score were parallel, until approximately 1,000 days before converging. 
For the other categorical variables tested, it can be seen that some variations at the 
beginning, (approximately within the first two months). As a result of the median 
time of the mortality event being over 2 years, these variations would not have major 
impact on the model, thus, the proportional assumption could be assumed to be 
reasonably supported. 
 
For all other outcomes examined, the LLS plots were found approximately parallel 
for all categorical variables and thus, the proportional assumption was assumed to be 
supported for them. 
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Figure 9.3 LLS plots for all categorical covariates tested 
a) Previous usage of bisphosphonates 
 
 
b) Previous CVD 
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c) Previous cerebrovascular disease 
 
 
d) Previous fractures 
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e) Previous hypertension 
 
f) Previous psychiatric conditions 
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g) Previous admissions for renal failure 
 
h) Previous admissions for renal stones 
 
 
 
270 
i) Pre-existing diabetes 
 
j) Gender 
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k) SIMD10 score 
 
For continuous covariates, however, when the proportionality was checked by using 
the time interaction term, as shown in Table 9.4, the proportional assumption was 
only supported for baseline creatinine and PTH (score test 0.1416 and 0.9599 
respectively) but was violated for baseline age, calcium and ALP (with significant 
score test for their time interaction terms) (Table 9.4).  This non-proportionality was 
held, even after the correct functional form was adopted (score test for calcium 
square and log ALP were 0.0025 and 0.0133 respectively). 
 
By examining of the patterns of residual changes over time for those non-
proportional variables, there appeared to be a change at around day 1000. A 
dichotomous time dummy variable (labelled as TMDM in tables), was, therefore, 
created indicating whether a case was followed up for less than or more than 1000 
days. This time cut-off point could also explain the variations in gender and SIMD 
score variables, as shown in Figure 9.3-i and 9.5-j. When the proportional 
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assumption was tested again for continuous variables in the two-time period 
separately, as shown in the last two columns of Table 9.4, it was supported in all 
instances. A time interaction term using this dummy time variable and the non-
proportional baseline covariate was, therefore, included to address the non-
proportionality, in order to improve the specification in the final model. To keep the 
consistency of the model and to enable the comparison between different models for 
the same outcome, this time dummy variable was also used for testing baseline 
creatinine and PTH, even though their proportional assumption was reasonable or at 
least, not statistically significant. 
 
Table 9.4 Score test results for proportional hazards (as show by p values) for 
continuous covariates 
 
Time interaction terms 
Entire time period <=1,000 days >1,000 days 
p-value p-value p-value 
AGET 0.0311 0.0954 0.4809 
ALPT 0.0219 0.4484 0.6244 
CAT 0.0004 0.0580 0.7116 
CRET 0.1416 0.8018 0.2110 
PTHT 0.9599 0.3224 0.7378 
AGET, ALPT, CAT, CRET and PTHT stand for the time interaction term with age, ALP, calcium, 
creatinine and PTH respectively.  
 
For these continuous variables, the proportional assumption was found supported in 
all outcomes examined, except for renal failure, when including a dummy variable 
distinguishing the data by 1,000 days. Appendix 11 shows the results of score test 
for continuous variables by outcome. In renal failure, the proportionality was 
violated for baseline calcium and creatinine. A time dummy variable of 500 days 
was used to address the non-proportionality of calcium and creatinine, where more 
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than 60% of the renal failure events occurred. The proportional assumption was 
found supportive within 500 days using the appropriate functional form (Score test 
of CASQT and LNCRET were 0.3591 and 0.5061, respectively). 
 
9.4.4 Survival analysis 
Once the proportional assumption was satisfied, both unadjusted, which only 
included the tested baseline biochemical variable and the adjusted HRs, were 
computed using the Cox proportional hazards model.  
 
9.4.4.1 Primary outcomes 
Table 9.5 shows the HRs of each tested baseline biochemical variables from 
unadjusted survival models for all primary outcomes. It can be seen that each of the 
tested biochemical variables, univariately, was significantly associated with an 
increased risk in all cause mortality and fatal CVD, in the short term (<=1000 days) 
but such an association diminished over the long term (>1000 days). Baseline serum 
PTH and creatinine, independently, were risk markers of non-fatal CVD. Serum 
calcium, univariately, did not predict non-fatal CVD, nor did serum ALP. 
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Table 9.5 Results of unadjusted survival analysis for primary outcomes, by biomarker  
Outcomes Bio-markers 
<= 1K days >1K days Model fit Discriminative power 
HR 95% CI p HR 95% CI p AIC C-stat 95% CI 
All cause 
mortality 
CASQ 1.356 1.252-1.468 <0.001 0.595 0.519-0.682 <0.001 8058.583 0.667 0.609-0.720 
LNPTH 3.168 2.854-3.517 <0.001 0.816 0.701-0.951 0.009 8199.657 0.546 0.487-0.604 
LNCRE 2.913 2.470-3.435 <0.001 0.956 0.795-1.150 0.635 8030.037 0.633 0.574-0.688 
LNALP 2.191 1.879-2.554 <0.001 0.669 0.551-0.812 <0.001 8047.210 0.660 0.602-0.713 
Fatal CVD CASQ 1.215 1.025-1.441 0.025 0.545 0.434-0.684 <0.001 3097.469 0.761 0.701-0.812 
 LNPTH 3.554 3.004-4.204 <0.001 0.837 0.652-1.073 0.160 3103.560 0.868 0.807-0.912 
 LNCRE 4.608 3.519-6.034 <0.001 1.282 0.931-1.765 0.128 3011.171 0.780 0.720-0.831 
 LNALP 1.911 1.470-2.485 <0.001 0.579 0.423-0.792 0.001 3090.514 0.759 0.699-0.810 
Non-fatal CVD CASQ 0.952 0.823-1.100 0.502 0.857 0.740-0.993 0.041 7215.749 0.294 0.238-0.357 
LNPTH 1.920 1.673-2.203 <0.001 1.407 1.214-1.630 <0.001 7168.210 0.449 0.385-0.514 
LNCRE 1.971 1.642-2.366 <0.001 1.699 1.411-2.044 <0.001 7175.115 0.470 0.406-0.535 
 LNALP 1.201 0.997-1.447 0.054 1.032 0.855-1.246 0.741 7219.187 0.275 0.220-0.336 
 
The abbreviations of included bio-markers stand for the squre of calcium, the natural log of PTH, the natural log of creatinine and the 
natural log of ALP, respectively.
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When other covariates were adjusted for, for each of the primary outcome observed, 
as shown in Table 9.6, the model fitted much better with smaller AIC and higher 
excellent C-statistic, than the corresponding univariate models. For all cause 
mortality, of the biochemical variables tested, only PTH was a consistent risk 
predictor over the study period (Table 9.6 a). Serum creatinine and ALP were 
associated with increased mortality in the short term but not over the long term. The 
effect of serum calcium changes from a risk factor in the short term to a risk 
protector, over the long term (having survived at least 1000 days). Previous hospital 
admission for CVD, cerebrovascular disease, psychiatric condition and cancer, also 
predicted increased mortality, whereas, being a female patient or coming from a 
higher social-economic status, decreased the risk. For fatal-CVD, again, only PTH 
was a bio-marker of increased risk over the study period (Table 9.6 b). Serum 
calcium did not have any significant effect and the increased risk of serum creatinine 
and ALP on the outcome, was only significant in the short term. In addition, age, 
being a male patient, previous usage of bisphosphonates, previous hospital 
admissions on CVD, cerebrovascular disease and psychiatric condition, were also 
risk factors for fatal-CVD. In addition to mortality, of all the tested biochemical 
indices, baseline PTH was the only significant risk factor of non-fatal CVD.  Age, 
being a male patient and previous hospital admissions on CVD and diabetes, also 
contributed to the increased risk of non-fatal CVD, whilst previous admissions for 
renal failure and fractures appeared to be risk protectors. For all the primary 
outcomes observed, the overall C-statistic of the adjusted models was greater than 
0.8, which can be considered as excellent discriminative ability.
270
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Table 9.6 Results of adjusted survival models for primary outcomes 
a) All cause mortality (AIC = 7674.570, C-statistic = 0.834 95% CI (0.785-0.873)) 
Covariates  B HR p-value 
CASQ <=1K Days 0.188 1.206 <0.001 
 >1K Days -0.341 0.711 0.002 
LNPTH <=1K Days 0.380 1.462 <0.001 
 >1K Days 1.141 3.130 <0.001 
LNCRE <=1K Days 0.378 1.459 0.002 
 >1K Days -0.174 0.841 0.210 
LNAP <=1K Days 0.477 1.611 <0.001 
 >1K Days -0.086 0.918 0.514 
AGE <=1K Days 0.041 1.042 <0.001 
 >1K Days 0.041 1.042 <0.001 
CASQ*TMDM  -0.529 0.589 <0.001 
LNPTH*TMDM  0.762 2.142 <0.001 
LNCRE*TMDM  -0.551 0.576 <0.001 
LNAP*TMDM  -0.563 0.570 <0.001 
AGE*TMDM  0.0001 1.000 0.990 
Female vs. male  -0.207 0.813 0.026 
SIMD (+ 1decile)  -0.044 0.813 0.026 
Previous conditions (yes vs. no)    
CVD  0.315 1.371 0.001 
Cerebrovascular  0.410 1.506 0.006 
Psychiatric condition  1.372 3.943 <0.001 
Osteoporotic fractures 0.298 1.348 0.071 
Cancer  0.336 1.399 0.003 
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b) Fatal CVD (AIC = 2833.861, C-Statistic = 0.896, 95% CI (0.836-0.935)) 
Covariates  B HR p-value 
CASQ <=1K Days 0.083 1.086 0.383 
 >1K Days -0.105 0.900 0.520 
LNPTH <=1K Days 0.535 1.708 <0.001 
 >1K Days 0.726 2.067 0.001 
LNCRE <=1K Days 0.813 2.255 <0.001 
 >1K Days -0.038 0.963 0.868 
LNAP <=1K Days 0.355 1.427 0.037 
 >1K Days -0.141 0.869 0.509 
CASQ*TMDM  -0.188 0.829 0.287 
LNPTH*TMDM  0.191 1.210 0.458 
LNCRE*TMDM  -0.851 0.427 0.001 
LNAP*TMDM  -0.496 0.609 0.052 
Age  0.050 1.051 <0.001 
Female vs. male  -0.319 0.727 0.030 
Previous bisphosphonates usage 0.450 1.569 0.034 
Previous condition (yes vs. no)    
CVD  1.151 3.162 <0.001 
Cerebrovascular  0.493 1.637 0.023 
Psychiatric condtion 1.456 4.290 0.005 
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c) Non-fatal CVD (AIC =  6255.963, C-statistic = 0.897 95% CI (0.856-0.927)) 
Covariates  B HR p-value 
CASQ <=1K Days 0.006 1.006 0.933 
 >1K Days -0.585 0.557 0.001 
LNPTH <=1K Days 0.389 1.475 <0.001 
 >1K Days 0.437 1.548 0.032 
LNCRE <=1K Days 0.150 1.161 0.248 
 >1K Days -0.186 0.830 0.288 
LNAP <=1K Days -0.017 0.983 0.878 
 >1K Days -0.214 0.807 0.298 
CASQ*TMDM  -0.591 0.554 <0.001 
LNPTH*TMDM  0.048 1.049 0.825 
LNCRE*TMDM  -0.335 0.715 0.082 
LNAP*TMDM  -0.197 0.374 0.821 
Age  0.026 1.026 <0.001 
Female vs. male  -0.343 0.710 <0.001 
Previous condition (yes vs. no)    
CVD  1.174 3.236 <0.001 
Renal failure  -0.307 0.736 0.045 
Fractures  -0.462 0.630 0.025 
Diabetes  0.358 1.430 <0.001 
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9.4.4.2 Secondary outcomes 
For all secondary outcomes observed, a crude measure of the risk association 
between each baseline biochemical index and the outcome was assessed, using the 
unadjusted Cox model. As shown in Table 9.7, baseline calcium did not predict any 
of the increased risk of co-morbidities that were associated with PHPT. A high level 
of serum PTH, however, was associated with an increased the risk of developing 
cerebrovascular disease, renal failure, fractures and cancer, after a positive PHPT 
diagnosis. Both serum creatinine and ALP were associated with an increased risk of 
hypertension and renal failure. ALP was also associated with an increased risk of 
cancer. 
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Table 9.7 Unadjusted HRs for secondary outcomes by biomarker  
  Calcium (CASQ) PTH (LNPTH) Creatinine (LNCRE) ALP (LNAP) 
Outcome Event HR p-value HR p-value HR p-value HR p-value 
Cerebrovascular 180 1.095 0.384 1.408 0.006 1.027 0.872 1.070 0.688 
Hypertension         218 0.739 0.035 1.105 0.392 1.071 <0.001 2.192 <0.001 
Renal failure
8
 434 0.836 0.050 2.336 <0.001 10.071 <0.001 10.058 <0.001 
Renal stones 35 1.126 0.563 0.722 0.251 0.910 0.806 0.626 0.108 
Psychiatric condition 36 0.389 0.058 1.015 0.958  1.528 0.204  0.505 0.004 
Fracture all 157 1.069 0.575 1.347 0.029 1.322 0.093 1.073 0.694 
Osteoporotic fractures 118 1.142 0.280 1.428 0.022 1.399 0.074 1.170 0.450 
Cancer 212 0.989 0.918 1.435 0.002 1.202 0.210 1.566 0.003 
Diabetes 86 1.088 0.598 1.055 0.776  1.206 0.418 0.899 0.776 
                                                 
8
 As calcium and creatinine were non-proportional over the study period, the HRs for these two variables were the results of less than 500 days, where the proportional 
assumption was supported. 
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In the adjusted models, when all the baseline biochemical variables were included 
with other possible factors being adjusted for, most of the significant associations 
between them and the outcomes became non-significant (Table 9.8). However, 
although score tests of the proportional hazard assumption for biochemical variables 
were not significant for secondary outcomes (except for renal failure), when time 
interaction terms were included in the adjusted models, as shown in Table 9.9, the 
hazard ratios for them changed over time, suggesting that the hazards were not 
proportional. Moreover, the model fitted better, with time interaction terms being 
included in terms lower of AIC (Appendix 12). In addition, when each of the 
biochemical variables was fitted in separate survival models, adjusting for other 
covariates, both the significance level of the effect (of biochemical variable on 
outcomes) and the discriminative ability improved, indicating that the correlation 
between these biochemical variables would bias the results, when they were all 
included together. Thus, the latter model was used to assess the impacts of 
biochemical variables on secondary outcomes and it was reasonable to assume that 
these biochemical indices provided better predicting power in the short term than in 
the long term. Table 9.10 presents the results of HRs from the final models (separate 
adjusted survival models for each biochemical index) in the short term (less than 
1000 days). As can be seen, baseline calcium did not predict any of outcomes 
observed, when other factors were adjusted for. Serum PTH at baseline, however, 
was significantly associated with an increased risk of all the secondary outcomes, the 
risk of renal failure being the highest. Both serum creatinine and ALP, 
independently, were significant risk factors of an increased risk of hypertension, 
renal failure, fractures and cancer, with other covariates being adjusted for. Overall, 
the adjusted models with PTH provided slightly better discriminative ability (Table 
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9.11), thus, the final models using baseline PTH as a potential predictor on each 
secondary outcome were presented in Appendix 13. In most cases, for the secondary 
outcomes observed, apart from the biochemical indices tested, other significant risk 
factors included age and previous history of hospital admission for the tested 
outcome. For example, both age and previous admission for cerebrovascular disease 
predicted a future cerebrovascular event (HR = 1.038, 1.132 for age and previous 
admission on cerebrovascular, respectively, p<0.001 in both instances). 
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Table 9.8 Adjusted* Cox models with all biochemical variables included in the same model for each outcome 
 Calcium (CASQ) PTH (LNPTH) Creatinine (LNCRE) ALP (LNAP) 
Outcome HR P HR P HR P HR P 
Cerebrovascular 1.096 0.406 1.241 0.155 0.689 0.045 0.896 0.514 
Hypertension 0.839 0.182 0.856 0.177 2.155 <0.001 1.183 0.258 
Renal failure
9
 0.889 0.196 1.062 0.422 9.842 <0.001 1.423 0.001 
Renal stones 1.149 0.549 1.071 0.818 0.548 0.061 0.913 0.817 
Psychiatric condition 0.339 0.028 1.458 0.250 0.448 0.001 1.524 0.196 
Fracture all 0.957 0.739 1.009 0.954 1.020 0.924 1.230 0.232 
Osteoporotic fractures 0.999 0.995 1.034 0.856 1.292 0.324 1.288 0.201 
Cancer 0.931 0.552 1.199 0.188 1.523 0.020 1.143 0.374 
Diabetes 1.176 0.343 1.115 0.598 0.849 0.716 1.092 0.716 
*Adjusted for gender, baseline age, previous usage on bisphosphonates, SIMD decile, history of co-morbidities prior to diagnosis 
                                                 
9
 As calcium and creatinine were non-proportional over the study period, the HRs for these two variables were the results of less than 500 days, where the proportional 
assumption was supported. 
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Table 9.9 Adjusted* HRs for secondary outcomes, with all baseline biochemical variables included in the same model 
  Calcium (CASQ) PTH (LNPTH) Creatinine (LNCRE) ALP (LNAP) 
Period Outcome HR P HR P HR P HR P 
 Cerebrovascular 1.071 0.521 1.413 0.269 0.480 0.002 1.005 0.978 
 Hypertension 0.977 0.848 0.842 0.192 2.047 <0.001 1.047 0.794 
 Renal failureᶺ
 
0.950 0.508 1.218 0.018 5.577 <0.001 1.247 0.066 
 Renal stones 1.248 0.276 1.200 0.590 0.475 0.188 1.159 0.748 
<=1K Days Psychiatric condition 0.340 0.036 2.063 0.041 0.111 <0.001 0.886 0.006 
 Fracture all 1.115 0.304 0.954 0.796 0.764 0.319 1.371 0.120 
 Osteoporotic fractures 1.107 0.345 1.104 0.253 0.869 0.666 1.532 0.058 
 Cancer 0.977 0.842 1.255 0.110 1.272 0.231 1.269 0.152 
 Diabetes 1.206 0.269 1.453 0.108 0.797 0.482 1.154 0.598 
 Cerebrovascular 0.570 0.060 1.151 0.685 0.689 0.166 0.517 0.069 
 Hypertension 0.338 <0.001 1.221 0.422 1.533 0.119 1.173 0.517 
 Renal failure 0.961 <0.001 1.212 0.195 4.918 <0.001 1.103 0.578 
 Renal stones 0.704 0.505 0.931 0.897 0.492 0.046 0.825 0.774 
>1K Days Psychiatric condition 0.022 0.001 0.826 0.788 0.504 0.135 2.621 0.098 
 Fracture all 0.421 0.001 1.584 0.129 0.903 0.712 0.927 0.780 
 Osteoporotic fractures 0.412 0.008 1.631 0.180 1.262 0.538 0.763 0.429 
 Cancer 0.507 0.011 1.800 0.044 0.994 0.981 0.798 0.428 
 Diabetes 0.889 0.719 0.710 0.341 0.570 0.061 0.739 0.479 
*Adjusted for gender, baseline age, previous usage on bisphosphonates, SIMD decile, history of co-morbidities prior to diagnosis; ᶺA time interaction of 500 days was used 
to improve model specification for renal failure. 
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Table 9.10 Results of adjusted* Cox models for less than 1000 days, with separate models for each bio-marker 
 Calcium (CASQ) PTH (LNPTH) Creatinine (LNCRE) ALP (LNAP) 
Outcome HR p-value HR p-value HR p-value HR p-value 
Cerebrovascular 1.117 0.232 1.813 <0.001 1.100 0.502 1.151 0.382 
Hypertension 0.914 0.498 1.781 <0.001 2.658 <0.001 1.398 0.022 
Renal failure 0.965 0.649 2.617 <0.001 8.534 <0.001 1.430 0.001 
Renal stones 1.300 0.116 1.746 0.023 0.999 0.998 1.449 0.360 
Psychiatric condition 0.454 0.127 1.625 0.039 0.960 0.875 1.521 0.192 
Fracture all 1.122 0.265 1.799 <0.001 1.758 0.002 1.724 0.002 
Osteoporotic fractures 1.126 0.278 1.926 <0.001 1.857 0.004 1.791 0.003 
Cancer 1.030 0.781 2.131 <0.001 1.955 <0.001 1.522 0.004 
Diabetes 1.341 0.045 2.237 <0.001 1.377 0.125 1.493 0.086 
*Adjusted for gender, baseline age, previous usage on bisphosphonates, SIMD decile, history of co-morbidities prior to diagnosis 
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Table 9.11 Comparisons of discriminative ability between adjusted models 
 Calcium (CASQ) PTH (LNPTH) Creatinine (LNCRE) ALP (LNAP) 
Outcome C-Stat 95% CI C-Stat 95% CI C-Stat 95% CI C-Stat 95% CI 
Cerebrovascular 0.687 0.625-0.744 0.695 0.631-0.751 0.688 0.626-0.745 0.690 0.627-0.746 
Hypertension 0.821 0.755-0.873 0.843 0.776-0.892 0.847 0.780-0.896 0.828 0.762-0.879 
Renal failure
10
 0.920 0.872-0.950 0.833 0.775-0.879 0.824 0.764-0.871 0.889 0.837-0.926 
Renal stones 0.533 0.473-0.593 0.533 0.473-0.593 0.533 0.473-0.592 0.533 0.473-0.593 
Psychiatric condition 0.542 0.475-0.608 0.535 0.474-0.595 0.535 0.474-0.595 0.536 0.474-0.597 
Fracture all 0.717 0.646-0.778 0.746 0.672-0.808 0.725 0.653-0.787 0.726 0.654-0.788 
Osteoporotic fractures 0.641 0.573-0.704 0.657 0.585-0.722 0.647 0.578-0.710 0.646 0.577-0.709 
Cancer 0.781 0.715-0.835 0.801 0.734-0.854 0.791 0.725-0.745 0.784 0.718-0.839 
Diabetes 0.611 0.540-0.678 0.614 0.542-0.681 0.612 0.541-0.679 0.614 0.542-0.681 
                                                 
10
 As calcium and creatinine were non-proportional over the study period, the HRs for these two variables were the results of less than 500 days, where the proportional 
assumption was supported. 
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9.5 Discussion 
This chapter, for the first time, assessed baseline biochemical indices as possible bio-
markers to predict the increased risk of mortality and co-morbidities associated with 
untreated PHPT, using survival analysis. It provides the first predictive models for 
all cause mortality, fatal and non-fatal CVD, in patients with untreated PHPT. For 
these primary outcomes, the predictive models provided good discrimination, with 
C-statistic over 0.8 in which is similar to the Framingham equation for CVD risk, 
which had a discrimination of 0.79.
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All the four tested biochemical indices, namely serum calcium, serum PTH, serum 
creatinine and serum ALP, predicted all cause mortality in the short term (up to 1000 
days) adjusting for other possible confounding factors, but not in the long term. 
Since the majority of patients in the study cohort had mild PHPT, meaning that their 
biochemical abnormality was not clinical significant, it makes clinical sense that 
these mildly elevated indices, e.g. calcium or PTH, could only predict the outcome in 
the short term. It would be unreasonable to expect these biochemical tests at the time 
of diagnosis, could predict patients‟ outcome over the long term, as patients would 
either be treated with normalised biochemistries, or would have progressed disease 
with even higher levels of calcium, or PTH, than those at diagnosis. If it were the 
latter, patients would be closely monitored with regular blood tests and therefore, 
any subsequent adverse risk would be more related to the results tested later on. 
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Although severe PHPT, as presented with a high level of calcium, has been found to 
be associated with an increased risk of mortality, in particular CVD deaths and CVD 
disease, we found the level of calcium was not significantly related to fatal CVD, nor 
non-fatal CVD.
23, 24, 51, 102, 112
 Serum PTH, however, was shown to be significantly 
associated with both fatal and non-fatal CVD (Table 9.6 b and c). This suggested that 
baseline PTH could be used as a reliable bio-marker to predict the risk associated 
with patients with PHPT, at the time of diagnosis. The results also suggested that in 
the situation of probable PHPT diagnosis, that is, patients with hypercalcaemia but 
an absence of PTH results, further tests on PTH should be recommended. This would 
firstly help to confirm the definite diagnosis of PHPT and secondly, identify the 
possible risk associated with these potential patients. 
 
As a secondary outcome, this chapter also assessed the short-term risk association 
between baseline biochemical indices and nine different co-morbidities, which have 
been shown to be associated with PHPT in previous chapters (Chapters 6 and 7). As 
with the results shown from the primary outcomes, PTH was significantly associated 
with all endpoints observed with renal failure being the highest (adjusted HR=2.6) 
(Table 9.10). Although baseline calcium was also associated with an increased risk 
of cerebrovascular disease, renal stones, fractures, cancer and diabetes, none of the 
effects were significant. Baseline creatinine was found to have a significant risk 
association with renal failure (HR of LNCRE was 8.534, p<0.001), as well as 
increased risk of hypertension, fractures and cancer in the short term. Baseline ALP 
had similar but slightly smaller effects on the outcomes observed, as did creatinine. 
These assessments on the secondary outcomes, again, demonstrated that baseline 
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PTH could be used as a reliable bio-marker, together with previous hospital 
admission records, to predict patients‟ outcomes, rather than calcium.  
 
I implemented an intensive modelling process, in order to assess the possible 
association between four different biochemical indices, which were related to PHPT 
condition and twelve different outcomes, with and without adjusting for other 
possible confounding factors. A number of methodological findings are worthy of 
comment, as an output from the complex statistical analysis. Firstly, MI is an 
appropriate approach to dealing with missing data, which can be estimated from 
existing complete variables about the patients. The analysis, using the dataset with 
imputed missing values, will incorporate all patients‟ information and will generate 
reliable results when the assumption of MCAR is reasonable.  
 
Secondly, it is important to check the functional form of continuous covariates, in 
particular biochemical tests (such as the biochemical indices used in this chapter), 
before entering them into survival models as the default linear term. This is because 
the non-linear relationship between them and the outcomes can bias the results and 
sometimes, the proportional hazards assumption could be supported, only when 
using the correct functional form.  
 
Thirdly, although the LLS plots and the score test of time interaction term have been 
used in existing studies to test for proportional assumption for categorical and 
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continuous covariates respectively, it is possible that these tests are under-powered, 
in order to detect non-proportionality when events are rare. In this study, although 
the proportional hazards assumption of biochemical variables was not violated for 
secondary outcomes, when time interaction terms were added, the hazards of these 
variables changed over time, indicating the existence of non-proportionality (Table 
9.8 and Table 9.9). In addition, the model fitted better (indicated by smaller AIC 
values), when time interaction terms were included.  
 
Fourthly, the effects of tested covariates can be masked if they were correlated with 
each other even when the correlation was relatively small, thus the multiple 
regression results should be dealt with cautiously, before drawing the final 
conclusions. In this study, as shown in Appendix 9.1, there were small to medium 
correlations between baseline biochemical indices. When they were all included in 
the adjusted model to assess the risk association between them and the secondary 
outcomes, no significant effects were shown (Table 9.8).  The impacts of PTH on all 
secondary outcomes and the impacts of creatinine and ALP on a number of 
outcomes were significant, however, when separate adjusted models were fitted for 
each of these biochemical indices (Table 9.10). This suggested that the inherent 
mechanism between these biochemistry indices offset the effects of them on the 
outcomes, although the correlation was small (Appendix 8) and the effects of 
correlation became more significant when the number of events was small. As a 
result, it was more appropriate to assess these biochemical variables separately, 
rather than considering them together.  
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Fifthly, depending on the aim of the analyses, a balanced judgement should be made 
on the model selection based on AIC and C-statistic. As illustrated in Table 9.10, the 
adjusted model fitted better (smaller AIC) with time interactions terms being 
included but the discriminative ability was slightly worse (lower C-statistic). In this 
study, however, because the data were demonstrated to have non-proportional 
hazards with the tested biochemical indices, the latter models, which addressed this 
issue, were chosen.  
  
9.6 Chapter Summary 
In summary, this chapter has demonstrated that the level of serum PTH at the time of 
diagnosis could be used as a reliable and important bio-marker, along with age and 
previous co-morbidities, to predict the increased risk of mortality and co-morbidities 
associated with untreated PHPT. Although calcium has been used as a surrogate of 
disease severity and selection criterion for surgery, it, however, was not strongly 
related to the adverse outcomes. The results for this chapter have suggested that 
PTH, as well as calcium, should be closely monitored in patients with diagnosed or 
suspected PHPT. The next chapter will draw together the final conclusion for the 
whole thesis. 
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CHAPTER 10  
 FINAL DISCUSSION AND CONCLUSIONS 
10.1  Overview 
This chapter will summarise the key findings from the work in relation to specific 
objectives defined at the beginning of the thesis. Lessons and knowledge that have 
been learnt during the period of the research will also be briefly discussed. The 
chapter concludes with a short paragraph suggesting further possible work from the 
findings of the thesis. 
 
10.2  Summary of key findings 
This thesis has studied the condition of PHPT identified from a less selective 
population data in Tayside, Scotland over a ten-year span. It has successfully 
identified a complete cohort of PHPT, and provided an up-to-date estimate of its 
epidemiology, in terms of prevalence and incidence on a year-on-year basis, with no 
pre-assumption on the distribution of patients‟ age and gender. It has examined the 
risk of mortality and co-morbidities associated with PHPT using both population 
based SMR and person-level survival analyses, with a sub-group of mild untreated 
patients. It has also provided valuable information on the long-term outcomes in 
mild, untreated PHPT patients, in terms of disease progression and assessed possible 
predictors of adverse outcomes in untreated PHPT. The key findings of the thesis in 
relation to the specific objectives set in Chapter 1 can be summarised as:  
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1. The record linkage technology has enabled a complete study population to be 
established, which forms the largest cohort of patients with diagnosed PHPT 
to-date. 
2. Similar to previous findings, the majority of patients (over 90%) in Tayside 
were adults aged over 40, with a female preponderance.  
3. The prevalence of diagnosed PHPT has increased steadily over the decade 
from 1997 to 2006. 
4. The aetiology of PHPT is associated with some underlying but unknown 
environmental and/or nutritional factors which affects its annual incidence 
being cyclical over a long-term period. 
5. There is an increased risk of mortality, in particular cardiovascular disease 
and cancer related deaths, and developing co-morbidities in patients with 
untreated PHPT, compared to both the general population and a matched 
cohort. 
6. Such an increased risk of mortality and co-morbidity was also found in a sub-
group of mild untreated PHPT patients, who did not meet the NIH criteria for 
surgery. 
7. Most of the untreated PHPT cases do not progress in terms of increase of 
calcium concentrations, but approximately one tenth do develop evidence of 
disease progression, with PTH concentration at the baseline being a 
significant predictor of progression. 
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8. Baseline serum calcium concentration and PTH concentration, 
independently, were significant predictors of adverse outcomes, including 
mortality and a number of co-morbidities, in the short term, but were not 
good predictors in the long term. 
9. Parathyroidectomy normalises patients‟ biochemistry and reduces the risks of 
developing renal complications. 
 
In addition to these main objectives, this thesis has also found some other interesting 
and informative results. 
1. It systematically reviewed existing literature on the long-term outcomes in 
patients with mild asymptomatic PHPT and found conflicting evidence which 
justifies the need for this thesis.  
2. Guidelines have only considered serum calcium not PTH as a surgical 
criterion. Both existing literature and my thesis findings suggested, however, 
that PTH predicts disease progression, as well adverse outcomes in patients 
with untreated PHPT. 
3. There was a similar sized group of hypercalcaemic patients, who are also 
possible PHPT patients but cannot be defined as definite PHPT cases due to a 
lack of PTH concentrations. 
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10.3  Strengths and weaknesses  
As is frequently the case, this thesis has a number of strengths and weaknesses. The 
wealth of data available at HIC, covering a whole regional population, is an evident 
strength for our study. The consistency in anonymisation and data recording enabled 
this thesis to carry out such a long-term observational study on a large population. 
The thesis has, so far, provided the most up-to-date epidemiological estimates of 
prevalence and incidence and natural history of PHPT based on a large cohort of 
relatively unselectedpopulation. Thus, it has fulfilled the research area identified at 
the third NIH conference (2008), where the panel acknowledged the lack of evidence 
from large long-term population studies of the natural history and long-term 
outcomes in mild PHPT.
43
 In addition, the detailed health records at person-level 
made possible an accurate estimate of the risk associated with PHPT.  
 
Whilst many datasets were available for the study, some potentially important factors 
of PHPT were not available or complete. These included smoking status, BMI, 
vitamin D levels and dietary information. However, these are either less accurately 
measured, e.g. smoking which depends on patients‟ self-report, or rarely measured 
with accuracy in primary care and patients‟ self-report tends to understate their 
intensity. Furthermore, since the models have been adjusted with a matched cohort, 
the effects of these factors on the results may be insignificant. Another important 
limitation of this thesis is that the patient diagnosis is subject to electronic data on 
calcium and PTH measurements, thus it is prone to the bias of underestimation. In 
addition, although the population base was, by far, the largest, it was subject to 
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calcium check. Thus, it was less-selective compared to the existing studies but was 
still not an unselected population. As the thesis has demonstrated that the majority of 
patients are mild with no overt clinical symptoms, patients who have mildly elevated 
serum calcium and no obvious other co-existing complications may never have had 
their calcium or PTH checked. It was also demonstrated in the results in Chapter 7, 
that having a calcium check is a significant risk factor of adverse outcomes. In other 
words, people having a calcium check are likely to be ill. However, such problems of 
under-ascertainment exist in many other conditions which are often asymptomatic, 
such as diabetes. Unless a potentially expensive national screening were available, it 
would not be possible to identify all of these patients, nor to undertake a study based 
on a real unselected population. These undiagnosed patients are more likely to be 
cases at the very mild end in whom there is no clear evidence of benefit from 
treatment of any kind. In addition, the results reported in this thesis are un-biased in 
terms of reporting patients with diagnosed PHPT, in that, all will be included. 
Moreover, a potential weakness is that creatinine was used to distinguish secondary 
and tertiary hyperparathyroid patients at diagnosis. |The chosen cut-off point of 150 
umol/l is, however, likely to include some people with renal disease. Thus, the use of 
eGFR as reported by the lab using age and sex adjusted estimates is planned in future 
work to overcome this weakness. 
 
10.4  Future work 
As well as providing valuable information on the condition with a large-scale 
population of patients, this thesis has also proposed recommendations for further 
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work and directions for future prospective randomised trials. Although most patients 
with PHPT do not have overt clinical symptoms associated with the condition, the 
overall quality of life in these patients has been reported as being decreased 
compared to the general population.
37, 64, 87
 Consequently, the cost of long term 
surveillance may far outweigh the cost of early surgical treatment. Diverse opinions 
exist regarding the criteria for surgical intervention. New options to be made 
available for mild PHPT, such as medical therapies, are required and more robust 
evidence to evaluate the cut-off between the decrease in life expectancy due to the 
disease and surgical risk to the general healthy mild PHPT is required. Hence, 
economic modelling of the cost-effectiveness of PTX in comparison to other 
alternative managements is required and has been planned in future work. Ethics 
approval has been obtained in carrying out such an economic study with the aim of 
trying to evaluate the optimal management of the condition which will balance both 
the patients‟ gain in QoL and the long-term health costs. 
 
As previously mentioned, there was a similar group of patients with prolonged 
hypercalcaemia who were identified as possible PHPT patients due to the lack of 
information on PTH measurements. Whether or not these are potential PHPT 
patients awaiting an affirmative diagnosis, is unknown. The long-term outcomes in 
these patients in comparison to those with diagnosed PHPT are worthy of further 
investigation and will form future work. 
 
Although there have been a few RCTs evaluating the benefits of PTX compared to 
those without treatment in patients with mild PHPT, the findings are inconclusive.
36-
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38
 
169-170
  This was due to the small sample sizes, limited follow-up, and an inevitable 
placebo effect of PTX. Thus, large RCTs with enhanced methodology to control for 
the confounding factors are required to truly estimate the benefits of surgery. 
 
10.5  Conclusion 
In summary, this thesis is the first such study to use a large, relatively unselected  
PHPT cohort identified from a large population base. It has therefore described an 
accurate epidemiology of the condition, as well as the associated risks and disease 
progression. It reflects the key research area emphasized at the third NIH workshop 
of asymptomatic PHPT in May 2008. The work has added further knowledge to 
better understand the contemporary mild asymptomatic PHPT and provides potential 
for future prospective cohort studies of non-traditional aspects of PHPT. The results 
of the thesis suggests that PHPT has become a condition of subtle biochemical 
abnormality with no assignable symptoms, however, it is still a condition with 
increased risks of mortality and co-morbidities that cannot be neglected and requires 
further rigorous study in order to find the optimal management. 
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Appendix 
Appendix 1 Details of further search strategies made within the initial results 
(numbers in brackets are the number of studies found). 
Question 1 
CVD: 
 S6: (MH “Cardiovascular Disease+”) 
 S7: CVD 
 S8: S6 or S7 (n=1616009) 
 S9: S5 and S8 (n=8) 
Fractures: 
 S10: (MH “Fractures, Bone+”) 
 S11: (MH “Osteoporosis+”) OR “osteoporosis” 
 S12: (MH “Bone Density”) 
 S13: S10 or S11 or S12 (n=174278) 
 S14: S5 and S13 (n=32) 
Renal functions: 
 S15: “renal function” 
S16: (MH “Kidney Failure, Chronic+”) OR “renal failure” OR (MH “Renal Insufficiency+”) OR 
(MH “Renal Insufficiency, Chronic+”) OR (MH “Kidney Diseases+”) 
S17: “renal stone” OR (MH “Kidney Calculi”) OR (MH “Nephrolithiasis+”) 
S18: S15 or S16 or S17 (n=396860) 
S19: S5 and S18 (n=17) 
Mortality/morbidity in general 
 S20: (MH “Morbidity+”) OR (MH “Mortality+”) 
 S21: S5 and S20 (n=4) 
 
Question 2 
 S22: (MH “Parathyroidectomy”) OR “parathyoidectomy” 
 S23: “surgical criteria” OR “surgery critieria” 
 S24: S22 or S23 (n=5446) 
 S25: S5 and S25 (n=40) 
Question 3 
 S26: “surgery outcome#” OR “surgical outcome#” 
 S27: S22 or S26 (n=12857) 
 S28: S5 and S27 (n=40) 
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Appendix 2 Surgical referral criteria or pre-operation baseline characteristics used in 
existing studies 
Author/year Preoperative baseline data 
Silverberg  
1996 US49 
Ca 11.1+/-.1 mg/dL 
serum phosphorus concentration (2.9+/-0.1mg/dL; ref: 2.5-4.5) 
Urinary ca excretion at upper end of the normal range (249+/-11mg/g 
creatinine) 
Wermers  
1997 US221 
Ca>2.52 
PTH:>2.1 pmol/L by two site immunochemiluminometric assay 
Or: 
hypercalcemia that had lasted for more than a year and had no cause 
(e.g. thiazide diuretics, cancer, creatinine >176.8 umol/L, or lithium 
therapy) other than PHPT 
Or: 
1. at least two elevated Ca from at least three determinations who 
were followed for less than 1 year; 2. elevated ca levels in at least 2 
different years that were followed by three or more normal calcium 
values 
Silverberg   
1999 US89 
Ca greater than 3mmol/L; marked hypercalciuria (Ur Ca over 
10mmol/day), markedly reduced cortical bone density (z score for 
distal third of radius <-2), unexplained reduction in Cr clearance, 
age<50 
Bilezikian  
2000 US 277  
Suggest patients with vitamin D deficiency and patients in their 
permientopausal years should undergo surgery, even if they do not 
fully meet the NIH (1990) guideline. 
Barletta  
2000 Italy75 
Ca: 2.89±0.36 mmol/L;  
PTH: 193±34 pg/mL;  
Systolic AP: 137±10mm/Hg 
Diastolic AP: 77±7 mm/Hg 
Lundgren  
2003 Sweden74 
Ca: 2.6+/-0.141mM 
PTH 5.8+/-3. 3 pmol/L  
Ambrogini  
2007 Italy38 
Ca: 2.55±.1mmol/L 
PTH: 12±5.1pmol/L 
Ur Ca: 63.5±19mmol/d 
BSAP: 21.8±11.7μg/L 
Bollerslev  
2007 Sweden37 
age 64.5+/-7.8  
Ca: 2.70+/-0.08 mmol/L 
no medications interfering with Ca metabolism, 
BSAP bone specific alkaline phophatase 
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 Appendix 3 Frequency of biochemistry tests extracted during patient identification 
Tests Number Specimen 
type 
Laboratory codes 
ALP 977,021 B AP 
Serum calcium 680,206 B CCA, AAC 
Total cholesterol 246,975 B CHOL, JCHO, CHO, SCHO 
Creatinine 1,309,179 B CRE, DCRE, CREA 
HDL cholesterol 145,261 B HDL, JHDL, SHDL 
HDL/Total Chol 10,727 B RHDL 
PTH 29,827 B PTH, QPTH, pth 
Total/HDL Chol 72,904 B CHR 
25hydroxyvitaminD 1,412 B VTD, RVTD 
Calcium excretion 41 U CAEX 
Urine calcium 1,853 U XCA,UCA 
Urine creatinine 54,426 U QUCR, UCRE, XCRE, UC 
Total 3,529,832   
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Appendix 4 Number of selected biochemical tests performed in Tayside by year 
 
 
Appendix 5 Number of probable PHPT patients identified by year and gender 
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Appendix 6 Annual incidence density (ID) for possible PHPT patients 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Male data           
Incident cases 66 60 109 153 82 77 94 112 77 20 
Unadjusted Incidence 4.70 4.29 7.79 10.95 5.86 5.50 6.68 7.98 5.44 1.40 
95% CI 3.54-5.84 3.20-5.38 6.33-9.26 9.21-12.68 4.59-7.12 4.27-7.12 5.33-8.04 6.50-9.46 4.23-6.66 0.79-2.02 
Age adjusted cases 69 62 111 156 83 77 92 109 74 19 
Age adjusted ID 4.90 4.41 7.93 11.08 5.90 5.49 6.58 7.73 5.28 1.35 
95% CI 3.74-6.06 3.34-5.51 6.45-9.40 9.34-12.82 4.62-7.16 4.26-6.71 5.24-7.92 6.28-9.18 4.08-6.48 0.74-1.96 
     
Female data     
Incident cases 132 151 247 323 193 173 169 212 124 33 
Unadjusted ID 8.32 9.54 15.62 20.47 12.24 10.99 10.75 13.43 7.81 2.06 
95% CI 6.90-9.73 8.02-11.06 13.68-17.57 18.24-22.70 10.52-13.97 9.35-12.62 9.13-12.38 11.62-15.24 6.44-9.19 1.36-2.77 
Age adjusted cases 134 153 251 327 194 173 168 209 122 32 
Age adjusted ID 8.48 9.67 15.90 20.66 12.27 10.92 10.64 13.21 7.69 2.03 
95% CI 7.05-9.92 8.14-11.20 13.93-17.86 18.42-22.90 10.54-13.99 9.29-12.55 9.03-12.25 11.42-15.01 6.33-9.06 1.33-2.73 
     
Total population           
Unadjusted ID 6.62 7.08 11.95 15.99 9.24 8.41 8.83 10.87 6.70 1.75 
95% CI 5.70-7.54 6.12-8.03 10.71-13.19 14.56-17.43 8.15-10.33 7.36-9.45 7.77-9.90 9.68-12.05 5.77-7.62 1.28-2.22 
Age and sex adjusted ID 6.80 7.20 12.15 16.15 9.27 8.37 8.73 10.63 6.56 1.71 
95% CI  5.86-7.73 6.24-8.16 10.90-13.40 14.71-17.59 8.18-10.36 7.33-9.40 7.67-9.79 9.46-11.80 5.64-7.48 1.24-2.18 
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Appendix 7 Annual period prevalence (PP) for all possible PHPT patients 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Male data           
Prevalent cases 168 214 310 444 495 529 581 653 675 618 
Unadjusted PP (‰) 1.20 1.53 2.22 3.18 3.54 3.78 4.13 4.65 4.77 4.33 
95% CI 1.02-1.38 1.33-1.73 1.97-2.46 2.88-3.47 3.22-3.85 3.46-4.10 3.80-4.47 4.30-5.01 4.41-5.13 3.99-4.67 
Age adjusted cases 177 222 318 451 399 529 574 638 653 593 
Adjusted PP (‰) 1.26 1.58 2.26 3.21 3.55 3.76 4.09 4.54 4.65 4.22 
95% CI 1.07-1.44 1.37-1.79 2.01-2.51 2.92-3.51 3.24-3.86 3.44-4.09 3.75-4.42 4.19-4.89 4.30-5.01 3.88-4.56 
       
Female data       
Prevalent cases 373 508 726 1008 1155 1248 1328 1442 1455 1379 
Unadjusted PP (‰) 2.35 3.21 4.59 6.39 7.33 7.93 8.45 9.14 9.17 8.62 
95% CI 2.11-2.59 2.93-3.49 4.26-4.93 5.99-6.78 6.91-7.75 7.49-8.36 8.00-8.90 8.67-9.61 8.70-9.63 8.17-9.07 
Age adjusted cases 380 516 738 1019 1161 1248 1322 1424 1428 1345 
Adjusted PP (‰) 2.40 3.26 4.67 6.44 7.34 7.89 8.36 9.00 9.03 8.50 
95% CI 2.16-2.64 2.98-3.54 4.33-5.00 6.05-6.84 6.92-7.76 7.46-8.33 7.91-8.81 8.54-9.47 8.56-9.49 8.05-8.95 
           
Total population           
Unadjusted PP (‰) 1.81 2.42 3.48 4.88 5.54 5.98 6.41 7.03 7.10 6.60 
95% CI 1.66-1.96 2.25-2.60 3.27-3.69 4.63-5.13 5.28-5.81 5.70-6.25 6.12-6.70 6.73-7.33 6.80-7.40 6.31-6.89 
Age & sex adjusted PP (‰) 1.86 2.47 3.53 4.92 5.56 5.95 6.35 6.90 6.97 6.49 
95% CI 1.71-2.02 2.41-2.53 3.47-3.60 4.85-5.00 5.48-5.64 5.87-6.04 6.26-6.44 6.81-6.99 6.88-7.06 6.40-6.58 
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Appendix 8 Results of Pearson correlation between biochemical covariates at 
baseline 
 
  CANEW APNEW CRENEW PTHNEW 
CANEW Pearson 
Correlation 
1 0.067
**
 -0.070
**
 0.180
**
 
Sig. (2-tailed)  0.002 0.001 <0.001 
N 2097 2097 2097 2097 
APNEW Pearson 
Correlation 
 1 -0.018 0.117
**
 
Sig. (2-tailed)   0.407 <0.001 
N  2097 2097 2097 
CRENEW Pearson 
Correlation 
  1 0.378
**
 
Sig. (2-tailed)    <0.001 
N   2097 2097 
PTHNEW Pearson 
Correlation 
   1 
Sig. (2-tailed)     
N    2097 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Appendix 9 SAS programmes demonstrating the complete MI process 
In the following demonstration, CABL was the original baseline calcium with four 
missing values, CAIM was the new imputed calcium using the combined parameter 
estimates and CANEW was the new created calcium with missing values being 
allocated by CAIM and was used in subsequent MI process and the survival analysis. 
 
 
*- PROC MI procedure to create five complete datasets using the 
MCMC method (default by SAS); 
 
PROC MI DATA=PRED OUT=MICA NIMPUTE=5; 
VAR SEX AGE CREDUM APDUM PTHDUM CHODUM DTH YRBL PREBISP CVDPRE 
CEREPRE HYPTPRE RENFPRE RENSPRE PSYPRE FRACPRE CANPRE DIABPRE CABL; 
RUN; 
 
*- Linear regression (PROC REG) to predict parameters for each 
imputed dataset (BY _IMPUTATION_); 
 
PROC REG DATA=MICA OUTEST=OUTREG1 COVOUT NOPRINT; 
MODEL CABL = SEX AGE CREDUM APDUM PTHDUM CHODUM DTH YRBL PREBISP 
CVDPRE CEREPRE HYPTPRE RENFPRE RENSPRE PSYPRE FRACPRE CANPRE 
DIABPRE; 
BY _IMPUTATION_; 
RUN; 
 
*-PROC MIAALYZE to combine the estimated parameters; 
 
PROC MIANALYZE DATA=OUTREG1; 
VAR INTERCEPT SEX AGE CREDUM APDUM PTHDUM CHODUM DTH YRBL PREBISP 
CVDPRE CEREPRE HYPTPRE RENFPRE RENSPRE PSYPRE FRACPRE CANPRE 
DIABPRE; 
RUN; 
 
*-Calculate CAIM using combined parameters; 
 
DATA PRED1; SET PRED; 
CAIM= 3.560157 + 0.004818 * SEX + 0.000968 * AGE + 0.012547 * 
CREDUM - 0.011847 * APDUM + 0.056231 * PTHDUM - 0.021963* CHODUM + 
0.005524 * DTH - 0.000494* YRBL 
- 0.003955 * PREBISP - 0.020864 * CVDPRE - 0.021840* CEREPRE - 
0.020159* HYPTPRE - 0.033019*RENFPRE + 0.019154* RENSPRE  
-0.028830 * PSYPRE + 0.000328* FRACPRE + 0.001817 * CANPRE -
0.003630* DIABPRE; 
 
 
*-Create CANEW for subsequent analyses; 
 
CANEW=CABL; 
IF CANEW=. THEN CANEW=CAIM; 
FORMAT CANEW 8.2; 
RUN; 
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Appendix 10  SPSS syntax for assessing functional form of baseline age 
 
To illustrate the transformation process, a natural logarithm of age, LNAGE, was 
calculated for testing the functional form, as compared to the original AGE value. 
Where the saved HAZARD was the Cox-Snell residual from the null model and the 
MARTR was the calculated Martingale residuals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Null model to save Cox-Snell residual. 
COXREG TIME 
/STATUS=DTH(1) 
/SAVE=HAZARD 
/CRITERIA=PIN(.05) POUT(.10) ITERATE(20). 
 
*Compute Martingale residual based on the saved value. 
COMPUTE MARTR=(DTH=1)-HAZ_2. 
EXECUTE. 
 
*Compute LNAGE for comparison. 
COMPUTE LNAGE=LN (AGE). 
EXECUTE. 
 
*Plot scatter plot with Martingale residual against AGE and LNAGE. 
GRAPH 
/SCATTERPLOT(BIVAR)=AGE WITH MARTR 
/MISSING=LISTWISE. 
GRAPH 
/SCATTERPLOT(BIVAR)=LNAGE WITH MARTR 
/MISSING=LISTWISE. 
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Appendix 11 Score test statistics for continuous covariates by outcome 
Outcome AGET ALPT CAT CRET PTHT 
Mortalities      
All cause 0.0311 0.0219 0.0004 0.1416 0.9599 
Fatal CVD 0.5268 0.7238 0.5609 0.0587 0.3456 
Cancer death 0.3088 0.0009 0.0006 0.5886 0.9557 
Co-morbidities      
Non-fatal CVD 0.4746 0.2802 0.9860 0.7816 0.6419 
Cerebrovascular 0.3287 0.6505 0.6184 0.1914 0.5063 
Hypertension 0.3589 0.9413 0.0705 0.8148 0.3016 
Renal failure 0.1429 0.4629 0.0002 0.0129 0.4368 
Renal stones 0.1349 0.1547 0.2971 0.1392 0.5929 
Psychiatric condition 0.9196 0.2131 0.1891 0.6679 0.9964 
All fractures 0.5595 0.7559 0.3949 0.1873 0.1928 
Osteoporotic fractures 0.6943 0.6412 0.4790 0.0649 0.3226 
Cancer 0.4088 0.0279 0.1490 0.9671 0.5545 
Diabetes 0.4394 0.9771 0.1713 0.9057 0.5109 
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Appendix 12 Comparison of model performance with and without time interactions 
for secondary outcomes 
Outcome Time 
interactions 
AIC C-Stats 95% CI 
Cerebrovascular Without 2512.237 0.669 0.609-0.724 
 With 2265.991 0.591 0.546-0.635 
Hypertension Without 3044.178 0.843 0.761-0.901 
 With 2720.449 0.640 0.589-0.687 
Renal failure Without 5582.053 0.955 0.916-0.976 
 With 4963.696 0.815 0.768-0.854 
Renal stones Without 476.883 0.752 0.689-0.806 
 With 439.224 0.516 0.474-0.558 
Psychiatric condition Without 508.706 0.539 0.474-0.603 
 With 442.145 0.517 0.474-0.558 
Fracture all Without 2116.846 0.690 0.622-0.750 
 With 1916.473 0.602 0.551-0.651 
Osteoporotic fractures Without 1586.931 0.607 0.547-0.663 
 With 1435.466 0.568 0.520-0.614 
Cancer Without 2988.218 0.885 0.818-0.929 
 With 2672.552 0.629 0.580-0.676 
Diabetes Without 1202.263 0.641 0.561-0.714 
 With 1050.627 0.555 0.505-0.605 
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Appendix 13 Final models of survival analysis on all secondary outcomes, using 
PTH as a potential predictor in the short term (<=1000 days) 
Outcomes Covariates HRs p-value 
Cerebrovascular LNPTH 1.183 <0.001 
 LNPTH*TMDM 0.186 <0.001 
 AGE 1.038 <0.001 
 FEMALE 0.723 0.043 
 SIMD 0.942 <0.001 
 PRE-CEREB 3.455 <0.001 
 PRE-RENF 0.552 0.037 
Hypertension LNPTH 1.781 <0.001 
 LNPTH*TMDM 0.227 <0.001 
 PRE-HYPT 2.365 <0.001 
Renal failure LNPTH 2.617 <0.001 
 LNPTH*TMDM 0.206 <0.001 
 FEMALE 0.598 <0.001 
 PRE-CVD 1.536 <0.001 
 PRE-CEREB 1.397 0.077 
 PRE-RENF 2.288 <0.001 
 PRE-DIAB 1.592 <0.001 
Renal stones LNPTH 1.746 0.023 
 LNPTH*TMDM 0.238 <0.001 
 AGE 0.965 0.002 
 FEMALE 0.467 0.028 
 PRE-RENS 9.737 <0.001 
Psychiatric condition LNPTH 1.625 0.039 
 LNPTH*TMDM 0.167 <0.001 
 FEMALE 2.688 0.041 
All fractures LNPTH 1.799 <0.001 
 LNPTH*TMDM 0.241 <0.001 
 AGE 1.049 <0.001 
 FEMALE 1.770 0.008 
 PRE-FRAC 3.607 <0.001 
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Outcomes Covariates HRs P 
Osteoporotic fractures LNPTH 1.926 <0.001 
 LNPTH*TMDM 0.230 <0.001 
 AGE 1.058 <0.001 
 FEMALE 1.742 0.029 
 PRE-RENF 0.422 0.064 
 PRE-FRAC 1.863 0.028 
Cancer LNPTH 2.131 <0.001 
 LNPTH*TMDM 0.198 <0.001 
 AGE 1.019 0.001 
 SIMD 0.953 0.054 
 PRE-RENF 0.613 0.071 
 PRE-CAN 1.905 0.001 
Diabetes LNPTH 2.237 <0.001 
 LNPTH*TMDM 0.147 <0.001 
 SIMD 0.815 <0.001 
 
 
